var title_f28_12_28864="Knee chest stretch PI";
var content_f28_12_28864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee chest stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lie on the back on a bed or on a towel on the floor. Bring knees up to chest. Place the hands behind the knees and pull toward the chest until you feel a stretch in the lower back and buttocks. Hold for 5 seconds. Rest. Repeat 10 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28864=[""].join("\n");
var outline_f28_12_28864=null;
var title_f28_12_28865="Gastric cardia";
var content_f28_12_28865=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic appearance of gastric cardia after gastric banding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retroflexed endoscopic appearance of the gastric cardia after laparoscopic adjustable gastric banding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher S Huang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28865=[""].join("\n");
var outline_f28_12_28865=null;
var title_f28_12_28866="ART dosing recommendations for renal or hepatic insufficiency";
var content_f28_12_28866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=21\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=21\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiretroviral dosing recommendations in patients with renal or hepatic insufficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antiretrovirals generic name (abbreviation)/trade name*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual daily dose",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Dosing in renal insufficiency (including with chronic ambulatory peritoneal dialysis [CAPD] and hemodialysis [HD])",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Dosing in hepatic impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        See reference section following tables for creatinine clearance (CrCl) calculation formulas and criteria for Child-Pugh classification.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\" colspan=\"7\">",
"        Nucleoside reverse transcriptase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Use of fixed-dose combination NRTI (+/- NNRTI) of Atripla, Combivir, Trizivir, or Epzicom is not recommended in patients with CrCl &lt;50 mL/min. Use of Truvada is not recommended in patients with CrCl &lt;30 mL/min.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"3\">",
"        <strong>",
"         Abacavir",
"        </strong>",
"        (ABC)/Ziagen",
"       </td>",
"       <td rowspan=\"3\">",
"        300 mg orally twice per day",
"       </td>",
"       <td colspan=\"3\" rowspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Child-Pugh score",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-6",
"       </td>",
"       <td>",
"        200 mg twice per day (use oral solution)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;6",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"5\">",
"        <strong>",
"         Didanosine enteric coated",
"        </strong>",
"        (ddI)/Videx EC",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         <strong>",
"          Body weight &ge;60 kg:",
"         </strong>",
"        </p>",
"        400 mg orally once daily",
"        <hr/>",
"        <p>",
"         <strong>",
"          Body weight &lt;60 kg:",
"         </strong>",
"        </p>",
"        <p>",
"         250 mg orally once daily",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_single\" rowspan=\"2\">",
"        CrCl (mL/min)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dose (once daily)",
"       </td>",
"       <td colspan=\"2\" rowspan=\"5\">",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        &ge;60 kg",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &lt;60 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-59",
"       </td>",
"       <td>",
"        200 mg",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-29",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;10, HD, CAPD",
"       </td>",
"       <td>",
"        125 mg",
"       </td>",
"       <td>",
"        Use oral solution",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"5\">",
"        <strong>",
"         Didanosine oral solution",
"        </strong>",
"        (ddI)/Videx",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         <strong>",
"          Body weight &ge;60 kg:",
"         </strong>",
"        </p>",
"        200 mg orally twice per day or 400 mg orally once daily",
"        <hr/>",
"        <p>",
"         <strong>",
"          Body weight &lt;60 kg:",
"         </strong>",
"        </p>",
"        <p>",
"         250 mg orally once per day or 125 mg orally twice per day",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_single\" rowspan=\"2\">",
"        CrCl (mL/min)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dose (once daily)",
"       </td>",
"       <td colspan=\"2\" rowspan=\"5\">",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        &ge;60 kg",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &lt;60 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-59",
"       </td>",
"       <td>",
"        200 mg",
"       </td>",
"       <td>",
"        150 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-29",
"       </td>",
"       <td>",
"        150 mg",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;10, HD, CAPD",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        75 mg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"6\">",
"        <strong>",
"         Emtricitabine",
"        </strong>",
"        (FTC)/Emtriva",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         200 mg oral capsule once daily; or",
"        </p>",
"        <p>",
"         240 mg (24 mL) oral solution once daily",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_single\" rowspan=\"2\">",
"        CrCl (mL/min)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dose",
"       </td>",
"       <td colspan=\"2\" rowspan=\"6\">",
"        No dosage recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Capsule",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-49",
"       </td>",
"       <td>",
"        200 mg Q 48 h",
"       </td>",
"       <td>",
"        120 mg Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-29",
"       </td>",
"       <td>",
"        200 mg Q 72 h",
"       </td>",
"       <td>",
"        80 mg Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;15 or HD",
"       </td>",
"       <td>",
"        200 mg Q 96 h",
"       </td>",
"       <td>",
"        60 mg Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Take dose after HD session on dialysis days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"6\">",
"        <strong>",
"         Lamivudine",
"        </strong>",
"        (3TC)/Epivir",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         300 mg orally once daily; or",
"        </p>",
"        <p>",
"         150 mg orally twice per day",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        CrCl (mL/min)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dose",
"       </td>",
"       <td colspan=\"2\" rowspan=\"6\">",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-49",
"       </td>",
"       <td colspan=\"2\">",
"        150 mg Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-29",
"       </td>",
"       <td colspan=\"2\">",
"        1 x 150 mg, then 100 mg Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-14",
"       </td>",
"       <td colspan=\"2\">",
"        1 x 150 mg, then 50 mg Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;5 or HD",
"       </td>",
"       <td colspan=\"2\">",
"        1 x 50 mg, then 25 mg Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Take dose after HD session on dialysis days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"5\">",
"        <strong>",
"         Stavudine",
"        </strong>",
"        (D4T)/Zerit",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         <strong>",
"          Body weight &ge;60 kg:",
"         </strong>",
"        </p>",
"        40 mg orally twice per day",
"        <hr/>",
"        <p>",
"         <strong>",
"          Body weight &lt;60 kg:",
"         </strong>",
"        </p>",
"        <p>",
"         30 mg orally twice per day",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_single\" rowspan=\"2\">",
"        CrCl (mL/min)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dose",
"       </td>",
"       <td colspan=\"2\" rowspan=\"5\">",
"        No dosage recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        &ge;60 kg",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &lt;60 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26-50",
"       </td>",
"       <td>",
"        20 mg Q 12 h",
"       </td>",
"       <td>",
"        15 mg Q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-25 or HD",
"       </td>",
"       <td>",
"        20 mg Q 24 h",
"       </td>",
"       <td>",
"        15 mg Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Take dose after HD session on dialysis days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"6\">",
"        <strong>",
"         Tenofovir",
"        </strong>",
"        (TDF)/Viread",
"       </td>",
"       <td rowspan=\"6\">",
"        300 mg orally once daily",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        CrCl (mL/min)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dose",
"       </td>",
"       <td colspan=\"2\" rowspan=\"6\">",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-49",
"       </td>",
"       <td colspan=\"2\">",
"        300 mg Q 48 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-29",
"       </td>",
"       <td colspan=\"2\">",
"        300 mg twice weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;10 not on HD",
"       </td>",
"       <td colspan=\"2\">",
"        No recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HD",
"       </td>",
"       <td colspan=\"2\">",
"        300 mg every 7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Take dose after HD session on dialysis days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"3\">",
"        <strong>",
"         Emtricitabine",
"        </strong>",
"        (FTC) +",
"        <strong>",
"         Tenofovir",
"        </strong>",
"        (TDF)/Truvada",
"       </td>",
"       <td rowspan=\"3\">",
"        1 tablet orally once daily",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        CrCl (mL/min)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dose",
"       </td>",
"       <td colspan=\"2\" rowspan=\"3\">",
"        No dosage recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-49",
"       </td>",
"       <td colspan=\"2\">",
"        1 tablet Q 48 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;30 or HD",
"       </td>",
"       <td colspan=\"2\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"2\">",
"        <strong>",
"         Zidovudine",
"        </strong>",
"        (ZDV)/Retrovir",
"       </td>",
"       <td rowspan=\"2\">",
"        300 mg orally twice per day",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        CrCl (mL/min)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dose",
"       </td>",
"       <td colspan=\"2\" rowspan=\"2\">",
"        No dosage recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;15 or HD",
"       </td>",
"       <td colspan=\"2\">",
"        100 mg three times per day or 300 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"7\">",
"        Non-nucleoside reverse transcriptase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Delavirdine",
"        </strong>",
"        (DLV)/Rescriptor",
"       </td>",
"       <td>",
"        400 mg orally three times per day",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        No dosage recommendation; use with caution in patients with hepatic impairment",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Efavirenz",
"        </strong>",
"        (EFV)/Sustiva",
"       </td>",
"       <td>",
"        600 mg orally at or before bedtime",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\" rowspan=\"2\">",
"        No dosage recommendation; use with caution in patients with hepatic impairment",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Efavirenz",
"        </strong>",
"        (EFV) +",
"        <strong>",
"         Emtricitabine",
"        </strong>",
"        (FTC) +",
"        <strong>",
"         Tenofovir",
"        </strong>",
"        (TDF)/Atripla",
"       </td>",
"       <td>",
"        1 tablet orally once daily",
"       </td>",
"       <td colspan=\"3\">",
"        Atripla not recommended if CrCl &lt;50 mL/min",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Etravirine",
"        </strong>",
"        (ETR)/Intelence",
"       </td>",
"       <td>",
"        200 mg orally twice per day",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Child-Pugh Class A or B:",
"         </em>",
"         no dosage adjustment",
"        </p>",
"        <p>",
"         <em>",
"          Child-Pugh Class C:",
"         </em>",
"         no dosage recommendation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Nevirapine",
"        </strong>",
"        (NVP)/Viramune or Viramune XR",
"       </td>",
"       <td>",
"        200 mg orally twice per day or 400 mg orally once daily (using Viramune XR formulation)",
"       </td>",
"       <td colspan=\"3\">",
"        <em>",
"         HD patients:",
"        </em>",
"        limited data; no dosage recommendation",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Child-Pugh Class A:",
"         </em>",
"         no dosage adjustment",
"        </p>",
"        <em>",
"         Child-Pugh Class B or C:",
"        </em>",
"        contraindicated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Rilpivirine",
"         </strong>",
"         (RPV)/Edurant",
"        </p>",
"       </td>",
"       <td>",
"        25 mg orally once daily",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Child-Pugh Class A or B:",
"         </em>",
"         no dosage adjustment",
"        </p>",
"        <p>",
"         <em>",
"          Child-Pugh Class C:",
"         </em>",
"         no dosage recommendation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Rilpivirine",
"        </strong>",
"        (RPV) +",
"        <strong>",
"         Tenofovir",
"        </strong>",
"        (TDF) +",
"        <strong>",
"         Emtricitabine",
"        </strong>",
"        (FTC)/Complera",
"       </td>",
"       <td>",
"        1 tablet orally once daily",
"       </td>",
"       <td colspan=\"3\">",
"        Not recommended if CrCl &lt;50 mL/minute; use individual drug components of fixed-dose combination and adjust TDF and FTC doses per CrCl",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Child-Pugh Class A or B:",
"         </em>",
"         no dosage adjustment",
"        </p>",
"        <p>",
"         <em>",
"          Child-Pugh Class C:",
"         </em>",
"         no dosage recommendation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"7\">",
"        Protease inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"4\">",
"        <strong>",
"         Atazanavir",
"        </strong>",
"        (ATV)/Reyataz",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         400 mg orally once daily or",
"        </p>",
"        <p>",
"         (ATV 300 mg + RTV 100 mg) orally once daily",
"        </p>",
"       </td>",
"       <td colspan=\"3\" rowspan=\"4\">",
"        <p>",
"         No dosage adjustment for patients with renal dysfunction not requiring HD",
"        </p>",
"        <p>",
"         <em>",
"          ARV-na&iuml;ve patients on HD:",
"         </em>",
"         (ATV 300 mg + RTV 100 mg) once daily",
"        </p>",
"        <p>",
"         <em>",
"          ARV-experienced patients on HD:",
"         </em>",
"         ATV or RTV-boosted ATV not recommended",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Child-Pugh score",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7-9",
"       </td>",
"       <td colspan=\"2\">",
"        300 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;9",
"       </td>",
"       <td colspan=\"2\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        RTV boosting is not recommended in patients with hepatic impairment (Child-Pugh score &ge;7)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Darunavir",
"        </strong>",
"        (DRV)/Prezista",
"       </td>",
"       <td>",
"        <p>",
"         (DRV 800 mg + RTV 100 mg) orally once daily (ARV-na&iuml;ve patients) or",
"        </p>",
"        <p>",
"         (DRV 600 mg + RTV 100 mg) orally twice per day",
"        </p>",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Mild to moderate hepatic impairment:",
"         </em>",
"         no dosage adjustment",
"        </p>",
"        <p>",
"         <em>",
"          Severe hepatic impairment:",
"         </em>",
"         not recommended",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\" rowspan=\"8\">",
"        <strong>",
"         Fosamprenavir",
"        </strong>",
"        (FPV)/Lexiva",
"       </td>",
"       <td rowspan=\"8\">",
"        <p>",
"         1400 mg orally twice per day or",
"        </p>",
"        <p>",
"         (FPV 1400 mg + RTV 100-200 mg) PO once daily or",
"        </p>",
"        <p>",
"         (FPV 700 mg + RTV 100 mg) orally twice per day",
"        </p>",
"       </td>",
"       <td colspan=\"3\" rowspan=\"8\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Child-Pugh score",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        PI-na&iuml;ve patients only:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5-9",
"       </td>",
"       <td>",
"        700 mg twice per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        10-15",
"       </td>",
"       <td>",
"        350 mg twice per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        PI-na&iuml;ve or PI-experienced patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        5-6",
"       </td>",
"       <td>",
"        700 mg twice per day + RTV 100 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        7-9",
"       </td>",
"       <td>",
"        450 mg twice per day + RTV 100 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        10-15",
"       </td>",
"       <td>",
"        300 mg twice per day + RTV 100 mg once daily",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Indinavir",
"        </strong>",
"        (IDV)/Crixivan",
"       </td>",
"       <td>",
"        800 mg orally every 8 hours",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        <em>",
"         Mild to moderate hepatic insufficiency because of cirrhosis:",
"        </em>",
"        600 mg Q 8 h",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Lopinavir/ritonavir",
"        </strong>",
"        (LPV/r) Kaletra",
"       </td>",
"       <td>",
"        <p>",
"         400/100 mg orally twice per day or",
"        </p>",
"        <p>",
"         800/200 mg orally once daily",
"        </p>",
"       </td>",
"       <td colspan=\"3\">",
"        Avoid once daily dosing in patients on HD",
"       </td>",
"       <td colspan=\"2\">",
"        No dosage recommendation; use with caution in patients with hepatic impairment",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Nelfinavir",
"        </strong>",
"        (NFV)/Viracept",
"       </td>",
"       <td>",
"        1250 mg orally twice per day",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Mild hepatic impairment:",
"         </em>",
"         no dosage adjustment",
"        </p>",
"        <p>",
"         <em>",
"          Moderate to severe hepatic impairment:",
"         </em>",
"         do not use",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Ritonavir",
"        </strong>",
"        (RTV)/Norvir",
"       </td>",
"       <td>",
"        <em>",
"         As a PI-boosting agent:",
"        </em>",
"        100-400 mg orally daily",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        Refer to recommendations for the primary PI",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Saquinavir",
"        </strong>",
"        (SQV)/Invirase",
"       </td>",
"       <td>",
"        (SQV 1000 mg + RTV 100 mg) orally twice per day",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Mild to moderate hepatic impairment:",
"         </em>",
"         use with caution",
"        </p>",
"        <p>",
"         <em>",
"          Severe hepatic impairment:",
"         </em>",
"         contraindicated",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent2\">",
"        <strong>",
"         Tipranavir",
"        </strong>",
"        (TPV)/Aptivus",
"       </td>",
"       <td>",
"        (TPV 500 mg + RTV 200 mg) orally twice per day",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Child-Pugh Class A:",
"         </em>",
"         use with caution",
"        </p>",
"        <p>",
"         <em>",
"          Child-Pugh Class B or C:",
"         </em>",
"         contraindicated",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"7\">",
"        Fusion inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Enfuvirtide",
"        </strong>",
"        (T20)/Fuzeon",
"       </td>",
"       <td>",
"        90 mg subcutaneous twice per day",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"7\">",
"        CCR5 antagonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Maraviroc",
"        </strong>",
"        (MVC)/Selzentry",
"       </td>",
"       <td>",
"        The recommended dose differs based on concomitant medications because of drug interactions",
"       </td>",
"       <td colspan=\"3\">",
"        <p>",
"         <strong>",
"          CrCl &lt;30 mL/min or HD",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Without potent CYP3A inhibitors or inducers:",
"         </em>",
"         300 mg twice per day; reduce to 150 mg twice per day if postural hypotension occurs",
"        </p>",
"        <p>",
"         <em>",
"          With potent CYP3A inducers or inhibitors:",
"         </em>",
"         not recommended",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        No dosage recommendations. Concentrations will likely be increased in patients with hepatic impairment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"7\">",
"        Integrase inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Raltegravir",
"        </strong>",
"        (RAL)/Isentress",
"       </td>",
"       <td>",
"        400 mg orally twice per day",
"       </td>",
"       <td colspan=\"3\">",
"        No dosage adjustment necessary",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <em>",
"          Mild to moderate hepatic insufficiency:",
"         </em>",
"         no dosage adjustment necessary",
"        </p>",
"        <p>",
"         <em>",
"          Severe hepatic insufficiency:",
"         </em>",
"         no recommendation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        REFERENCE SECTION",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"7\">",
"        Creatinine clearance calculation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Male:",
"        </strong>",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        (140 - age in years) x weight (kg)",
"        <sup>",
"         &bull;",
"        </sup>",
"        <hr/>",
"        72 x Serum creatinine",
"       </td>",
"       <td class=\"indent1\">",
"        <strong>",
"         Female:",
"        </strong>",
"       </td>",
"       <td class=\"centered\" colspan=\"3\">",
"        (140 - age in years) x weight (kg)",
"        <sup>",
"         &bull;",
"        </sup>",
"        x 0.85",
"        <hr/>",
"        72 x Serum creatinine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"7\">",
"        Note: calculators for estimation of creatinine clearance with this equation (Cockcroft-Gault) and ideal body weight are included with UpToDate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        &bull; Estimate of ideal body weight used for patients who are obese.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"7\">",
"        Child-Pugh score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Component",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"6\">",
"        Points scored",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        1",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        2",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        None",
"       </td>",
"       <td colspan=\"2\">",
"        Grade 1-2",
"       </td>",
"       <td colspan=\"2\">",
"        Grade 3-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"       <td colspan=\"2\">",
"        None",
"       </td>",
"       <td colspan=\"2\">",
"        Mild or controlled by diuretics",
"       </td>",
"       <td colspan=\"2\">",
"        Moderate or refractory despite diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;3.5 g/dL",
"       </td>",
"       <td colspan=\"2\">",
"        2.8-3.5 g/dL",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;2.8 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total bilirubin",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;2 mg/dL (&lt;34 &micro;mol/L)",
"       </td>",
"       <td colspan=\"2\">",
"        2-3 mg/dL (34 &micro;mol/L to 50 &micro;mol/L)",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;3 mg/dL (&gt;50 &micro;mol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Modified total bilirubin",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;4 mg/dL",
"       </td>",
"       <td colspan=\"2\">",
"        4-7 mg/dL",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;7 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin time (seconds prolonged)",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;4",
"       </td>",
"       <td colspan=\"2\">",
"        4-6",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        International normalized ratio (INR)",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;1.7",
"       </td>",
"       <td colspan=\"2\">",
"        1.7-2.3",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;2.3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"7\">",
"        Note: calculators for Child-Pugh classification for severity of liver disease are included with UpToDate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\" colspan=\"7\">",
"        &Delta;",
"        <strong>",
"         Encephalopathy grades:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"7\">",
"        <strong>",
"         Grade 1:",
"        </strong>",
"        Mild confusion, anxiety, restlessness, fine tremor, slowed coordination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"7\">",
"        <strong>",
"         Grade 2:",
"        </strong>",
"        Drowsiness, disorientation, asterixis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"7\">",
"        <strong>",
"         Grade 3:",
"        </strong>",
"        Somnolent but rousable, marked confusion, incomprehensible speech, incontinence, hyperventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"7\">",
"        <strong>",
"         Grade 4:",
"        </strong>",
"        Coma, decerebrate posturing, flaccidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        &loz; Modified total bilirubin used to score patients who have Gilbert's syndrome or who are taking indinavir or atazanavir.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Child-Pugh classification",
"       </td>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Total score",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Class A",
"       </td>",
"       <td colspan=\"3\">",
"        5-6 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Class B",
"       </td>",
"       <td colspan=\"3\">",
"        7-9 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Class C",
"       </td>",
"       <td colspan=\"3\">",
"        &gt;9 points",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"7\">",
"        &sect; Sum of points for each component.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     3TC: lamivudine; ABC: abacavir; ARV: antiretroviral; ATV: atazanavir; CAPD: chronic ambulatory peritoneal dialysis; CrCl: creatinine clearance; CYP: cytochrome P450; D4T: stavudine; ddI: didanosine; DLV: delavirdine; DRV: darunavir; EFV: efavirenz; ETR: etravirine; FPV: fosamprenavir; FTC: emtricitabine; h: hours; HD: hemodialysis; IDV: indinavir; LPV/r: lopinavir/ritonavir; MVC: maraviroc; NVP: nevirapine; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; RAL: raltegravir; RPV: rilpivirine; RTV: ritonavir; SQV: saquinavir; T20: enfuvirtide; TDF: tenofovir; TPV: tipranavir; ZDV: zidovudine.",
"     <br>",
"      * Trade names may be specific to the United States.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated October 14, 2011.",
"     <a href=\"file://aidsinfo.nih.gov\">",
"      file://aidsinfo.nih.gov",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28866=[""].join("\n");
var outline_f28_12_28866=null;
var title_f28_12_28867="Measurement right atrial volume";
var content_f28_12_28867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right atrial volume",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right atrial (RA) volume is measured from single plane area length algorithm computed from digitizing the chamber in the four chamber view. The volume of this very large atrium is 153 ml.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; LV: left ventricle; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28867=[""].join("\n");
var outline_f28_12_28867=null;
var title_f28_12_28868="Eszopiclone: Patient drug information";
var content_f28_12_28868=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Eszopiclone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"     see \"Eszopiclone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lunesta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eszopiclone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug unless you can get at least 8 hours of sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take naps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid taking this drug with high-fat meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11206 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28868=[""].join("\n");
var outline_f28_12_28868=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167830\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011118\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011120\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011119\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011224\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011225\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011227\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011122\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011123\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011228\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011229\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=related_link\">",
"      Eszopiclone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_12_28869="Anaplastic thyroid cancer 1";
var content_f28_12_28869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F88833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F88833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Anaplastic thyroid cancer: Findings on histology (giant cells, spindle cells)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anaplastic thyroid cancer demonstrating giant cells (A) and spindle cells (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ronald A Ghossein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28869=[""].join("\n");
var outline_f28_12_28869=null;
var title_f28_12_28870="Sq cell ca lung keratin B";
var content_f28_12_28870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Squamous cell carcinoma with evidence of keratinization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henry D. Tazelaar MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28870=[""].join("\n");
var outline_f28_12_28870=null;
var title_f28_12_28871="Overview of vitamin E";
var content_f28_12_28871=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of vitamin E",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28871/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28871/contributors\">",
"     Sassan Pazirandeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28871/contributors\">",
"     David L Burns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28871/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28871/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28871/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28871/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28871/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/12/28871/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamins are a number of chemically unrelated families of organic substances that cannot be synthesized by humans but need to be ingested in the diet in small quantities to prevent disorders of metabolism. They are divided into water-soluble and fat-soluble vitamins (",
"    <a class=\"graphic graphic_table graphicRef63827 \" href=\"UTD.htm?12/15/12541\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In 1922, Evans and Bishop discovered a substance that was deficient in rats fed a diet that contained lard and that resulted in infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/1\">",
"     1",
"    </a>",
"    ]. The deficiency was corrected when a lipid extract of cereals was added to the diet; this was termed the \"anti-sterility factor\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/2\">",
"     2",
"    </a>",
"    ]. In 1925, vitamin E was officially recognized as the fifth vitamin. A few years later the name tocopherol from the Greek word of \"toc\" (child) and \"phero\" (to bring forth) was coined to describe its role as an essential dietary substance in normal fetal and childhood development [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/3\">",
"     3",
"    </a>",
"    ]. In 1969, the FDA formally recognized vitamin E as an essential nutrient for humans. Vitamin E is a fat-soluble compound and an antioxidant and protects cell membranes from oxidation and destruction.",
"   </p>",
"   <p>",
"    This topic review will focus on vitamin E. Overviews of the other fat-soluble vitamins, minerals and water-soluble vitamins are available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link\">",
"     \"Overview of vitamin K\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link\">",
"     \"Overview of dietary trace minerals\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E is found in a variety of foods including oils, meat, eggs, and leafy vegetables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHEMISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of biologically active vitamin E compounds in nature. Approximately eight naturally occurring vitamin E compounds have been described, including alpha-, beta-, gamma-, and delta- tocopherol. The only forms of tocopherol that are efficiently maintained in human plasma are four of the many isomers of alpha-tocopherol (RRR-, RSR-, RRS-, and RSS- alpha-tocopherol, which are present in \"all racemic\" synthetic vitamin E; only the RRR-form is present in foods). These are the forms of vitamin E that are most biologically active, and are the forms to which the Recommended Daily Allowances apply [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/4\">",
"     4",
"    </a>",
"    ]. Synthetic vitamin E supplements containing all the eight isomers of alpha-tocopherol (\"All racemic\") has approximately half of the activity of \"natural source\" vitamin E. However, all of the isomers of alpha tocopherol may contribute to the potential adverse effects of supplemental vitamin E, and are included in the calculation of an upper limit for supplementation.",
"   </p>",
"   <p>",
"    Gamma-tocopherol is transported less efficiently than alpha-tocopherol, but is more abundant in the US diet, so similar tissue levels are achieved from dietary vitamin E&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/5\">",
"     5",
"    </a>",
"    ]. Pharmacological doses of alpha-tocopherol taken in supplements reduce levels of gamma-tocopherol in plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E works as a free radical scavenger, protecting polyunsaturated fatty acids (PUFA), a major structural component of the cell membranes, from peroxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/7\">",
"     7",
"    </a>",
"    ]. In the past few decades, there has been increasing interest in the role of free radicals and anti-oxidants in atherosclerosis and carcinogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .) Deficiency of vitamin E has been connected to cardiovascular events. Low-density lipoprotein (LDL) plays a central role in these hypotheses. When LDL is exposed to oxidative stress, it undergoes a cascade of changes affecting the vascular endothelium, thereby facilitating atherogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. This theory is referred to as the oxidative modification hypothesis, and has fueled epidemiologic studies and clinical trials in cardiology to determine the role of antioxidants, such as vitamin E, in prevention and treatment of atherosclerotic cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/11\">",
"     11",
"    </a>",
"    ]. However, trials of vitamin E supplementation have generally shown no effect in prevention of heart disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Gamma-tocopherol has unique anti-inflammatory activities, mediated by reductions in prostaglandin E2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/12\">",
"     12",
"    </a>",
"    ]. High doses of vitamin E (as alpha-tocopherol) reduce levels of gamma-tocopherol, perhaps explaining the adverse effects of pharmacological doses of the vitamin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some functions of vitamin E are independent of the",
"    <span class=\"nowrap\">",
"     antioxidant/radical",
"    </span>",
"    scavenging activity, including inhibition of cell proliferation, platelet aggregation, and monocyte adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/13\">",
"     13",
"    </a>",
"    ]. Several other effects at the molecular level have been identified, but the clinical implications of these actions have not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other fat-soluble vitamins, bioavailability of vitamin E depends upon physiologic mechanisms for fat digestion and absorption. This process requires lipolytic function of pancreatic enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/14\">",
"     14",
"    </a>",
"    ]. Pancreatic esterases are the enzymes responsible for breaking down the tocopheryl-ester bonds between vitamin E and fatty acids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/15\">",
"     15",
"    </a>",
"    ]. Within the intestinal mucosal cells, chylomicrons are produced from phospholipids, triglycerides, apolipoproteins, and fat-soluble vitamins. The synthesis of chylomicrons is required for transport of vitamin E via the lymphatic system to the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/16\">",
"     16",
"    </a>",
"    ]. Within hepatocytes, chylomicron remnants are broken down by lysosomes, and RRR-alpha-tocopherol is preferentially secreted into the bloodstream, packaged within VLDL molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/17\">",
"     17",
"    </a>",
"    ]. The transport protein for alpha-tocopherol is named alpha-tocopherol transfer protein (A-TTP) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary vitamin E content is variable and proportional to vegetable oil intake. American diets of 2000 to 3000",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    contain 7 to 10 mg of alpha-tocopherol equivalents. However, this is likely an underestimate because dietary fat intake is commonly under-reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26561062\">",
"    <span class=\"h2\">",
"     Healthy population",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States National Academy of Sciences Food and Nutrition Board recommends 15 mg of dietary alpha-tocopherol units per day for adolescents and adult men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/4\">",
"     4",
"    </a>",
"    ]. This is the equivalent of 22 International Units (IU) of \"natural-source\" vitamin E (RRR-alpha-tocopherol), or 33 IUs of the synthetic form (all-rac-alpha-tocopherol) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/4\">",
"     4",
"    </a>",
"    ]. In children, the recommended daily allowance rises from 6 mg at 1 to 3 years of age to 15 mg by 14 to 18 years (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"UTD.htm?19/31/19967\">",
"     table 2",
"    </a>",
"    ). Note that although the requirements are stated in terms of alpha-tocopherol equivalents, a substantial portion of this will be provided as gamma-tocopherol if dietary sources are used. For this reason, dietary vitamin E may have advantages over vitamin E taken as a supplement. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Actions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26561069\">",
"    <span class=\"h2\">",
"     Cholestatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cholestasis or pancreatic exocrine insufficiency are at risk for vitamin E deficiency because of malabsorption of fat and fat-soluble vitamins. Patients with cholestasis also tend to have hyperlipidemia, which strongly influences vitamin E levels, so assessment of their vitamin E status requires simultaneous measurement of alpha-tocopherol and serum lipids (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Measurement'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If vitamin E deficiency is diagnosed, these patients are treated with large oral doses of vitamin E. Water-miscible vitamin E (d-alpha-tocopherol glycol 1000 succinate, TPGS) is most effective in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/19\">",
"     19",
"    </a>",
"    ]. However, water-miscible preparations have not been shown to be superior for patients with cystic fibrosis who are taking concurrent pancreatic enzyme supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical supplementation regimens for infants and children with cholestasis are 25 to 50 int.",
"    <span class=\"nowrap\">",
"     units/kg/day",
"    </span>",
"    of vitamin E (alpha tocopherol), or 15 to 25 int.",
"    <span class=\"nowrap\">",
"     units/kg/day",
"    </span>",
"    of water-miscible vitamin E [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of vitamin E deficiency in adults with cholestatic liver diseases has not been well defined. It is probably most common in patients with severe and prolonged primary biliary cirrhosis, in whom estimates of vitamin E deficiency range from 10 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. For patients with significant cholestasis (eg, bilirubin &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    routine monitoring of vitamin E levels is recommended, with vitamin E replacement as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E deficiency is uncommon in humans except in unusual circumstances. This is due to the abundance of tocopherols in the diet. Individuals eating a vegetarian or vegan diet typically are not at increased risk for vitamin E deficiency. Individuals with fat malabsorption and steatorrhea are at risk for deficiency of all lipid-soluble vitamins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/28\">",
"     28",
"    </a>",
"    ]. These disorders include cirrhosis, cholestatic liver disease, cystic fibrosis, small bowel bacterial overgrowth, pancreatic insufficiency, celiac disease, and Crohn disease. The degree of deficiency is generally proportional to the magnitude and the duration of steatorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also several genetic disorders that lead to vitamin E deficiency. As an example, a genetic defect in the A-TTP (alpha-tocopherol transfer protein) is associated with neurologic deficits and is known as ataxia with vitamin E deficiency (AVED). Affected patients have symptoms similar to Friedreich's ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/30\">",
"     30",
"    </a>",
"    ]. These patients sometimes respond to oral supplementation of vitamin E in doses of 800 to 1200 mg per day. More often, supplementation serves to prevent progression of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of the hereditary ataxias\", section on 'Treatable diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults and children, vitamin E deficiency can cause neuromuscular disorders and hemolysis. Low serum levels of vitamin E (defined as below 0.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    may cause no appreciable symptoms, or may manifest as subtle neurologic abnormalities. Neuromuscular disorders associated with vitamin E deficiency are mostly of the neuropathic and myopathic type [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/31\">",
"     31",
"    </a>",
"    ]. The neuropathy generally consists of a spinocerebellar syndrome, with variable involvement of the peripheral nerves. Clinical manifestations include ataxia, hyporeflexia, and loss of proprioceptive and vibratory sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/32\">",
"     32",
"    </a>",
"    ]. A skeletal myopathy and pigmented retinopathy also may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin E deficiency can shorten the lifespan of red blood cells. In premature infants, vitamin E deficiency may cause a hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/33\">",
"     33",
"    </a>",
"    ]. Congenital hemolytic disorders such as thalassemia, sickle cell anemia, glucose-6-phosphate dehydrogenase deficiency (G-6-PD), and spherocytosis may be associated with low vitamin E plasma levels, likely because of increased oxidant stress and antioxidant consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Oral therapy with vitamin E supplementation may be of benefit, but efficacy has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EXCESS AND TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term effects and the safety of vitamin E supplementation are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/39\">",
"     39",
"    </a>",
"    ]. Most studies suggest that doses of vitamin E supplementation in doses of 100 to 400 IU per day are safe for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/11\">",
"     11",
"    </a>",
"    ]. However, other reports caution against the use of higher doses. One study, for example, found a higher evidence of mortality due to hemorrhagic strokes in vitamin E supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/8\">",
"     8",
"    </a>",
"    ]. Other studies caution against the use of vitamin E in patients with an increased propensity to bleeding or those taking oral anticoagulants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Animal models have demonstrated impaired absorption of fat-soluble vitamins A and K with large vitamin E supplements. Large oral supplements of vitamin E have been associated with necrotizing enterocolitis in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/40\">",
"     40",
"    </a>",
"    ]. Vitamin E may impair the hematologic response to iron in children with iron-deficiency anemia.",
"   </p>",
"   <p>",
"    A meta-analysis examined the dose-response relationship between vitamin E and overall mortality in a total of 19 randomized clinical trials which included a total of 135,967 participants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/41\">",
"     41",
"    </a>",
"    ]. Doses of vitamin E ranged from 16.5 to 2000",
"    <span class=\"nowrap\">",
"     IU/day",
"    </span>",
"    (median, 400 IU). Vitamin E supplementation with a dose &ge;400",
"    <span class=\"nowrap\">",
"     IU/day",
"    </span>",
"    was associated with a significantly increased risk of all-cause mortality (95% CI 3-74 per 10,000 persons). Thus, patients without special indications should not take vitamin E supplements for disease prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H26#H26\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Vitamin E'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although significant, these findings should be interpreted with some caution since trials of high dose vitamin E were small, and most of these included patients with chronic diseases. Furthermore, there was heterogeneity among the studies that showed an increase in all-cause mortality.",
"   </p>",
"   <p>",
"    Because of concerns about raised risks of bleeding, the Institute of Medicine recommends a Tolerable Upper Intake Level (UL) for vitamin E consumption from supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/4\">",
"     4",
"    </a>",
"    ]. The recommended upper limit is 1000 mg of alpha-tocopherol daily (approximately 1,500 IU of natural source or 1,100 IU of synthetic vitamin E) for adults without fat malabsorption or other cause of vitamin E malabsorption. The UL in children rises from 200 mg daily at 1 to 3 years to 600 mg daily at 9 to 13 years (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"UTD.htm?19/31/19967\">",
"     table 2",
"    </a>",
"    ). Because of increasing evidence showing adverse effects of pharmacologic doses of vitamin E, it is possible that this UL is too high [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. We do not recommend supplementation near this level except when necessary to correct a deficiency state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     THERAPEUTIC ROLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of vitamin E supplementation on cancer, cardiovascular disease, stroke, dementia, and liver disease (such as nonalcoholic fatty liver disease) continue to be evaluated. A benefit of supplementation in cardiovascular disease appears to be unlikely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=see_link\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In premature infants, hemolytic anemia is a common abnormality encountered in the presence of vitamin E deficiency. Vitamin E therapy slightly increases hemoglobin concentrations and reduces the incidence of periventricular hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/43\">",
"     43",
"    </a>",
"    ]. However, the risk of sepsis also was increased with high-dose supplementation, regardless of whether administered by intravenous or oral routes. A few studies suggest some benefit in preventing retinopathy of prematurity, but overall the evidence is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggest some association between development of Alzheimer disease and vitamin E deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/47\">",
"     47",
"    </a>",
"    ]. However, randomized trials suggest that vitamin E supplementation does not affect the risk of cognitive impairment or dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/48\">",
"     48",
"    </a>",
"    ], but a possible role for slowing progression of Alzheimer disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of dementia\", section on 'Vitamin E and selegiline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although controversial, a few studies support potential benefits of vitamin E supplementation in treating cataracts or age-related macular degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/45,49,50\">",
"     45,49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link&amp;anchor=H11#H11\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies suggest benefit in preventing or treating tardive dyskinesia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/51\">",
"     51",
"    </a>",
"    ]. A meta-analysis concluded that it may protect against deterioration of tardive dyskinesia, but probably does not improve symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link&amp;anchor=H28219052#H28219052\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\", section on 'Tardive dyskinesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum vitamin E levels are strongly influenced by concentration of serum lipids, and do not accurately reflect tissue vitamin levels. Therefore, effective vitamin E levels are calculated as the following ratio:",
"   </p>",
"   <p>",
"    Effective serum vitamin E level = Alpha-tocopherol",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    (cholesterol + triglycerides)",
"   </p>",
"   <p>",
"    A normal ratio is &gt;0.8 mg",
"    <span class=\"nowrap\">",
"     alpha-tocopherol/gram",
"    </span>",
"    total lipids.",
"   </p>",
"   <p>",
"    For patients with normal levels of serum lipids, serum alpha-tocopherol levels provide an adequate estimate of vitamin E sufficiency. Alpha-tocopherol levels of less than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     &micro;g/mL,",
"    </span>",
"    or 11.5",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    are considered deficient. In a United States national survey, the 5th percentile for serum levels of vitamin E was 0.62",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (14.3",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and the 25th percentile was 0.79",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (18.5",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28871/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin E (tocopherol) is a fat-soluble vitamin with antioxidant properties; it protects cell membranes from oxidation and destruction. Vitamin E is found in a variety of foods including oils, meat, eggs, and leafy vegetables. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Requirements'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Actions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum vitamin E levels are strongly influenced by concentration of serum lipids, and do not accurately reflect tissue vitamin levels. Effective vitamin E levels are calculated as the ratio of serum alpha-tocopherol per gram total lipids. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absorption of dietary vitamin E requires effective pancreatic exocrine function and fat absorption, unless provided in a synthetic water-soluble form. In addition, a specific protein (alpha-tocopherol transfer protein) is required for effective transport and use. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs and symptoms of vitamin E deficiency include hemolysis, neuromuscular disorders, ataxia, and peripheral neuropathy. Because of an abundance of tocopherols in the human diet, vitamin E deficiency is rare except in individuals with pancreatic insufficiency or other conditions causing substantial fat malabsorption, or protein-energy malnutrition. Vitamin E deficiency also may be caused by rare genetic defects affecting vitamin E metabolism or transport. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No syndrome of acute vitamin E toxicity has been described. In premature infants, high-dose vitamin E treatment was associated with increased risk for sepsis (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Therapeutic roles'",
"      </a>",
"      above). Chronic intake of supplements in excess of 400 IU daily has been associated with increased risk of hemorrhage and all-cause mortality. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Excess and toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients without special indications avoid taking daily supplements containing high doses (&gt;400 IU) of vitamin E&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Excess and toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with severe pancreatic insufficiency or cholestatic liver disease may have vitamin E deficiency due to fat malabsorption. For these individuals, we recommend vitamin E supplementation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Doses of about 25 to 50 int.",
"      <span class=\"nowrap\">",
"       units/kg/day",
"      </span>",
"      are generally effective in children. Alternatively, water miscible vitamin E can be used to maximize absorption, at a dose of 15 to 25 int.",
"      <span class=\"nowrap\">",
"       units/kg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Current evidence does not support a role for vitamin E supplementation in the prevention or treatment of cancers, cardiovascular and cerebrovascular disease, dementia, and retinopathy of prematurity. Weak evidence suggests a possible role in slowing the progression of Alzheimer disease, tardive dyskinesia, and macular degeneration. In premature infants, vitamin E supplementation may reduce the risk of periventricular hemorrhage, but also increases the risk of sepsis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Therapeutic roles'",
"      </a>",
"      above.) See associated topic reviews.",
"     </li>",
"     <li>",
"      There is no evidence that supplementation of vitamin E improves outcomes in healthy children or adults. High-dose supplementation may increase mortality and the risk of hemorrhage. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Therapeutic roles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Excess and toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Traber MG. Vitamin E. In: Modern Nutrition in Health and Disease, Shils M, Olson J, Shike M, et al (Eds), Lippincott, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/2\">",
"      Evans HM. The pioneer history of vitamin E. Vitam Horm 1963; 20:379.",
"     </a>",
"    </li>",
"    <li>",
"     Mason, KE. The first two decades of vitamin E history. In: Vitamin E: A Comprehensive Treatise, Machlin, LJ (Eds), Marcel Dekker, New York 1980. p.1.",
"    </li>",
"    <li>",
"     Food and Nutrition Board of the Institute of Medicine. DRI Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. National Academies Press, Washington DC, 2000. p. 186. Available at: file://books.nap.edu/catalog.php?record_id=9810#toc (Accessed on July 23, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/5\">",
"      Wolf G. How an increased intake of alpha-tocopherol can suppress the bioavailability of gamma-tocopherol. Nutr Rev 2006; 64:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/6\">",
"      Huang HY, Appel LJ. Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. J Nutr 2003; 133:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/7\">",
"      Burton GW, Joyce A, Ingold KU. Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? Arch Biochem Biophys 1983; 221:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/8\">",
"      Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/9\">",
"      Jialal I, Fuller CJ, Huet BA. The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol 1995; 15:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/10\">",
"      Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 273:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/11\">",
"      Stampfer MJ, Rimm EB. Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Am J Clin Nutr 1995; 62:1365S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/12\">",
"      Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A 2000; 97:11494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/13\">",
"      Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. Curr Med Chem 2004; 11:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/14\">",
"      Traber MG, Goldberg I, Davidson E, et al. Vitamin E uptake by human intestinal cells during lipolysis in vitro. Gastroenterology 1990; 98:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/15\">",
"      Nakamura T, Aoyama Y, Fujita T, Katsui G. Studies on tocopherol derivatives: V. Intestinal absorption of several d,1-3,4-3H2-alpha-tocopheryl esters in the rat. Lipids 1975; 10:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/16\">",
"      Cohn JS, McNamara JR, Cohn SD, et al. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988; 29:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/17\">",
"      Cohn W, Loechleiter F, Weber F. Alpha-tocopherol is secreted from rat liver in very low density lipoproteins. J Lipid Res 1988; 29:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/18\">",
"      Yoshida H, Yusin M, Ren I, et al. Identification, purification, and immunochemical characterization of a tocopherol-binding protein in rat liver cytosol. J Lipid Res 1992; 33:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/19\">",
"      Traber MG, Kayden HJ, Green JB, Green MH. Absorption of water-miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats. Am J Clin Nutr 1986; 44:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/20\">",
"      Soltani-Frisk S, Gronowitz E, Andersson H, Strandvik B. Water-miscible tocopherol is not superior to fat-soluble preparation for vitamin E absorption in cystic fibrosis. Acta Paediatr 2001; 90:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/21\">",
"      Winklhofer-Roob BM, van't Hof MA, Shmerling DH. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. Am J Clin Nutr 1996; 63:722.",
"     </a>",
"    </li>",
"    <li>",
"     Feranchak AP, Sokol RJ. Medical and nutritional management of cholestasis in infants and children. In: Liver disease in children, 3rd ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2007. p.213.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/23\">",
"      Sokol RJ, Butler-Simon N, Conner C, et al. Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastroenterology 1993; 104:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/24\">",
"      Kowdley KV. Lipids and lipid-activated vitamins in chronic cholestatic diseases. Clin Liver Dis 1998; 2:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/25\">",
"      Jeffrey GP, Muller DP, Burroughs AK, et al. Vitamin E deficiency and its clinical significance in adults with primary biliary cirrhosis and other forms of chronic liver disease. J Hepatol 1987; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/26\">",
"      Mu&ntilde;oz SJ, Heubi JE, Balistreri WF, Maddrey WC. Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology 1989; 9:525.",
"     </a>",
"    </li>",
"    <li>",
"     Lindor KD, Gershwin ME, Poupon R et al. AASLD Practice Guidelines, Primary Biliary Cirrhosis. Available at: file://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/PrimaryBillaryCirrhosis7-2009.pdf (Accessed on April 25, 2012).",
"    </li>",
"    <li>",
"     Farrell PM. Deficiency states pharmacological effects, and nutrient requirements. In: Vitamin E: A Comprehensive Treatise, Machlin LJ (Ed), Marcel Dekker, New York 1980. p.520.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/29\">",
"      Sokol RJ, Heubi JE, Iannaccone S, et al. Mechanism causing vitamin E deficiency during chronic childhood cholestasis. Gastroenterology 1983; 85:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/30\">",
"      Ben Hamida M, Belal S, Sirugo G, et al. Friedreich's ataxia phenotype not linked to chromosome 9 and associated with selective autosomal recessive vitamin E deficiency in two inbred Tunisian families. Neurology 1993; 43:2179.",
"     </a>",
"    </li>",
"    <li>",
"     Sokol RJ. Vitamin E deficiency and neurological disorders. In: Vitamin E in Health and Disease, Packer L, Fuchs J (Eds), Marcel Dekker, New York 1993. p.815.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/32\">",
"      Kumar N. Nutritional neuropathies. Neurol Clin 2007; 25:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/33\">",
"      Oski FA, Barness LA. Vitamin E deficiency: a previously unrecognized cause of hemolytic anemia in the premature infant. J Pediatr 1967; 70:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/34\">",
"      Natta C, Machlin L. Plasma levels of tocopherol in sickle cell anemia subjects. Am J Clin Nutr 1979; 32:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/35\">",
"      Ray D, Deshmukh P, Goswami K, Garg N. Antioxidant vitamin levels in sickle cell disorders. Natl Med J India 2007; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/36\">",
"      Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006; 135:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/37\">",
"      Rachmilewitz EA, Shifter A, Kahane I. Vitamin E deficiency in beta-thalassemia major: changes in hematological and biochemical parameters after a therapeutic trial with alpha-tocopherol. Am J Clin Nutr 1979; 32:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/38\">",
"      Jaja SI, Aigbe PE, Gbenebitse S, Temiye EO. Changes in erythrocytes following supplementation with alpha-tocopherol in children suffering from sickle cell anaemia. Niger Postgrad Med J 2005; 12:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/39\">",
"      Hathcock JN. Vitamins and minerals: efficacy and safety. Am J Clin Nutr 1997; 66:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/40\">",
"      Finer NN, Peters KL, Hayek Z, Merkel CL. Vitamin E and necrotizing enterocolitis. Pediatrics 1984; 73:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/41\">",
"      Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/42\">",
"      Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012; 3:CD007176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/43\">",
"      Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003; :CD003665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/44\">",
"      Bieri JG, Corash L, Hubbard VS. Medical uses of vitamin E. N Engl J Med 1983; 308:1063.",
"     </a>",
"    </li>",
"    <li>",
"     Trevithick, JR, Robertson, JM, Mitton, KP. Vitamin E and the eye. In: Vitamin E in Health and Disease, Packer, L, Fuchs, J (Eds), Marcel Dekker, New York 1993. p.873.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/46\">",
"      Tasman W, Patz A, McNamara JA, et al. Retinopathy of prematurity: the life of a lifetime disease. Am J Ophthalmol 2006; 141:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/47\">",
"      Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 2000; 71:630S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/48\">",
"      Tabet N, Birks J. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 2000; :CD002854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/49\">",
"      Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001; 119:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/50\">",
"      Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2006; :CD000254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/51\">",
"      Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28871/abstract/52\">",
"      Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001; :CD000209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2582 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-FD3AE0A3B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28871=[""].join("\n");
var outline_f28_12_28871=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHEMISTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26561062\">",
"      Healthy population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26561069\">",
"      Cholestatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EXCESS AND TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      THERAPEUTIC ROLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2582|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/15/12541\" title=\"table 1\">",
"      Clinical symptoms of selected vitamin deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/31/19967\" title=\"table 2\">",
"      Fat sol vit DRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=related_link\">",
"      Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=related_link\">",
"      Natural history and management of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_12_28872="Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients";
var content_f28_12_28872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28872/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28872/contributors\">",
"     Christine Johnston, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28872/contributors\">",
"     Anna Wald, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28872/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28872/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28872/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28872/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/12/28872/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6231103\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 2 (HSV���2) is the leading cause of genital ulcer disease (GUD) worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. HIV-infected persons have a higher prevalence of HSV-2 infection, an increased risk of asymptomatic HSV genital shedding, and may have unusual clinical manifestations of HSV-2-related disease compared with HSV-2-seropositive patients who are HIV-uninfected.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, clinical manifestations and diagnosis of HSV-2 infection in the HIV-infected host. The treatment of genital HSV in the HIV-infected host and the viral interactions between HIV and HSV-2 are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29016?source=see_link\">",
"     \"Effect of herpes simplex virus on HIV infection: Implications for HIV prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41799?source=see_link\">",
"     \"Treatment of genital herpes simplex virus type 2 in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34024?source=see_link\">",
"     \"Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H970262\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical designations of genital HSV infection are: primary, nonprimary first episode, and recurrent or reactivation disease (",
"    <a class=\"graphic graphic_table graphicRef80693 \" href=\"UTD.htm?9/63/10235\">",
"     table 1",
"    </a>",
"    ). Among patients presenting with first episode of genital herpes, both virologic and serologic information is needed to accurately define the category of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H970224\">",
"    <span class=\"h2\">",
"     Primary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infection refers to HSV infection in a patient without preexisting antibodies to either HSV-1 or HSV-2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H970231\">",
"    <span class=\"h2\">",
"     Nonprimary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonprimary first episode infection refers to the acquisition of genital HSV-1 in a patient with preexisting antibodies to HSV-2 or the acquisition of genital HSV-2 in a patient with preexisting antibodies to HSV-1. Most HIV-infected adults with a first episode HSV infection have nonprimary infection because of prior exposure to HSV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H970361\">",
"    <span class=\"h2\">",
"     Reactivation disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral treatment during newly acquired infection lessens morbidity, but does not eradicate latent virus, which can subsequently reactivate in immunocompetent or immunocompromised hosts. Patients with a new diagnosis of HSV-2 infection should be counseled to expect recurrence of genital ulcers. In addition, a substantial proportion of patients seen with their first clinical episode of genital herpes actually have recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392163\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies demonstrate that HSV���2 seroprevalence is disproportionately higher among HIV���infected persons compared with HIV-seronegative persons with comparable demographic and behavioral risk factors for HSV-2 acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Additional studies conducted around the world show increased HSV-2 seroprevalence in HIV infected persons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a surveillance study of 3280 Peruvian men who have sex with men (MSM), a significantly greater proportion of HIV-seropositive men were coinfected with HSV-2 compared with HIV-seronegative men (81 versus 41 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in a cohort of 300 women in the Central African Republic, a significantly greater proportion of HIV-infected women were HSV-2-seropositive compared with HIV-seronegative women (91 versus 78 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective cohort of 700 HIV-infected persons in the United States, 60 percent of HIV-infected persons were HSV-2-seropositive, a figure that is threefold higher than among the general US population [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392466\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H744885\">",
"    <span class=\"h2\">",
"     Clinical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of HSV-2 infection is altered among patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/16\">",
"     16",
"    </a>",
"    ]. Among HSV-2 seropositive patients, concomitant HIV infection is associated with [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased frequency and severity of HSV-2 reactivation disease",
"     </li>",
"     <li>",
"      Atypical clinical manifestations of HSV-2 reactivation episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among immunocompetent hosts, an average of four recurrences will occur during the first year after acquisition; recurrent genital lesions generally resolve within a median of four days with antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/22\">",
"     22",
"    </a>",
"    ]. In comparison with HIV-seronegative persons, genital HSV-2 recurrences in HIV-infected patients are more frequent and the episodes are of longer duration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Persistent, non-healing lesions caused by HSV-2 are more common in patients with advanced immunosuppression (eg, CD4 cell counts less than 100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/17,24\">",
"     17,24",
"    </a>",
"    ], supporting the importance of cell-mediated immunity in controlling genital herpes. In addition, severe genital ulcers are associated with impaired HSV���specific CD8+ cytotoxic T-cell responses in HIV���infected persons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6231117\">",
"     'Ulcerative disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H744892\">",
"    <span class=\"h2\">",
"     Viral shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV���2 is detected frequently from mucosal genital surfaces in the absence of genital ulcerative disease, referred to as &ldquo;subclinical shedding&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. HSV���2 shedding is more frequent among HIV���infected men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/25\">",
"     25",
"    </a>",
"    ] and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/19,30\">",
"     19,30",
"    </a>",
"    ] compared with HIV���seronegative persons. Among HIV-infected patients, the risk of HSV-2 shedding, as measured by polymerase chain reaction (PCR), is approximately six-fold greater among those patients with CD4 cell counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/31\">",
"     31",
"    </a>",
"    ]. Increased rates of HSV-2 detection in the genital tract, using culture-based methods, are associated with higher plasma HIV���1 RNA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29016?source=see_link\">",
"     \"Effect of herpes simplex virus on HIV infection: Implications for HIV prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13152652\">",
"    <span class=\"h2\">",
"     Effect of antiretroviral therapy on HSV-2-related disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small observational studies report conflicting results as to whether antiretroviral therapy (ART) ameliorates HSV-related ulcers and viral shedding among HIV-infected patients with immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/8,33,34\">",
"     8,33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 77 HIV���infected persons with recurrent disease, ART was associated with fewer days with genital ulceration (3 percent versus 11 percent of days); however, no significant change in the frequency or quantity of HSV���2 shedding was seen [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Women&rsquo;s Interagency HIV Study (WIHS), the frequency of genital ulcers did not change with the initiation of ART; genital HSV-2 shedding was not measured [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11525287\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the HIV-infected patient usually presents with HSV-related reactivation disease; the clinical manifestations are influenced by the patient&rsquo;s current and prior immunologic status, as evidenced by CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H970262\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6231117\">",
"    <span class=\"h2\">",
"     Ulcerative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with well-controlled HIV disease, HSV-2-related genital ulcerations may range from asymptomatic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/25,29,35\">",
"     25,29,35",
"    </a>",
"    ] to typical shallow, erosive genital lesions approximately 2 to 7 millimeters in size. Symptoms of genital ulcers can include pain, tingling, and pruritis. Patients with ulcers near the urethra may complain of external dysuria. Others may have only subclinical shedding of virus without any mucocutaneous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the patient with AIDS, deep genital or perianal ulcerations or fissures have been described, which can be quite painful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/25,26,36\">",
"     25,26,36",
"    </a>",
"    ]. In the era prior to ART, chronic expanding ulcerative perianal lesions associated with HSV-2 infection were commonly observed among patients with severe immunosuppression (eg, CD4 counts &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/17,37\">",
"     17,37",
"    </a>",
"    ]. Of note, persistent mucocutaneous HSV-2-related ulcers lasting greater than one month were among the first opportunistic infections to be classified as an AIDS-defining event (",
"    <a class=\"graphic graphic_picture graphicRef81569 \" href=\"UTD.htm?8/25/8596\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/26,36,38\">",
"     26,36,38",
"    </a>",
"    ]. These patients often had fever and weight loss related to other concomitant opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6231124\">",
"    <span class=\"h2\">",
"     Hypertrophic masses and pseudotumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical manifestations of HSV-2 infection described in HIV-infected patients include hypertrophic masses, pseudotumors, nodular, or plaque-like lesions, which may be mistaken for squamous cell carcinoma of the vulva, scrotum, or other malignancies (",
"    <a class=\"graphic graphic_picture graphicRef63362 \" href=\"UTD.htm?8/57/9111\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/18,26,39-45\">",
"     18,26,39-45",
"    </a>",
"    ]. Hypertrophic lesions are often observed among patients with advanced immunodeficiency (eg, CD4 counts &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </span>",
"    This type of lesion can also be seen in a patient with a history of recurrent herpes and a low nadir CD4 cell count, despite ART-associated improvements in CD4 cell counts and HIV RNA suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/18,26,45\">",
"     18,26,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertrophic lesions may also be found in ectopic locations including the orofacial area or the endobronchial tree [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/18,46,47\">",
"     18,46,47",
"    </a>",
"    ]. Genital HSV���2 lesions mimicking condyloma acuminata secondary to human papillomavirus infection have also been described (",
"    <a class=\"graphic graphic_picture graphicRef75196 \" href=\"UTD.htm?14/45/15058\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6231138\">",
"    <span class=\"h2\">",
"     Other unusual manifestations of HSV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;More serious clinical presentations of HSV reactivation include esophagitis, tracheitis, meningoencephalitis, hepatitis, pneumonitis, retinal necrosis, and disseminated disease, which are rare among HIV-seropositive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, herpetic lesions in atypical locations, such as the back, face or fingers (paronychia) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/37\">",
"     37",
"    </a>",
"    ] do occur and thus HSV should be considered in the differential of cutaneous lesions outside of the genital area.",
"   </p>",
"   <p>",
"    Severe genital ulcers may occur in patients starting on antiretroviral therapy as part of the Immune Reconstitution Inflammatory Response (IRIS). The prevalence of IRIS and its implications for treatment of HIV and HSV are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41799?source=see_link&amp;anchor=H4856507#H4856507\">",
"     \"Treatment of genital herpes simplex virus type 2 in HIV-infected patients\", section on 'Immune reconstitution syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6231152\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of genital herpes infection should be confirmed with diagnostic testing; this is particularly true in the HIV-infected individual where the clinical manifestations of disease may be altered. The diagnostic approach is similar to that in the HIV-seronegative patient [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/23\">",
"     23",
"    </a>",
"    ]. Techniques include viral culture, polymerase chain reaction (PCR), and type-specific serologic tests. Occasionally, a biopsy may be required, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11525273\">",
"    <span class=\"h2\">",
"     Ulcerative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell culture and PCR-based testing are commonly used for a patient presenting with active lesions. Although both culture and PCR can determine the type of genital herpes (HSV-1 or HSV-2), PCR-based testing has greater overall sensitivity than culture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/23\">",
"     23",
"    </a>",
"    ]. The diagnostic yield of either test is highest when the sample is taken from the base of a ruptured vesicle; diagnosis accuracy declines rapidly as the lesion heals. Serologic testing may be the preferred diagnostic test in patients with healing or small atypical lesions.",
"   </p>",
"   <p>",
"    Serologic testing performance appears to vary by assay; caution is suggested in interpreting low positive results, as false positive tests can occur in both HIV-positive and HIV-negative persons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details on the performance of these various tests are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H24#H24\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11525280\">",
"    <span class=\"h2\">",
"     Hypertrophic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high index of suspicion for HSV���2 infection is needed in patients with pseudotumors or hypertrophic lesions, which can be mistaken for papillomatous lesions or other genital pathology. Surface samples of the lesion should be sent for PCR testing; if PCR testing is not available, a viral culture may be sent. If laboratory testing is not informative, the lesion should be biopsied for examination for viral inclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/26\">",
"     26",
"    </a>",
"    ]. Histologically, these tumors may be characterized by pseudoepitheliomatous hyperplasia, which may be difficult to differentiate from squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/41,44,45\">",
"     41,44,45",
"    </a>",
"    ]. Dermatologic consultation is advised if the diagnosis is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12678014\">",
"    <span class=\"h2\">",
"     Patients with a recent history of genital disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing may also be helpful in the patient with a history of recent genital ulcers who does not have any clinical findings on examination; antibodies to HSV-2 usually develop within 12 weeks after newly acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/52\">",
"     52",
"    </a>",
"    ]. Caution is suggested in interpreting low titer positive results, as false positive tests can occur in both HIV-infected and HIV-uninfected persons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/51\">",
"     51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Routine serologic screening for HSV-2 in the asymptomatic patient is discussed below. (See",
"    <a class=\"local\" href=\"#H11524735\">",
"     'Screening for HSV-2 infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11524576\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-2 is the leading cause of genital ulcer disease in both HIV-infected [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/53\">",
"     53",
"    </a>",
"    ] and HIV-uninfected persons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/1,54\">",
"     1,54",
"    </a>",
"    ]. The differential diagnosis of genital ulcerative disease, regardless of HIV status, includes other sexually transmitted diseases, such as syphilis and chancroid.",
"   </p>",
"   <p>",
"    Painful ulcers tend to be more typical of HSV and chancroid, while ulcers associated with syphilis, lymphogranuloma venereum (LGV), and granuloma inguinale are usually painless. HSV-related ulcers are also usually recurrent by history. However, a clinical diagnosis made solely on these distinctions may be misleading, emphasizing the importance of laboratory testing. Noninfectious etiologies include fixed drug reactions, Beh&ccedil;et&rsquo;s disease, neoplasms, and trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the patient with genital ulcers\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine diagnostic evaluation of a patient with genital ulcers includes HSV culture or PCR testing for HSV and a screening test for syphilis, such as a rapid plasma reagin (RPR). The decision to test for chancroid will be influenced by epidemiologic risk factors, such as travel to an endemic area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the patient with genital ulcers\", section on 'General diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with atypical manifestations or hypertrophic lesions or masses, the differential diagnosis is broad and includes a variety of dermatologic disorders of the genital skin and mucosa, such as HPV infection. Malignancy must also be considered in the differential diagnosis, since cancer is an increasing cause of morbidity and mortality among HIV-infected patients in the era of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/55\">",
"     55",
"    </a>",
"    ]. If treatment of documented HSV infection does not lead to resolution, drug-resistant HSV or an alternative diagnosis must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/56\">",
"     56",
"    </a>",
"    ]. Dermatologic consultation and a skin biopsy may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11524735\">",
"    <span class=\"h1\">",
"     SCREENING FOR HSV-2 INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high prevalence of HSV���2 in HIV���infected individuals, screening for HSV���2 infection using HSV type���specific serology is suggested by some experts in all HIV���infected persons, including those who are asymptomatic, since they may be at risk for subclinical genital shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/57\">",
"     57",
"    </a>",
"    ]. Such information can be used for counseling, particularly if the patient has a sex partner who is HSV-2-seronegative. Although viral suppression with antiviral agents decreases transmission of HSV to HSV-seronegative sex partners, such an approach has not been evaluated among HIV-infected persons with HSV-2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Risk of transmission to uninfected partner'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the HIV-infected patient is HSV-2-seronegative, the patient should ask his or her partner to be tested for HSV-2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/57\">",
"     57",
"    </a>",
"    ]. If the partner is HSV-2 seropositive, consistent use of condoms and antiviral suppressive therapy in the HSV-2-seropositive partner can reduce the risk of HSV-2 transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28872/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of genital herpes virus infections\", section on 'Chronic suppressive therapy in discordant couples'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6231095\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpes simplex virus type 2 (HSV���2) is the leading cause of genital ulcer disease (GUD) worldwide. (See",
"      <a class=\"local\" href=\"#H6231103\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical designations of genital HSV infection are: primary, nonprimary first episode, and recurrent or reactivation disease. Nonprimary first episode infection refers to the acquisition of genital HSV-1 in a patient with preexisting antibodies to HSV-2 or the acquisition of genital HSV-2 in a patient with preexisting antibodies to HSV-1 (eg, an individual with prior orolabial herpes and an HSV-1 antibody response develops genital herpes due to acquisition of HSV-2 infection). Most HIV-infected adults with a first episode HSV infection have nonprimary infection because of prior exposure to HSV-1. (See",
"      <a class=\"local\" href=\"#H970262\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiviral treatment during newly acquired infection lessens morbidity, but does not eradicate latent virus, which can subsequently reactivate in immunocompetent or immunocompromised hosts. (See",
"      <a class=\"local\" href=\"#H970361\">",
"       'Reactivation disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic studies demonstrate that HSV���2 seroprevalence is disproportionately higher among HIV���infected persons compared with HIV-seronegative persons. (See",
"      <a class=\"local\" href=\"#H2392163\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of HSV-2 infection is altered among patients with HIV infection. Among HSV-seropositive patients, concomitant HIV infection is associated with increased frequency and severity of genital ulcers. Advanced immunosuppression is associated with an increased risk of persistent non-healing ulcers and higher rates of subclinical viral shedding, which increases the risk of HSV-2 transmission. (See",
"      <a class=\"local\" href=\"#H2392466\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of HSV-2 infection vary according to the patient&rsquo;s immunologic status. Genital ulcerations may range from unnoticed ulcers to typical herpetic lesions in the patient with well-controlled HIV infection to large, deep genital or perianal ulcerations in persons with advanced AIDS. Atypical presentations include pseudotumors or hypertrophic masses. (See",
"      <a class=\"local\" href=\"#H11525287\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical diagnosis of genital herpes infection should be confirmed with diagnostic laboratory testing; this is particularly true in the HIV-infected individual where the clinical manifestations of disease may be altered. The diagnostic approach is similar to that in the HIV-seronegative patient. Techniques include: polymerase chain reaction (PCR), viral culture, and type-specific serologic tests. The choice of test will vary depending on the clinical presentation. (See",
"      <a class=\"local\" href=\"#H6231152\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine HSV-2 serologic testing is helpful for patient counseling regarding risk of HSV-2 acquisition or transmission to an HSV-2-seronegative partner. (See",
"      <a class=\"local\" href=\"#H11524735\">",
"       'Screening for HSV-2 infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/1\">",
"      Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/2\">",
"      Nilsen A, Kasubi MJ, Mohn SC, et al. Herpes simplex virus infection and genital ulcer disease among patients with sexually transmitted infections in Dar es Salaam, Tanzania. Acta Derm Venereol 2007; 87:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/3\">",
"      Brankin AE, Tobian AA, Laeyendecker O, et al. Aetiology of genital ulcer disease in female partners of male participants in a circumcision trial in Uganda. Int J STD AIDS 2009; 20:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/4\">",
"      Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/5\">",
"      Sanchez J, Volquez C, Totten PA, et al. The etiology and management of genital ulcers in the Dominican Republic and Peru. Sex Transm Dis 2002; 29:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/6\">",
"      Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/hiv/surveillance/resources/reports/2009report/ (Accessed on January 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/8\">",
"      Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006; 20:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/9\">",
"      Rabenau HF, Lennemann T, Kircher C, et al. Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho. Sex Transm Dis 2010; 37:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/10\">",
"      Boulos R, Ruff AJ, Nahmias A, et al. Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type I infections. The Johns Hopkins University (JHU)/Centre pour le Developpement et la Sant&eacute; (CDS) HIV Study Group. J Infect Dis 1992; 166:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/11\">",
"      Romanowski B, Myziuk LN, Walmsley SL, et al. Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis 2009; 36:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/12\">",
"      Gwanzura L, McFarland W, Alexander D, et al. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J Infect Dis 1998; 177:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/13\">",
"      Lama JR, Lucchetti A, Suarez L, et al. Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru. J Infect Dis 2006; 194:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/14\">",
"      Mbopi-K&eacute;ou FX, Gr&eacute;senguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/15\">",
"      Patel P, Bush T, Mayer KH, et al. Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. Sex Transm Dis 2012; 39:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/16\">",
"      Schacker T. The role of HSV in the transmission and progression of HIV. Herpes 2001; 8:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/17\">",
"      Bagdades EK, Pillay D, Squire SB, et al. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS 1992; 6:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/18\">",
"      Cury K, Valin N, Gozlan J, et al. Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient. Sex Transm Dis 2010; 37:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/19\">",
"      Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995; 123:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/20\">",
"      DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/21\">",
"      Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/22\">",
"      Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996; 156:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/23\">",
"      Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/24\">",
"      Aumakhan B, Gaydos CA, Quinn TC, et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010; 5:e9973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/25\">",
"      Schacker T, Zeh J, Hu HL, et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/26\">",
"      Mosunjac M, Park J, Wang W, et al. Genital and perianal herpes simplex simulating neoplasia in patients with AIDS. AIDS Patient Care STDS 2009; 23:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/27\">",
"      Posavad CM, Koelle DM, Shaughnessy MF, Corey L. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 1997; 94:10289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/28\">",
"      Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/29\">",
"      Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/30\">",
"      Mbopi Keou FX, Gr&eacute;senguet G, Mayaud P, et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 1999; 13:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/31\">",
"      Mostad SB, Kreiss JK, Ryncarz A, et al. Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. Am J Obstet Gynecol 2000; 183:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/32\">",
"      Wright PW, Hoesley CJ, Squires KE, et al. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis 2003; 36:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/33\">",
"      Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004; 190:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/34\">",
"      Mayaud P, Nagot N, Konat&eacute; I, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect 2008; 84:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/35\">",
"      Sandlin MI, Johnston C, Bowe D, et al. Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men. Sex Transm Dis 2011; 38:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/36\">",
"      Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981; 305:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/37\">",
"      Mindel A, Carney O, Williams P. Cutaneous herpes simplex infections. Genitourin Med 1990; 66:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/38\">",
"      1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/39\">",
"      Yudin MH, Kaul R. Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy. Infect Dis Obstet Gynecol 2008; 2008:592532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/40\">",
"      Maharaj R, Parboosing R, Moodley M, et al. An unusual hypertrophic genital mass lesion--a diagnostic and treatment dilemma. J Clin Virol 2009; 46:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/41\">",
"      Frimer M, Chudnoff S, Hebert T, Shahabi S. Pseudoepitheliomatous hyperplasia mimicking vulvar cancer in a patient with AIDS. J Low Genit Tract Dis 2011; 15:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/42\">",
"      Boothby M, Radcliffe K. An unusual vulval lesion in an HIV-infected woman. Int J STD AIDS 2007; 18:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/43\">",
"      Lautenschlager S, Schwarzkopf S, Keller B. Exophytic ulcerated tumors in HIV patients: diagnostic and therapeutic problems. Dermatology 2008; 216:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/44\">",
"      Samaratunga H, Weedon D, Musgrave N, McCallum N. Atypical presentation of herpes simplex (chronic hypertrophic herpes) in a patient with HIV infection. Pathology 2001; 33:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/45\">",
"      Ranu H, Lee J, Chio M, Sen P. Tumour-like presentations of anogenital herpes simplex in HIV-positive patients. Int J STD AIDS 2011; 22:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/46\">",
"      Husak R, Tebbe B, Goerdt S, et al. Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient. Br J Dermatol 1998; 139:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/47\">",
"      Plowman GM, Watson MW, D'Souza H, Thomas MG. Obstructive endo-bronchial pseudotumour due to herpes simplex type 2 infection in an HIV-infected man. Int J STD AIDS 2009; 20:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/48\">",
"      Tong P, Mutasim DF. Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease. Br J Dermatol 1996; 134:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/49\">",
"      Baras L, Farber CM, Van Vooren JP, Parent D. Herpes simplex virus tracheitis in a patient with the acquired immunodeficiency syndrome. Eur Respir J 1994; 7:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/50\">",
"      Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. Drugs 2007; 67:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/51\">",
"      Safrin S, Arvin A, Mills J, Ashley R. Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS. J Clin Microbiol 1992; 30:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/52\">",
"      Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003; 30:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/53\">",
"      Ahmed HJ, Mbwana J, Gunnarsson E, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. Sex Transm Dis 2003; 30:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/54\">",
"      Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect 2007; 83:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/55\">",
"      Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011; 117:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/56\">",
"      Green T, Rogstad KE, Paterson ME. Genital herpes may mask underlying neoplasia. Sex Transm Infect 2001; 77:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/57\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28872/abstract/58\">",
"      Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16254 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28872=[""].join("\n");
var outline_f28_12_28872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6231095\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6231103\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H970262\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H970224\">",
"      Primary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H970231\">",
"      Nonprimary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H970361\">",
"      Reactivation disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2392163\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2392466\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H744885\">",
"      Clinical disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H744892\">",
"      Viral shedding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13152652\">",
"      Effect of antiretroviral therapy on HSV-2-related disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11525287\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6231117\">",
"      Ulcerative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6231124\">",
"      Hypertrophic masses and pseudotumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6231138\">",
"      Other unusual manifestations of HSV disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6231152\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11525273\">",
"      Ulcerative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11525280\">",
"      Hypertrophic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12678014\">",
"      Patients with a recent history of genital disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11524576\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11524735\">",
"      SCREENING FOR HSV-2 INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6231095\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16254\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16254|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/25/8596\" title=\"picture 1\">",
"      Severe mucosal HSV-2 ulceration in an HIV woman",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/57/9111\" title=\"picture 2\">",
"      Hypertrophic lesion due to HSV-2 in an HIV-infected woman",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/45/15058\" title=\"picture 3\">",
"      HSV-2 lesion mimicking condyloma accuminata in HIV patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16254|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/63/10235\" title=\"table 1\">",
"      Designation of genital HSV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29016?source=related_link\">",
"      Effect of herpes simplex virus on HIV infection: Implications for HIV prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=related_link\">",
"      Prevention of genital herpes virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34024?source=related_link\">",
"      Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41799?source=related_link\">",
"      Treatment of genital herpes simplex virus type 2 in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_12_28873="Surgical principles of ostomy construction";
var content_f28_12_28873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical principles of ostomy construction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28873/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28873/contributors\">",
"     Todd D Francone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28873/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28873/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28873/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28873/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/12/28873/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21064825\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical principles for the construction of an ostomy, including indications, site selection, and technical insights to decrease the risk of complications (eg, prolapse, herniation) are reviewed here. The types of ostomies, routine management, and the management of ostomy complications are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link\">",
"     \"Management of patients with a colostomy or ileostomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link\">",
"     \"Parastomal hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21062978\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ostomy is indicated when restoration of intestinal continuity is contraindicated or not feasible. A clear understanding of the desired role of the ostomy (eg, temporary or permanent) will help determine the type (eg, loop or end) and location (eg, colon or ileum) of the stoma. As an example, patients who are at high risk of anastomotic leaks (eg, severely malnourished, immunosuppressed, low anterior resection with anastomosis below the dentate line) or hemodynamically unstable (eg, trauma, septic) may benefit from a temporary ostomy until continuity of bowel can be restored safely.",
"   </p>",
"   <p>",
"    Clinical settings appropriate for a temporary ostomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large bowel obstruction",
"     </li>",
"     <li>",
"      Colonic stricture",
"     </li>",
"     <li>",
"      Rectovaginal fistula",
"     </li>",
"     <li>",
"      Fecal incontinence",
"     </li>",
"     <li>",
"      Penetrating rectal injuries",
"     </li>",
"     <li>",
"      Penetrating colon injuries",
"     </li>",
"     <li>",
"      Complex perianal fistulas",
"     </li>",
"     <li>",
"      Fecal peritonitis",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Severe/destructive",
"      </span>",
"      injury of the colon or rectum following penetrating trauma",
"     </li>",
"     <li>",
"      High risk of anastomotic leak",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical settings that warrant construction of a permanent ostomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal perineal resection for rectal cancer",
"     </li>",
"     <li>",
"      Total abdominal proctocolectomy for severe Crohn&rsquo;s colitis",
"     </li>",
"     <li>",
"      Total abdominal proctocolectomy for severe ulcerative colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21062994\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative counseling and education with a skilled enterostomal nurse therapist and site selection for optimal placement of the ostomy are the key components of preoperative preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063003\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients undergoing elective construction of a stoma, preoperative counseling by an enterostomal therapist improves the quality of life by helping patients psychologically adapt to the significant lifestyle changes associated with living with a stoma. Patients experience physical, psychological, and emotional stress, often related to misconceptions and fears regarding sexuality, social acceptance, and economic burden [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Counseling also includes stoma site selection, preoperative and postoperative technical advice, emotional support, discharge planning, outpatient follow-up, and ongoing rehabilitation care for the patient and family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to improved overall quality of life, preoperative counseling is associated with decreased stoma-related postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], improved post-operative patient stoma proficiency, and earlier discharge from the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063010\">",
"    <span class=\"h2\">",
"     Site selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper site selection is important for minimizing postoperative complications and for achieving a good quality of life. Typically, the site is selected with the assistance of an enterostomal nurse, the surgeon, and the patient. Factors to consider in relation to stoma placement include abdominal wall contour (sitting and standing), prior abdominal incisions, bony prominences, occupation, clothing style (belt line), disability, and physical limitations.",
"   </p>",
"   <p>",
"    These general principles are followed when identifying an acceptable ostomy site:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ostomy should lie on either side of the abdominal midline, just lateral and inferior to the umbilicus. Often, a site is selected that overlays the rectus abdominis muscle, which can provide additional support and stability for the stoma.",
"     </li>",
"     <li>",
"      The patient must be able to visualize the stoma and access it without difficulty. In the morbidly obese, the stoma often must sit higher on the abdominal wall (above the umbilicus) to avoid increased abdominal girth in the lower abdominal wall and poor visualization.",
"     </li>",
"     <li>",
"      The ostomy placement must be at least 5 cm from all folds, creases, previous incisions, belt line, umbilicus, and bony prominences because these can interfere with appliance adherence. This is particularly important in patients who are morbidly obese or who have had prior abdominal surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonoptimal stoma placement increases risk of complications and worsens quality of life. (See",
"    <a class=\"local\" href=\"#H532626\">",
"     'Inappropriate stoma site'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063025\">",
"    <span class=\"h1\">",
"     TECHNICAL INSIGHTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stoma is essentially an anastomosis of the intestine to the anterior abdominal wall skin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/6\">",
"     6",
"    </a>",
"    ]. Construction of an ostomy should always utilize healthy, well-vascularized bowel, and, if needed, the limb of bowel should be adequately mobilized to ensure a tension-free approximation to the abdominal wall.",
"   </p>",
"   <p>",
"    Selection of the appropriate intestinal segment is determined by several factors, including age, co-morbidities, body habitus, and whether permanent or temporary fecal diversion is desired [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, attention to technical detail while maturing the ostomy is essential in creating an appropriate well-formed stoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063032\">",
"    <span class=\"h2\">",
"     Aperture size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate size of the aperture in the abdominal wall can be difficult to judge. Large apertures are a risk factor for parastomal hernias, while small apertures can result in ischemia, stricture, stomal outlet obstruction strictures, or stomal necrosis.",
"   </p>",
"   <p>",
"    The skin and fascial openings should be large enough to extract the selected intestine through the abdominal wall without occlusion of the mesenteric vessels and intestinal lumen (",
"    <a class=\"graphic graphic_figure graphicRef79596 \" href=\"UTD.htm?43/5/44114\">",
"     figure 1",
"    </a>",
"    ). A 2 cm vertical or cruciate incision (&ldquo;plus sign&rdquo;) is made in the anterior rectus fascia. The author prefers a 2 cm vertical incision that minimizes fascial disruption and allows two-finger breadths to pass snugly (",
"    <a class=\"graphic graphic_figure graphicRef68865 \" href=\"UTD.htm?31/25/32147\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063039\">",
"    <span class=\"h2\">",
"     Stomal fixation to the fascia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal fixation to the fascia is optional. One approach is to place absorbable sutures transabdominally from the posterior fascia or peritoneum to the seromuscular layer of the bowel, effectively fixing the limb to the abdominal wall. However, this technique does not reduce the risk of stomal herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/8\">",
"     8",
"    </a>",
"    ] or prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/9\">",
"     9",
"    </a>",
"    ] compared to stomas that were not fixed to the fascia. In the absence of data to support this technique, the author does not fix the stoma to the fascia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063046\">",
"    <span class=\"h2\">",
"     Closure of the lateral space",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixation of the ileal or colonic mesentery to the abdominal lateral sidewall in order to close the lateral sulcus has been suggested as a means for preventing the rare complication of a volvulus around the stoma limb [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Given the rare occurrence of small bowel obstruction related to a volvulus after stoma construction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/12\">",
"     12",
"    </a>",
"    ], this is not the current practice of the author.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532260\">",
"    <span class=\"h2\">",
"     Maturing the ostomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14009873\">",
"    <span class=\"h3\">",
"     End ostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The segment of intestine to be used for an end ostomy is advanced through the abdominal wall. The abdominal incision is closed and protected from possible spillage while maturing the ostomy.",
"   </p>",
"   <p>",
"    An ileostomy should protrude at least 2 to 3 cm above the abdominal wall after eversion to allow adequate output of its contents into the appliance (",
"    <a class=\"graphic graphic_figure graphicRef72724 \" href=\"UTD.htm?0/31/497\">",
"     figure 3",
"    </a>",
"    ). In contrast, because of a more solid output, colostomies require only a 1 to 2 cm protrusion above the abdominal wall. It is the practice of the author to construct at least a small amount of protrusion for the colostomy to assure adequate ostomy appliance placement and adherence.",
"   </p>",
"   <p>",
"    The technical principles for maturing an end ileostomy or colostomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deliver the end of the small bowel or colon through the abdominal wall (",
"      <a class=\"graphic graphic_figure graphicRef78707 \" href=\"UTD.htm?2/42/2725\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55613 \" href=\"UTD.htm?15/18/15653\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Transect the staple line with electrocautery (",
"      <a class=\"graphic graphic_figure graphicRef61779 \" href=\"UTD.htm?11/63/12274\">",
"       figure 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef67367 \" href=\"UTD.htm?23/33/24085\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Place four absorbable stay sutures equidistant at 12, 3, 6, and 9 o&rsquo;clock to evert the intestine and secure it to the abdominal wall trephine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When constructing an ileostomy, the suture includes the full thickness end of bowel, seromuscular layer of the bowel wall approximately 3 cm proximal to the end, and the dermis of the abdominal wall (",
"      <a class=\"graphic graphic_figure graphicRef82021 \" href=\"UTD.htm?31/24/32130\">",
"       figure 8",
"      </a>",
"      ). When creating a colostomy, the suture includes the full thickness of the end of the colon and the dermis of the abdominal wall (",
"      <a class=\"graphic graphic_figure graphicRef60697 \" href=\"UTD.htm?12/59/13234\">",
"       figure 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tag the sutures with small clamps. Evert the intestine by gently pulling on the sutures, then tie in place. If eversion has not occurred with tying of the sutures, gently push on the seromuscular layer in between sutures to complete the process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place one to two additional sutures in between the originally placed stay sutures, approximating the full thickness distal bowel with the dermis.",
"     </li>",
"     <li>",
"      Place a clear ostomy appliance over the stoma. A clear appliance allows for visual inspection at the bedside.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14009881\">",
"    <span class=\"h3\">",
"     Loop ostomy with a defunctionalized distal limb",
"    </span>",
"    &nbsp;&mdash;&nbsp;A loop ileostomy or loop colostomy can be performed with a defunctionalized distal limb (",
"    <a class=\"graphic graphic_figure graphicRef56828 \" href=\"UTD.htm?35/23/36223\">",
"     figure 10",
"    </a>",
"    ) or as a double barrel ostomy (",
"    <a class=\"graphic graphic_figure graphicRef70912 \" href=\"UTD.htm?39/21/40286\">",
"     figure 11",
"    </a>",
"    ). The defunctionalized distal limb allows for a more efficient stoma with a compressed distal limb and the proximal functioning limb occupies the majority of the abdominal wall aperture. This is the author&rsquo;s preference for both a loop ileostomy and loop colostomy.",
"   </p>",
"   <p>",
"    The segment of intestine to be used for a loop ostomy is advanced through the abdominal wall trephine, using a penrose drain under the bowel loop to facilitate advancement through the aperture. The abdominal incision is closed and protected from possible spillage while maturing the ostomy.",
"   </p>",
"   <p>",
"    The technical principles for maturing a loop ileostomy or colostomy with a defunctionalized distal limb include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pass a Penrose drain around the bowel and gently advance through the abdominal wall, as shown in the figure for exteriorizing the colon (",
"      <a class=\"graphic graphic_figure graphicRef72478 \" href=\"UTD.htm?35/34/36386\">",
"       figure 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pass a 14Fr red rubber catheter through a small opening in the mesentery of the exteriorized intestine, this will replace the Penrose drain used to exterior the loop. The red rubber catheter is shaped in a large loop and secured to itself with 0 silk ties. An alternative to the catheter is a plastic rod (",
"      <a class=\"graphic graphic_figure graphicRef51441 \" href=\"UTD.htm?39/8/40064\">",
"       figure 13",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Transect 80 percent of the circumference of the bowel wall with electrocautery, beginning on the anti-mesenteric wall at the distal-most portion of the descending, or nonfunctional limb (",
"      <a class=\"graphic graphic_figure graphicRef54987 \" href=\"UTD.htm?11/40/11919\">",
"       figure 14",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef66702 \" href=\"UTD.htm?39/63/40958\">",
"       figure 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Secure the distal descending limb to the abdominal wall with three absorbable sutures, tacking the full thickness bowel to the dermis, without everting the distal portion of the loop ostomy (",
"      <a class=\"graphic graphic_figure graphicRef78445 \" href=\"UTD.htm?30/17/31007\">",
"       figure 16",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Secure and evert the proximal functional limb by suturing the full thickness bowel wall to the seromuscular layer 3 cm proximal to the partially transected end with the dermis of the abdominal wall opening (",
"      <a class=\"graphic graphic_figure graphicRef78445 \" href=\"UTD.htm?30/17/31007\">",
"       figure 16",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Four absorbable stay sutures are placed on the antimesenteric border of the bowel at the junction of the proximal and distal limbs of the stoma and secured (not tied) with small clamps.",
"     </li>",
"     <li>",
"      The functional proximal limb should occupy 25 percent of the aperture site.",
"     </li>",
"     <li>",
"      Tie the sutures in place to evert the proximal limb.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place one to two additional sutures in between the originally placed stay sutures, approximating the full thickness distal bowel with the dermis.",
"     </li>",
"     <li>",
"      Place a clear ostomy appliance over the stoma. A clear appliance allows for visual inspection at the bedside. The catheter or rod is removed approximately 7 to 10 days after the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172221585\">",
"    <span class=\"h3\">",
"     Double barrel ostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A double barrel ileostomy or colostomy can be constructed as a loop ostomy with both limbs everted and the back wall intact, or as completely divided proximal and distal limbs that are brought together through the abdominal wall trephine. The resulting ostomies are larger and more cumbersome to manage (eg, leakage) than the loop ostomy with a compressed distal limb. The double barrel ostomy may be preferable in emergent settings as some surgeons find it takes less time to perform.",
"   </p>",
"   <p>",
"    The general principles for constructing a double barrel loop ostomy are similar to the construction of a loop ostomy with a defunctionalized limb and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A longitudinal or circumferential incision can be used to create the opening in the stoma at the apex of the selected limb, with the back wall remaining intact (",
"      <a class=\"graphic graphic_figure graphicRef59093 \" href=\"UTD.htm?8/50/9007\">",
"       figure 17",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Both the proximal and distal limbs are everted (",
"      <a class=\"graphic graphic_figure graphicRef70912 \" href=\"UTD.htm?39/21/40286\">",
"       figure 11",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The bowel is secured to the abdominal wall as described above (see",
"      <a class=\"local\" href=\"#H14009881\">",
"       'Loop ostomy with a defunctionalized distal limb'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      A clear ostomy appliance is placed over the stoma. A clear appliance allows for visual inspection at the bedside. The catheter or rod is removed approximately 7 to 10 days after the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general principles for constructing a double barrel end ostomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bowel is divided with a stapler and the functioning proximal limb and decompressed distal limb are brought through the abdominal wall (",
"      <a class=\"graphic graphic_figure graphicRef68563 \" href=\"UTD.htm?17/52/18243\">",
"       figure 18",
"      </a>",
"      ). One abdominal wall aperture is created for the stoma when no bowel is resected (eg, emergency decompression of an obstruction). The proximal and distal limbs are brought through separate apertures if bowel is resecting between the two ends.",
"     </li>",
"     <li>",
"      The ends are matured and secured to the abdominal wall as previously described (see",
"      <a class=\"local\" href=\"#H14009873\">",
"       'End ostomy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      A clear ostomy appliance is placed over the stoma. A clear appliance allows for visual inspection at the bedside.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4776081\">",
"    <span class=\"h2\">",
"     Technical challenges in obese patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Construction of a protruding, well-vascularized, tension-free stoma in an obese patient with a thick abdominal wall and short, thick mesentery is challenging. Obesity is an independent risk factor for stomal complications, including retraction, skin excoriation, and parastomal hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,6,13,14\">",
"     3,6,13,14",
"    </a>",
"    ]. The following maneuvers will help minimize the risk of complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ileostomy or colostomy is placed in the upper abdomen, above the umbilicus, where the abdominal wall is less thick.",
"     </li>",
"     <li>",
"      Peritoneal attachments should be adequately mobilized, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Completely mobilize the splenic flexure when creating a descending colostomy",
"     </li>",
"     <li>",
"      Transect the medial peritoneal attachments at the base of the colon mesentery",
"     </li>",
"     <li>",
"      Transect the inferior mesenteric artery proximal to the left colonic arterial origin to decrease tethering effect",
"     </li>",
"     <li>",
"      Create peritoneal windows over the colonic mesentery just below the stoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trim the thickened colonic mesentery to ease the passage of the intestine through the abdominal wall, while preserving the marginal artery.",
"     </li>",
"     <li>",
"      Enlarge the trephine aperture in the abdominal wall to ease passage of the intestine, decrease tension, and minimize venous congestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If these steps are unsuccessful, a loop-end stoma can be created. The distal end of the colon is stapled and left in the peritoneal cavity. The anti-mesenteric border of the colon is extracted through an oversized aperture and matured without eversion. Although less than ideal, the patient is provided with a functioning stoma that can be later revised [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4775536\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscopic approach is a safe and effective alternative to a laparotomy for identifying the segment of bowel to be used for an ileostomy or colostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. It is also the preferred approach by the author if construction of a defunctioning stoma is the principle indication for the procedure (eg, emergent relief of a bowel obstruction) and there is an absence of multiple previous surgeries.",
"   </p>",
"   <p>",
"    Advantages of the laparoscopic approach are that it provides excellent anatomic visualization of the abdominal cavity and minimizes the risks and complications of an open procedure. A prospective study included 19 patients undergoing a laparoscopic approach for constructing a stoma and compared their results with historic controls of 23 patients undergoing a laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/18\">",
"     18",
"    </a>",
"    ]. The laparoscopic approach was associated with significantly lower postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    requirements (48 versus 90 mg), earlier time for return of bowel function (2.2 versus 3.6 days), earlier tolerance of solid diet (3.6 versus 5.5 days), and fewer postoperative complications (1 of 19 versus 4 of 23 patients). Conversion rates from a laparoscopy to a laparotomy range from 0 to 16 percent and are mainly related to adhesions from previous surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several techniques have been described, varying in location and number of port sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"     \"Abdominal access techniques used in laparoscopic surgery\"",
"    </a>",
"    .) The author prefers a three-port technique for a loop or end ileostomy. A similar approach is used for sigmoid loop or end colostomy, with the lateral working ports positioned in a mirror image to those placed for a loop ileostomy.",
"   </p>",
"   <p>",
"    Creation of loop ileostomy or loop sigmoid colostomy are preferred since they do not routinely require significant mobilization, except in the presence abdominal or pelvic adhesions or in creating an loop sigmoid ostomy which often requires minimal lateral-to-medial mobilization. A loop stoma is preferred as future reversal is typically straight forward allowing the procedure to be performed locally through the stoma aperture without having to create or re-open an abdominal incision.",
"   </p>",
"   <p>",
"    The following general principles are used in the laparoscopic approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial access to the peritoneal cavity is achieved via a 12 mm port placed at the pre-selected stoma site.",
"     </li>",
"     <li>",
"      The entire abdominal cavity is examined visually. If adhesions limit visibility and accessibility to the segment of bowel to be used for the ostomy, the procedure is converted to a laparotomy.",
"     </li>",
"     <li>",
"      If feasibility is confirmed, two additional 5 mm ports are placed in the suprapubic and left iliac fossa, two fingerbreadths above and two fingerbreadths medial to the anterior superior iliac spine.",
"     </li>",
"     <li>",
"      When creating an end or loop sigmoid ostomy, the bowel is mobilized in the lateral to medial direction, extending from the recto-sigmoid to the mid-descending colon.",
"     </li>",
"     <li>",
"      When creating an end or loop ileostomy, bowel is not routinely mobilized, except in the presence abdominal or pelvic adhesions.",
"     </li>",
"     <li>",
"      The surgeon must verify the correct orientation of the proximal and distal orientation of the intestine by re-establishing the pneumoperitoneum.",
"     </li>",
"     <li>",
"      An adequate abdominal wall aperture must be created for a loop and end ostomy to avoid stoma outlet obstruction.",
"     </li>",
"     <li>",
"      The stoma is matured using the same approaches as previously described (see",
"      <a class=\"local\" href=\"#H21063025\">",
"       'Technical insights'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063053\">",
"    <span class=\"h1\">",
"     PROPHYLACTIC MESH PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of mesh at the time of the ostomy construction is a contemporary option designed to reduce the risk of parastomal herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link\">",
"     \"Parastomal hernia\"",
"    </a>",
"    .) The placement of prosthetic and biologic mesh adjacent to the bowel is associated with low rates of adherence to bowel wall, stenosis, erosion, fistula formation, and peristomal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063060\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approaches for placement of abdominal wall mesh includes the sublay technique (below rectus abdominis muscle, above the posterior rectus sheath) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/21,25-28\">",
"     21,25-28",
"    </a>",
"    ], the onlay technique (above the fascia) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/29\">",
"     29",
"    </a>",
"    ], and the intraperitoneal technique (directly beneath the peritoneum) (",
"    <a class=\"graphic graphic_figure graphicRef82341 \" href=\"UTD.htm?39/17/40210\">",
"     figure 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72219 \" href=\"UTD.htm?2/35/2616\">",
"     figure 20",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The types of mesh available for surgical reconstruction, including synthetic and biologic substitutes, are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of abdominal hernias\", section on 'Types of mesh'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11799?source=see_link&amp;anchor=H5#H5\">",
"     \"Reconstructive materials used in surgery: Classification and host response\", section on 'Types of reconstructive materials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1190264663\">",
"    <span class=\"h3\">",
"     Sublay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles for placement of mesh in the sublay position include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The skin overlying the previously determined ostomy site is excised using a full thickness circular incision.",
"     </li>",
"     <li>",
"      The rectus muscle is split in the direction of its fibers, the posterior rectus sheath is incised, and a plane is developed between the rectus muscle and the posterior rectus sheath (",
"      <a class=\"graphic graphic_figure graphicRef72219 \" href=\"UTD.htm?2/35/2616\">",
"       figure 20",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A circular opening is created in the center of a 6 by 6 cm biologic mesh, large enough to accommodate the circumference of the bowel used for the ostomy.",
"     </li>",
"     <li>",
"      The mesh is tacked in place at the 12, 3, 6, and 9 o&rsquo;clock positions, in order to prevent displacement of the mesh during extraction of the intestine.",
"     </li>",
"     <li>",
"      The bowel is guided through the mesh and the abdominal wall. The bowel may be tacked to the mesh without added morbidity, but this has not been shown to provide any added benefit and is not performed by the author.",
"     </li>",
"     <li>",
"      The ostomy is matured by everting the full thickness bowel and securing to the skin without tension (see",
"      <a class=\"local\" href=\"#H532260\">",
"       'Maturing the ostomy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063067\">",
"    <span class=\"h3\">",
"     Onlay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same general principles described in the preceding section apply to the onlay approach, except the mesh is placed above the anterior rectus sheath (",
"    <a class=\"graphic graphic_figure graphicRef82341 \" href=\"UTD.htm?39/17/40210\">",
"     figure 19",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063081\">",
"    <span class=\"h3\">",
"     Intra-peritoneal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of an intra-abdominal mesh at the time of the construction of the ostomy is not commonly performed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The technique includes bringing the bowel out directly through a &ldquo;key hole&rdquo; defect in the mesh [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/31\">",
"     31",
"    </a>",
"    ], or the mesh is placed over the loop of intestine after it has been brought through the abdominal wall, similar to that of the Sugarbaker technique for parastomal hernia repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link&amp;anchor=H13#H13\">",
"     \"Parastomal hernia\", section on 'Laparoscopic mesh repair'",
"    </a>",
"    .) Both techniques avoid extensive dissection of the abdominal wall and are feasible via laparoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1190265902\">",
"    <span class=\"h2\">",
"     Choice of technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of using mesh at the time of an ostomy construction to reduce the risk of a parastomal hernia is dependent upon the location of mesh placement, and possibly the type of mesh. Large, long-term prospective comparative trials are not available and are needed to determine whether mesh should be used at the time of construction of an ostomy and the optimal location for its placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4775430\">",
"    <span class=\"h3\">",
"     Location of mesh placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;When mesh is placed in the sublay position, there is a limited contact between mesh and bowel wall and the mesh adapts to the abdominal wall, which prevents its dislocation. Three randomized trials found that the use of mesh in the sublay position reduced the risk of a parastomal hernia compared to no mesh (range 0 to 22 versus 44 to 81 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/21,27,33\">",
"     21,27,33",
"    </a>",
"    ]. There were no differences in the incidence of stomal infection, necrosis, and stenosis between conventional groups without mesh and study groups with mesh. The sublay technique is the most frequently used approach and is preferred by the author.",
"   </p>",
"   <p>",
"    Compared to the sublay technique, placing the mesh in the onlay position is less challenging technically, requires a shorter time for the operation, and avoids extensive dissection beneath the rectus muscle. It also can reduce the development of a parastomal hernia, at least in the short-term. In a prospective study of 24 patients undergoing the onlay technique with polypropylene mesh for construction of the ostomy, only two patients had signs of parastomal hernia with a median follow-up of 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/29\">",
"     29",
"    </a>",
"    ]. No wound infections were reported and two patients had minor complications requiring revision of the mesh placement.",
"   </p>",
"   <p>",
"    The sublay technique is the most frequently used approach and is preferred by the author. This approach provides for minimal contact of the mesh with the stoma, and potentially decreased risk for migration of the mesh, which can occur with the overlay technique.",
"   </p>",
"   <p>",
"    A disadvantage of intraperitoneal mesh placement is that it creates the possibility of adhesions and intestinal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In a prospective study of 24 patients with intraperitoneal mesh placed at construction of an ostomy, no parastomal hernias or infections were observed with a median follow-up period of 11 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/36\">",
"     36",
"    </a>",
"    ]. Follow-up was too short to determine the risk of long-term complications, such as obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4775350\">",
"    <span class=\"h3\">",
"     Biologic versus synthetic mesh",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal mesh product, biologic or synthetic, for prevention of a parastomal hernia has not been determined. Both types of mesh are safe and associated with low rates of complications, such as infection, erosion, fistula, and stenosis. Despite the relatively high cost, the author&rsquo;s preference is to use biologic rather than synthetic mesh. Biologic mesh is a more biocompatible alternative to synthetic prosthetic mesh due to its better tissue compatibility, orderly collagen deposition, and comparable tensile strength [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Biologic mesh has been advocated for use in patients with inflammatory bowel disease due to the high risk of re-operative surgery and in contaminated fields [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The use of an acellular dermal matrix (ADM), which becomes vascularized and remodeled into autologous tissue after implantation, may represent a low-morbidity alternative to prosthetic mesh.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063116\">",
"    <span class=\"h1\">",
"     INCIDENCE OF STOMAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ostomy complications ranges from 14 to 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,9,39-44\">",
"     3,9,39-44",
"    </a>",
"    ]. Complications vary with type of ostomy, with the least complications occurring in patients with end colostomies and ileostomies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/42,45\">",
"     42,45",
"    </a>",
"    ]. Loop ileostomies are associated with the highest complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/13,43,44\">",
"     13,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective and retrospective studies disagree on the specific risk factors associated with stomal complications. The following risk factors appear to be associated with stomal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,4,13,42,45-51\">",
"     3,4,13,42,45-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of peri-operative siting",
"     </li>",
"     <li>",
"      Height of stoma &lt;10 mm",
"     </li>",
"     <li>",
"      Emergent stoma formation",
"     </li>",
"     <li>",
"      Comorbid medical illnesses, such as obesity, Crohn&rsquo;s disease, inflammatory bowel disease, diabetes",
"     </li>",
"     <li>",
"      Tobacco usage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parastomal herniation and retraction are the most common complications for end and loop ileostomies and colostomies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/42,50,51\">",
"     42,50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link\">",
"     \"Parastomal hernia\"",
"    </a>",
"    .) Dehydration and skin irritation, related to the high-output, high alkaline enzymatic effluent, and small bowel obstruction are common complications of end and loop ileostomies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/42,50\">",
"     42,50",
"    </a>",
"    ]. Prolapse occurs in all types of stomas, but is more prevalent in loop colostomies, especially those constructed using the transverse colon [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/42,51\">",
"     42,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications are typically categorized into early or late occurrences. Early complications include inappropriate stoma site, stomal necrosis, stomal retraction, mucocutaneous separation, peristomal skin dermatitis, surgical wound infection, and sepsis. Late complications include parastomal hernia, stomal prolapse, retraction, stenosis, and stomal bleeding.",
"   </p>",
"   <p>",
"    The management of stomal complications is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link&amp;anchor=H24#H24\">",
"     \"Management of patients with a colostomy or ileostomy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063123\">",
"    <span class=\"h2\">",
"     Early complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many complications occur within days after ostomy construction and are primarily related to technical failures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/13,44\">",
"     13,44",
"    </a>",
"    ]. Early complications are defined as those occurring within three months of stoma construction.",
"   </p>",
"   <p>",
"    The most common early complications and approaches to reduce the risk of occurrence include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532626\">",
"    <span class=\"h3\">",
"     Inappropriate stoma site",
"    </span>",
"    &nbsp;&mdash;&nbsp;A poorly sited stoma increases the risk of complications (eg, leakage, skin irritation, skin breakdown) and adversely affects the patient&rsquo;s quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/4,43\">",
"     4,43",
"    </a>",
"    ]. A retrospective review of 593 patients found that those who had preoperative stoma site markings were significantly less likely to develop complications compared with those without stoma site markings (74 of 292 [32 percent] versus 131 of 301 patients [44 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A poorly sited stoma occurs more often in patients who are undergoing emergency surgery compared with elective surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,12,13\">",
"     3,12,13",
"    </a>",
"    ]. Optimal siting of the stoma should be determined prior to elective and emergency procedures by an enterostomal nurse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the surgeon. In the setting of an emergent procedure without stoma site markings, the optimal location is two-thirds of the way along the line from the anterior superior iliac spine and the umbilicus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/43\">",
"     43",
"    </a>",
"    ]. The stoma should be visible to the patient standing and sitting, and should not be placed in a crease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532903\">",
"    <span class=\"h3\">",
"     Stomal necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia or necrosis of the stoma typically results from either venous congestion from excessive tension, arterial insufficiency from aggressive mesenteric dissection, or a tight fascial aperture. The incidence is as high as 14 percent in the immediate post-operative period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. Emergency surgery, obesity, and inflammatory bowel disease, in particular Crohn&rsquo;s Disease, have been identified as independent risk factors for stomal necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adequate mobilization of the bowel, preservation of the blood supply to the stoma, and an adequate trephine are critical factors for avoiding this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532774\">",
"    <span class=\"h3\">",
"     Stomal retraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal retraction is defined as a stoma that is 0.5 cm or more below the skin surface within six weeks of construction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,43\">",
"     3,43",
"    </a>",
"    ]. The incidence of stomal retraction ranges between 1 and 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,12,13,43\">",
"     3,12,13,43",
"    </a>",
"    ]. Approximately 1 percent of patients experience stomal retraction more than 30 days after construction, most likely related to postoperative weight gain. Obesity, because of the thickness of the abdominal wall and foreshortened mesentery, and stoma height &lt; 10 mm, are the most common risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/13\">",
"     13",
"    </a>",
"    ]. Retraction leads to leakage and difficulties with pouch adherence, resulting in peristomal skin irritation.",
"   </p>",
"   <p>",
"    The best method to prevent stomal retraction is to construct a stoma at least 10 mm high for colostomies and 2 to 3 cm high for ileostomies. The large bowel must be sufficiently mobilized to avoid tension of the stoma while preserving distal blood supply. Bowel length is rarely a problem for ileostomies. Another technique used to prevent stomal retraction is the use of a supporting rod. However, a prospective study of 60 consecutive patients found no difference in retraction rate for loop ileostomies supported by an ileostomy rod compared with those constructed without a rod [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532781\">",
"    <span class=\"h3\">",
"     Mucocutaneous separation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Separation of the ostomy from the peristomal skin may be partial or completely circumferential. Typically, it occurs in 12 to 24 percent of patients in the early postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. As a result, stomal stenosis or retraction can occur if the mucocutaneous separation is circumferential and heals by secondary intention. Mucocutaneous separation also results in leakage and skin irritation. Complete dehiscence of the suture line with retraction of the stoma should be revised immediately. For less severe separations, the defect can be filled with absorptive material, such as calcium alginate, skin barrier powder, paste, or hydrofiber, and then covering the area with the wafer will protect it from the effluent and allow healing.",
"   </p>",
"   <p>",
"    The best approach to preventing this complication is meticulous technique when approximating the bowel to the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063131\">",
"    <span class=\"h3\">",
"     Peristomal skin dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peristomal skin irritation is more common for patients with an ileostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/43\">",
"     43",
"    </a>",
"    ]. This complication presents early and can be a long-term problem. Creating a protuberant spout for the ileostomy approximately 2 to 3 cm high is the best method to avoid direct contact of effluent with the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532553\">",
"    <span class=\"h3\">",
"     Parastomal ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parastomal ulceration, defined as discontinuity of peristomal skin with adjacent inflammation, can occur within the first three months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/43\">",
"     43",
"    </a>",
"    ]. It is the result of an infected hematoma or bowel fistula. The best prevention methods include complete hemostasis and gentle handling of the bowel when constructing the stoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063160\">",
"    <span class=\"h2\">",
"     Late stomal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most temporary stomas are closed within six weeks to three months, late stomal complications are generally described for permanent ostomies. Even the stoma site itself is associated with postoperative complications after closure (eg, wound infection, delayed healing) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/53\">",
"     53",
"    </a>",
"    ]. The most common late complications include parastomal hernia, stomal prolapse, stenosis, and peristomal dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532368\">",
"    <span class=\"h3\">",
"     Parastomal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This subject is discussed in detail in a separate topic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link\">",
"     \"Parastomal hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532446\">",
"    <span class=\"h3\">",
"     Stomal prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolapse is the telescoping of the intestine through the stoma and can occur with any type of stoma. The incidence ranges from 7 to 26 percent, with the highest rate associated with a loop transverse colostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,12,42,53,54\">",
"     3,12,42,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postulated risk factors for prolapse include a large abdominal trephine, increased intra-abdominal pressure, and a redundant loop of bowel proximal to the stoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/43\">",
"     43",
"    </a>",
"    ]. Prolonged prolapse results in edema and swelling that can lead to incarceration or strangulation.",
"   </p>",
"   <p>",
"    Several techniques have been proposed to prevent prolapse, such as peritoneal fixation of the stoma mesentery or fixation of the bowel wall to the fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/40,45,55,56\">",
"     40,45,55,56",
"    </a>",
"    ]. However, there is no data to support these approaches, and they are not routinely performed by the author.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063178\">",
"    <span class=\"h3\">",
"     Stomal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stenosis refers to narrowing of the lumen of the stoma as it passes through the fascia or obstruction of the stoma outlet secondary to scarring or tightness of the mucocutaneous junction. Stomal stenosis may occur in the early postoperative period, but is more likely to develop months later. The incidence ranges from 2 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/43,57,58\">",
"     43,57,58",
"    </a>",
"    ], and is more common with an end colostomy.",
"   </p>",
"   <p>",
"    Stenosis may be attributable to peristomal sepsis, retraction, an ill-fitting pouching system, or poor surgical technique. Evaluation should include evaluation for Crohn&rsquo;s disease or primary or recurrent malignancy.",
"   </p>",
"   <p>",
"    The optimal approach to reduce the risk of stenosis is to create an adequate trephine size to accommodate the bowel, proper surgical technique to assure adequate mobilization and blood supply, and avoid local infections with meticulous stoma management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534191\">",
"    <span class=\"h3\">",
"     Peristomal pyoderma gangrenosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peristomal pyoderma gangrenosum (PPG) is an unusual variant of pyoderma gangrenosum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/59\">",
"     59",
"    </a>",
"    ]. PPG most often occurs in patients with inflammatory bowel disease (ulcerative colitis), although it has been identified in patients with Crohn&rsquo;s disease and intra-abdominal malignancy. These ulcers can develop within weeks to years after stoma construction, with an incidence of less than one percent of stomas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. The lesion is frequently misdiagnosed as a stitch abscess, contact dermatitis, urinary or fecal fistula, an extension of Crohn&rsquo;s disease, or a wound infection. Biopsy of the skin lesion in nondiagnostic, but does help to exclude certain pathologies (eg, cancer, Crohn&rsquo;s disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best preventive approach is to select an unaffected segment of bowel for the stoma in patients with inflammatory bowel disease and optimize medical therapy of the underlying condition. PPG can recur with stomal relocation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21063215\">",
"    <span class=\"h1\">",
"     EMERGENCY SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal complications are common when constructed on an emergent basis and include necrosis, mucocutaneous separation, and skin excoriation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28873/abstract/3,12,13,57\">",
"     3,12,13,57",
"    </a>",
"    ]. The lack of preoperative site selection contributes to stomal complications (eg, leak, poor fitting appliance) (see",
"    <a class=\"local\" href=\"#H532626\">",
"     'Inappropriate stoma site'",
"    </a>",
"    above). On rare occasions, the selected segment of intestine is extremely edematous, friable, and fragile, and cannot be anastomosed to the abdominal wall. In these settings, the intestine can be extracted at least 5 cm above the abdominal wall and wrapped in a moist gauze for five to seven days, until the ostomy has matured.",
"   </p>",
"   <p>",
"    Timing of maturation in the emergent clinical setting depends upon the appearance of the bowel and the condition of the patient. Maturation should occur within 2-7 days when the patient is stable, the intestine is viable with adequate blood flow, and edema has resolved enough to properly secure the stoma to the abdominal wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21064833\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative evaluation includes counseling and site selection with a skilled enterostomal therapist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgeon for optimal placement of the ostomy. (See",
"      <a class=\"local\" href=\"#H21062994\">",
"       'Preoperative preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typically, the stoma is formed on either side of the abdominal midline, just lateral and inferior to the umbilicus. The patient must be able to visualize the stoma and access it without difficulty. The ostomy placement must be at least 5 cm from all folds, creases, previous incisions, belt line, umbilicus, and bony prominences for optimal appliance adherence. (See",
"      <a class=\"local\" href=\"#H21063010\">",
"       'Site selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of mesh for construction of an ostomy to reduce the risk of a parastomal herniation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21063053\">",
"       'Prophylactic mesh placement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link\">",
"       \"Parastomal hernia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients undergoing a defunctioning stoma as the sole indication for an operative procedure, the author prefers the laparoscopic approach for patients who have not had multiple abdominal surgeries. (See",
"      <a class=\"local\" href=\"#H4775536\">",
"       'Laparoscopic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications are typically categorized into early or late occurrences. Early complications (within three months) include peristomal skin breakdown, stomal retraction, stomal necrosis, mucocutaneous separation, and dermatitis. Late complications include parastomal hernia, prolapse, retraction, and stenosis. (See",
"      <a class=\"local\" href=\"#H21063116\">",
"       'Incidence of stomal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal siting of the stoma should be determined prior to elective and emergency procedures by an enterostomal nurse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the surgeon. In the setting of an emergent procedure without stoma site markings, the optimal location is two-thirds of the way along the line from the anterior superior iliac spine and the umbilicus. (See",
"      <a class=\"local\" href=\"#H21063010\">",
"       'Site selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H532626\">",
"       'Inappropriate stoma site'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/1\">",
"      Holzer B, Matzel K, Schiedeck T, et al. Do geographic and educational factors influence the quality of life in rectal cancer patients with a permanent colostomy? Dis Colon Rectum 2005; 48:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/2\">",
"      National guidelines for enterostomal patient education. Prepared by the Standards Development Committee of the United Ostomy Association with the Assistance of Prospect Associates. Dis Colon Rectum 1994; 37:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/3\">",
"      Arumugam PJ, Bevan L, Macdonald L, et al. A prospective audit of stomas--analysis of risk factors and complications and their management. Colorectal Dis 2003; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/4\">",
"      Bass EM, Del Pino A, Tan A, et al. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum 1997; 40:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/5\">",
"      Chaudhri S, Brown L, Hassan I, Horgan AF. Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial. Dis Colon Rectum 2005; 48:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/6\">",
"      Cataldo PA. Technical tips for stoma creation in the challenging patient. Clin Colon Rectal Surg 2008; 21:17.",
"     </a>",
"    </li>",
"    <li>",
"     Dykes SL. Ostomies and stomal therapy. American Society of Colon &amp; Rectal Surgeons (ASCRS). file://www.fascrs.org/physicians/education/core_subjects/2010/Ostomies_and_Stomal_Therapy/ (Accessed on October 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/8\">",
"      von Smitten K, Husa A, Kyll&ouml;nen L. Long-term results of sigmoidostomy in patients with anorectal malignancy. Acta Chir Scand 1986; 152:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/9\">",
"      Leong AP, Londono-Schimmer EE, Phillips RK. Life-table analysis of stomal complications following ileostomy. Br J Surg 1994; 81:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/10\">",
"      Anderson DN, Driver CP, Park KG, et al. Loop ileostomy fixation: a simple technique to minimise the risk of stomal volvulus. Int J Colorectal Dis 1994; 9:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/11\">",
"      Sugarbaker PH. Prevention of hernia after enterostomy. Surg Gynecol Obstet 1989; 169:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/12\">",
"      Harris DA, Egbeare D, Jones S, et al. Complications and mortality following stoma formation. Ann R Coll Surg Engl 2005; 87:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/13\">",
"      Cottam J, Richards K, Hasted A, Blackman A. Results of a nationwide prospective audit of stoma complications within 3 weeks of surgery. Colorectal Dis 2007; 9:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/14\">",
"      De Raet J, Delvaux G, Haentjens P, Van Nieuwenhove Y. Waist circumference is an independent risk factor for the development of parastomal hernia after permanent colostomy. Dis Colon Rectum 2008; 51:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/15\">",
"      Oliveira L, Reissman P, Nogueras J, Wexner SD. Laparoscopic creation of stomas. Surg Endosc 1997; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/16\">",
"      Hellinger MD, Al Haddad A. Minimally invasive stomas. Clin Colon Rectal Surg 2008; 21:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/17\">",
"      Ludwig KA, Milsom JW, Garcia-Ruiz A, Fazio VW. Laparoscopic techniques for fecal diversion. Dis Colon Rectum 1996; 39:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/18\">",
"      Young CJ, Eyers AA, Solomon MJ. Defunctioning of the anorectum: historical controlled study of laparoscopic vs. open procedures. Dis Colon Rectum 1998; 41:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/19\">",
"      Jugool S, McKain ES, Swarnkar K, et al. Laparoscopic or trephine faecal diversion: is there a preferred approach and why? Colorectal Dis 2005; 7:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/20\">",
"      Liu J, Bruch HP, Farke S, et al. Stoma formation for fecal diversion: a plea for the laparoscopic approach. Tech Coloproctol 2005; 9:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/21\">",
"      Hammond TM, Huang A, Prosser K, et al. Parastomal hernia prevention using a novel collagen implant: a randomised controlled phase 1 study. Hernia 2008; 12:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/22\">",
"      Aldridge AJ, Simson JN. Erosion and perforation of colon by synthetic mesh in a recurrent paracolostomy hernia. Hernia 2001; 5:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/23\">",
"      Carne PW, Robertson GM, Frizelle FA. Parastomal hernia. Br J Surg 2003; 90:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/24\">",
"      Hammond TM, Chin-Aleong J, Navsaria H, Williams NS. Human in vivo cellular response to a cross-linked acellular collagen implant. Br J Surg 2008; 95:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/25\">",
"      J&auml;nes A, Cengiz Y, Israelsson LA. Preventing parastomal hernia with a prosthetic mesh. Arch Surg 2004; 139:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/26\">",
"      J&auml;nes A, Cengiz Y, Israelsson LA. Preventing parastomal hernia with a prosthetic mesh: a 5-year follow-up of a randomized study. World J Surg 2009; 33:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/27\">",
"      Serra-Aracil X, Bombardo-Junca J, Moreno-Matias J, et al. Randomized, controlled, prospective trial of the use of a mesh to prevent parastomal hernia. Ann Surg 2009; 249:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/28\">",
"      Vijayasekar C, Marimuthu K, Jadhav V, Mathew G. Parastomal hernia: Is prevention better than cure? Use of preperitoneal polypropylene mesh at the time of stoma formation. Tech Coloproctol 2008; 12:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/29\">",
"      G&ouml;genur I, Mortensen J, Harvald T, et al. Prevention of parastomal hernia by placement of a polypropylene mesh at the primary operation. Dis Colon Rectum 2006; 49:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/30\">",
"      Berger D, Bientzle M. Polyvinylidene fluoride: a suitable mesh material for laparoscopic incisional and parastomal hernia repair! A prospective, observational study with 344 patients. Hernia 2009; 13:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/31\">",
"      L&oacute;pez-Cano M, Lozoya-Trujillo R, Espin-Basany E. Prosthetic mesh in parastomal hernia prevention. Laparoscopic approach. Dis Colon Rectum 2009; 52:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/32\">",
"      Sugarbaker PH. Peritoneal approach to prosthetic mesh repair of paraostomy hernias. Ann Surg 1985; 201:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/33\">",
"      J&auml;nes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a prosthetic mesh to prevent parastomal hernia. Br J Surg 2004; 91:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/34\">",
"      Koehler RH, Begos D, Berger D, et al. Minimal adhesions to ePTFE mesh after laparoscopic ventral incisional hernia repair: reoperative findings in 65 cases. JSLS 2003; 7:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/35\">",
"      Joels CS, Matthews BD, Kercher KW, et al. Evaluation of adhesion formation, mesh fixation strength, and hydroxyproline content after intraabdominal placement of polytetrafluoroethylene mesh secured using titanium spiral tacks, nitinol anchors, and polypropylene suture or polyglactin 910 suture. Surg Endosc 2005; 19:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/36\">",
"      Berger D. Prevention of parastomal hernias by prophylactic use of a specially designed intraperitoneal onlay mesh (Dynamesh IPST). Hernia 2008; 12:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/37\">",
"      Butler CE, Langstein HN, Kronowitz SJ. Pelvic, abdominal, and chest wall reconstruction with AlloDerm in patients at increased risk for mesh-related complications. Plast Reconstr Surg 2005; 116:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/38\">",
"      Patton JH Jr, Berry S, Kralovich KA. Use of human acellular dermal matrix in complex and contaminated abdominal wall reconstructions. Am J Surg 2007; 193:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/39\">",
"      Park JJ, Del Pino A, Orsay CP, et al. Stoma complications: the Cook County Hospital experience. Dis Colon Rectum 1999; 42:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/40\">",
"      Londono-Schimmer EE, Leong AP, Phillips RK. Life table analysis of stomal complications following colostomy. Dis Colon Rectum 1994; 37:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/41\">",
"      Porter JA, Salvati EP, Rubin RJ, Eisenstat TE. Complications of colostomies. Dis Colon Rectum 1989; 32:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/42\">",
"      Robertson I, Leung E, Hughes D, et al. Prospective analysis of stoma-related complications. Colorectal Dis 2005; 7:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/43\">",
"      Shabbir J, Britton DC. Stoma complications: a literature overview. Colorectal Dis 2010; 12:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/44\">",
"      Persson E, Berndtsson I, Carlsson E, et al. Stoma-related complications and stoma size - a 2-year follow up. Colorectal Dis 2010; 12:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/45\">",
"      Caricato M, Ausania F, Ripetti V, et al. Retrospective analysis of long-term defunctioning stoma complications after colorectal surgery. Colorectal Dis 2007; 9:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/46\">",
"      Duchesne JC, Wang YZ, Weintraub SL, et al. Stoma complications: a multivariate analysis. Am Surg 2002; 68:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/47\">",
"      Leenen LP, Kuypers JH. Some factors influencing the outcome of stoma surgery. Dis Colon Rectum 1989; 32:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/48\">",
"      Nastro P, Knowles CH, McGrath A, et al. Complications of intestinal stomas. Br J Surg 2010; 97:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/49\">",
"      Rondelli F, Reboldi P, Rulli A, et al. Loop ileostomy versus loop colostomy for fecal diversion after colorectal or coloanal anastomosis: a meta-analysis. Int J Colorectal Dis 2009; 24:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/50\">",
"      Tang CL, Yunos A, Leong AP, et al. Ileostomy output in the early postoperative period. Br J Surg 1995; 82:607.",
"     </a>",
"    </li>",
"    <li>",
"     Guenaga KF, Lustosa SA, Saad SS, Saconato H, et al. Ileostomy or colostomy for temporary decompression of colorectal anastomosis. Cochrane Database Syst Rev 2007; Jan24:CD004647.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/52\">",
"      Speirs M, Leung E, Hughes D, et al. Ileostomy rod--is it a bridge too far? Colorectal Dis 2006; 8:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/53\">",
"      Shellito PC. Complications of abdominal stoma surgery. Dis Colon Rectum 1998; 41:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/54\">",
"      Cheung MT. Complications of an abdominal stoma: an analysis of 322 stomas. Aust N Z J Surg 1995; 65:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/55\">",
"      Maeda K, Maruta M, Utsumi T, et al. Pathophysiology and prevention of loop stomal prolapse in the transverse colon. Tech Coloproctol 2003; 7:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/56\">",
"      M&auml;kel&auml; JT, Turku PH, Laitinen ST. Analysis of late stomal complications following ostomy surgery. Ann Chir Gynaecol 1997; 86:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/57\">",
"      Husain SG, Cataldo TE. Late stomal complications. Clin Colon Rectal Surg 2008; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/58\">",
"      Beraldo S, Titley G, Allan A. Use of W-plasty in stenotic stoma: a new solution for an old problem. Colorectal Dis 2006; 8:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/59\">",
"      Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/60\">",
"      Walling AD, Sweet D. Pyoderma gangrenosum. Am Fam Physician 1987; 35:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/61\">",
"      Lyon CC, Smith AJ, Griffiths CE, Beck MH. The spectrum of skin disorders in abdominal stoma patients. Br J Dermatol 2000; 143:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28873/abstract/62\">",
"      Callen JP. Pyoderma gangrenosum. Lancet 1998; 351:581.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15026 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28873=[""].join("\n");
var outline_f28_12_28873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21064833\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21064825\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21062978\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21062994\">",
"      PREOPERATIVE PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21063003\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21063010\">",
"      Site selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21063025\">",
"      TECHNICAL INSIGHTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21063032\">",
"      Aperture size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21063039\">",
"      Stomal fixation to the fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21063046\">",
"      Closure of the lateral space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H532260\">",
"      Maturing the ostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14009873\">",
"      - End ostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14009881\">",
"      - Loop ostomy with a defunctionalized distal limb",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172221585\">",
"      - Double barrel ostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4776081\">",
"      Technical challenges in obese patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4775536\">",
"      LAPAROSCOPIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21063053\">",
"      PROPHYLACTIC MESH PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21063060\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1190264663\">",
"      - Sublay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21063067\">",
"      - Onlay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21063081\">",
"      - Intra-peritoneal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1190265902\">",
"      Choice of technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4775430\">",
"      - Location of mesh placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4775350\">",
"      - Biologic versus synthetic mesh",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21063116\">",
"      INCIDENCE OF STOMAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21063123\">",
"      Early complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H532626\">",
"      - Inappropriate stoma site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H532903\">",
"      - Stomal necrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H532774\">",
"      - Stomal retraction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H532781\">",
"      - Mucocutaneous separation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21063131\">",
"      - Peristomal skin dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H532553\">",
"      - Parastomal ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21063160\">",
"      Late stomal complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H532368\">",
"      - Parastomal hernia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H532446\">",
"      - Stomal prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21063178\">",
"      - Stomal stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H534191\">",
"      - Peristomal pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21063215\">",
"      EMERGENCY SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21064833\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15026|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/5/44114\" title=\"figure 1\">",
"      Construction of an ostomy - skin incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/25/32147\" title=\"figure 2\">",
"      Construction of an ostomy cruciate incision fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/31/497\" title=\"figure 3\">",
"      Brooke end ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/42/2725\" title=\"figure 4\">",
"      Construction of an ileostomy - segment through abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/18/15653\" title=\"figure 5\">",
"      Construction of an end colostomy segment through abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/63/12274\" title=\"figure 6\">",
"      Construction of an ileostomy - transection proximal limb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/33/24085\" title=\"figure 7\">",
"      Construction of a colostomy - proximal and distal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/24/32130\" title=\"figure 8\">",
"      Construction of an ileostomy - suture to abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/59/13234\" title=\"figure 9\">",
"      Construction of a colostomy - suture to abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/23/36223\" title=\"figure 10\">",
"      Construction of a loop ileostomy - defunctionalized distal limb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/21/40286\" title=\"figure 11\">",
"      Construction of a double barrel loop colostomy - maturing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/34/36386\" title=\"figure 12\">",
"      Construction of a loop colostomy - exteriorization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/8/40064\" title=\"figure 13\">",
"      Construction of a loop colostomy - abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/40/11919\" title=\"figure 14\">",
"      Construction of a loop colostomy - circumferential incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/63/40958\" title=\"figure 15\">",
"      Construction of a loop colostomy - everting proximal limb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/17/31007\" title=\"figure 16\">",
"      Construction of a loop colostomy- defunctionalized distal limb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/50/9007\" title=\"figure 17\">",
"      Construction of a double barrel loop colostomy - colotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/52/18243\" title=\"figure 18\">",
"      Construction of a double barrel end colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/17/40210\" title=\"figure 19\">",
"      Abdominal wall mesh placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/35/2616\" title=\"figure 20\">",
"      Muscles of the anterior abdominal wall",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=related_link\">",
"      Parastomal hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11799?source=related_link\">",
"      Reconstructive materials used in surgery: Classification and host response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_12_28874="Pathogenesis of Behçet’s disease";
var content_f28_12_28874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of Beh&ccedil;et&rsquo;s disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28874/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28874/contributors\">",
"     Ellison L Smith, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28874/contributors\">",
"     Yusuf Yazici, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28874/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28874/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/12/28874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/12/28874/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/12/28874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease is an inflammatory disease characterized by recurrent oral aphthous ulcers and numerous potential systemic manifestations. These include genital ulcers; skin lesions; and ocular, neurologic, vascular, articular, and gastrointestinal disease.",
"   </p>",
"   <p>",
"    Many, but not all, clinical manifestations of Beh&ccedil;et&rsquo;s disease are believed to be due to vasculitis. Among the systemic vasculitides, Beh&ccedil;et&rsquo;s disease is remarkable for its ability to involve blood vessels of all sizes (small, medium, and large) on both the arterial and venous sides of the circulation.",
"   </p>",
"   <p>",
"    The etiology and pathogenesis of Beh&ccedil;et&rsquo;s disease are discussed in this review. The clinical manifestations, diagnosis, and treatment of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=see_link\">",
"     \"Treatment of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease is more common (and often more severe) along the ancient silk road, which extends from eastern Asia to the Mediterranean [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/1\">",
"     1",
"    </a>",
"    ]. It is most common in Turkey (80 to 370 cases per 100,000), while the prevalence ranges from 13.5 to 20 per 100,000 in Japan, Korea, China, Iran, and Saudi Arabia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/1\">",
"     1",
"    </a>",
"    ]. Prevalence in Paris, France in 2003 was 7.1 per 100,000, with rates of 2.4 per 100,000 in those of European ancestry, of 34.6 per 100,000 in those of North African ancestry, and of 17.5 per 100,000 in those of Asian ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Estimates of prevalence in the United States and Europe have ranged from 0.12 to 7.5 per 100,000. Analysis of residents of Olmsted County, Minnesota over a 45-year period identified a prevalence of 5.2 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/4\">",
"     4",
"    </a>",
"    ]. It is somewhat more common in men in the eastern Mediterranean area and in women in north European countries, and it typically affects young adults 20 to 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying cause of Beh&ccedil;et&rsquo;s disease is unknown. As with other autoimmune diseases, the disorder may represent aberrant immune activity triggered by exposure to an agent, perhaps infectious, in patients with a genetic predisposition to develop the disease. Major disease mechanisms in Beh&ccedil;et&rsquo;s disease include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genetic influences including association with certain human leukocyte antigens (HLA)",
"     </li>",
"     <li>",
"      Bacterial antigens with cross reactivity to human peptides",
"     </li>",
"     <li>",
"      Altered populations of hematopoietic cells and associated cytokines",
"     </li>",
"     <li>",
"      Presence of immune complexes and autoantibodies",
"     </li>",
"     <li>",
"      Vascular endothelial activation and hypercoagulability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proposed triggering agents include viral and bacterial antigens or other environmental sources, such as chemicals or heavy metals. Direct infection of affected tissues has not been observed, although it is still a possible contributor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic predisposition to the disease is likely polygenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     HLA genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased risk of developing Beh&ccedil;et&rsquo;s disease is associated with the presence of certain human leukocyte antigens, particularly HLA-B51. A meta-analysis of 4800 cases and 16,289 controls has shown a significant increase in the risk of",
"    <span class=\"nowrap\">",
"     HLA-B51/B5",
"    </span>",
"    carriers to develop Beh&ccedil;et&rsquo;s disease compared with noncarriers (pooled odds ratio of 5.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/6\">",
"     6",
"    </a>",
"    ]. This relationship was consistent across multiple geographic locations, including Eastern Asia, Middle",
"    <span class=\"nowrap\">",
"     East/North",
"    </span>",
"    Africa, Southern Europe, and",
"    <span class=\"nowrap\">",
"     Northern/Eastern",
"    </span>",
"    Europe, but insufficient data were available for analysis of North American studies.",
"   </p>",
"   <p>",
"    In individual studies, higher than baseline prevalences of HLA-B51 has been found in Beh&ccedil;et&rsquo;s patients in Italy (odds ratio of 5.9), in Germany, and in Middle Eastern and Far Eastern countries along the silk road (63 versus 9 percent in controls), of HLA-B52 (21 versus 9 percent) in Israel, and of HLA-B57 in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/1,7-12\">",
"     1,7-12",
"    </a>",
"    ]. HLA-B5101 and, to a lesser extent, HLA-5108 alleles have been most closely linked in patients along the Silk Road [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13\">",
"     13",
"    </a>",
"    ]. Other HLA alleles may increase or decrease the risk for Beh&ccedil;et&rsquo;s in various populations and in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. However, the HLA contribution was estimated to be less than 20 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may also be a genetic contribution to disease severity. Presence of a HLA-B51 allele has been associated with worse disease in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/1,18-21\">",
"     1,18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several possible mechanisms for the genetic linkage to HLA-B51 have been suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alterations in the B pocket of the antigen binding groove conformed by HLA-B51 may determine whether Beh&ccedil;et&rsquo;s disease associated peptides bind and contribute to Beh&ccedil;et&rsquo;s disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cross reactivity between HLA-B51 and organ specific antigens may exist [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Linkage disequilibrium with other disease-associated genes has been reported on chromosome 6, including a TNF promoter polymorphism in proximity to the HLA B gene locus, to the MICA gene (major histocompatibility complex class I chain-related gene A), and to another locus telomeric to the HLA-B site [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/10,12,25-28\">",
"       10,12,25-28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though most cases of Beh&ccedil;et&rsquo;s are sporadic, families with multiple affected members, known as familial clustering, have been reported, and having a first degree relative with Beh&ccedil;et&rsquo;s does increase risk for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. HLA-B51 rates are higher in familial than in sporadic cases. Affected children of patients with Beh&ccedil;et&rsquo;s disease may have an earlier age of onset, a property termed genetic anticipation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/31\">",
"     31",
"    </a>",
"    ]; this characteristic has been linked, in many genetic disorders, to an increased number of nucleotide repeats within each successive generation. In Beh&ccedil;et&rsquo;s disease for example, a triplet repeat microsatellite polymorphism of (GCT)n found within a major histocompatibility complex (MHC) Class I related gene was found to be associated with the disorder in one study of 77 affected patients in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Non-HLA genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-HLA genes also play a role in determining susceptibility to disease. Genome-wide screening of affected families with more than one affected member has identified additional, non-HLA regions of potential interest [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/33\">",
"     33",
"    </a>",
"    ]. Examples include associations between Beh&ccedil;et&rsquo;s disease and:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymorphisms of the intercellular adhesion molecule (ICAM)-1 gene, the endothelial nitric oxide synthase gene, tumor necrosis factor (TNF) genes, the vascular endothelial growth factor (VEGF) gene, manganese superoxide dismutase, cytochrome P450, and many other genes [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/10,18,34-53\">",
"       10,18,34-53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Missense mutations of the familial Mediterranean fever (MEFV) gene, encoding the protein pyrin that is expressed of the surface of neutrophils [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/54-57\">",
"       54-57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Molecular mimicry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest a possible pathogenic role of certain bacterial antigens that have cross-reactivity with human peptides. The cross reactive self antigens may include the heat shock proteins, a family of 60 to 90 kDa proteins produced by many cells in response to stress. These proteins have significant sequence homology between humans and bacteria. T cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibodies may recognize epitopes shared by both host and infectious organism heat shock proteins, thereby initiating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perpetuating Beh&ccedil;et&rsquo;s disease.",
"   </p>",
"   <p>",
"    Elevated levels of antibodies against epitopes of mycobacterial heat shock protein, some of which have significant homology to human heat shock proteins, have been observed among patients with Beh&ccedil;et&rsquo;s disease. One study evaluated the antigenicity of 47 synthetic peptides (each 15 amino acids in length) derived from the sequence of the mycobacterial 65 kD heat shock protein [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/58\">",
"     58",
"    </a>",
"    ]. Increased levels of IgG and IgA antibodies against three of these synthetic peptides was observed, two of which had significant homology to two areas of a human mitochondrial 60 kD heat shock protein. Exacerbations of ocular disease coincided with enhanced levels of these autoimmune antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/59\">",
"     59",
"    </a>",
"    ]. Furthermore, these peptides can induce uveitis when injected into Lewis rats.",
"   </p>",
"   <p>",
"    A response to mycobacterial heat shock proteins by gamma-delta T cells may play a role in the pathogenesis of Beh&ccedil;et&rsquo;s disease. One study found that 25 of 33 patients with Beh&ccedil;et&rsquo;s disease showed significant increases in gamma-delta T cells in response to exposure to mycobacterial heat shock proteins; by comparison, only 2 of 55 control individuals exhibited such an increase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific bacteria, particularly streptococci, may also be important contributors to a cross-reacting response among patients with Beh&ccedil;et&rsquo;s disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin testing to streptococcal antigens often induces hypersensitivity reactions and sometimes results in systemic exacerbations of Beh&ccedil;et&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 106 Beh&ccedil;et's patients from Turkey showed a higher rate of Streptococcal mutans salivary colonization compared with controls, and colonization was associated with low levels of serum mannose binding lectin compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indirect evidence for crossreactivity is suggested by the finding that patients with Beh&ccedil;et&rsquo;s disease are more likely than normals to have significant antibody titers to Streptococcus sanguis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]; this organism, particularly some with uncommon serotypes, is found at increased levels in the oral cavities of patients with the disorder. Circulating antibodies have been detected to streptococcal heat shock proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/65\">",
"       65",
"      </a>",
"      ]. Patients with Beh&ccedil;et&rsquo;s demonstrate increased reactivity to lipoteichoic acid, a streptococcal antigen.",
"     </li>",
"     <li>",
"      Streptococcal antigens have been shown to increase interleukin (IL)-6 and interferon gamma secretion from Beh&ccedil;et&rsquo;s patients&rsquo; T lymphocytes and to upregulate Beh&ccedil;et&rsquo;s patients' gamma delta T cells, which secrete IL-6, IL-8 and TNF-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/66-68\">",
"       66-68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The importance of streptococcal infection was indirectly assessed by a prospective study which compared the efficacy of benzathine penicillin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      in 94 patients with Beh&ccedil;et&rsquo;s disease with that of colchicine alone in 60 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/69\">",
"       69",
"      </a>",
"      ]. Compared with colchicine alone, penicillin plus colchicine resulted in a significantly greater degree of improvement in mucocutaneous lesions.",
"     </li>",
"     <li>",
"      Host response to Helicobacter pylori infection may play a role. This was illustrated in a study that found similar rates of serum Helicobacter pylori IgG levels between patients and controls but found a higher rate of Helicobacter pylori cytotoxin-associated gene-A antibodies in Beh&ccedil;et&rsquo;s patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/70\">",
"       70",
"      </a>",
"      ]. These antibodies have been postulated to be mediators of vascular damage in other conditions via cross reaction with endothelin antigens. Helicobacter eradication in these patients decreased Beh&ccedil;et&rsquo;s disease activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Herpes simplex virus (HSV) has been investigated as a possible infectious trigger in Beh&ccedil;et&rsquo;s. HSV type-1 genome has been isolated from the nuclei of lymphocytes in Beh&ccedil;et&rsquo;s patients, and immune complexes containing HSV-1 antigen have been reported. Other studies have not shown an association between HSV and Beh&ccedil;et&rsquo;s, including polymerase chain reaction (PCR) testing of saliva and a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    treatment that was not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parvovirus B19 was the subject of an investigation that used a semiquantitative technique to assess the amount of parvovirus B19 DNA present in 40 patients and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/11\">",
"     11",
"    </a>",
"    ]. There was more B19 DNA present in the nonulcerative skin lesions of Beh&ccedil;et&rsquo;s patients than in the ulcerative skin lesions or in control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Altered innate immune function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mannose binding lectin (MBL) is part of the innate immune system and activates the complement cascade after binding to carbohydrate structures on microorganisms. Low serum levels of MBL and MBL gene mutations have been observed in Beh&ccedil;et&rsquo;s as well as in other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Very low levels of MBL correlated with increased disease severity. Since MBL deficiencies are associated with increased risk of some infections, and since infectious disease has been associated with Beh&ccedil;et&rsquo;s, MBL deficiencies may lead to impaired immune response against microorganisms and subsequent immune activation in Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/62,71\">",
"     62,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toll-like receptors are receptors on lymphocytes and some solid tissue cells which are directed against pathogenic microbes and which are a part of the innate immune system. Altered patterns of toll-like receptors have been described in Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/72\">",
"     72",
"    </a>",
"    ]. Monocytes of Beh&ccedil;et&rsquo;s patients with active disease demonstrate increased activity of toll-like receptors 2 and 4, and, in one study, this was inversely correlated with 25-OH vitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/73\">",
"     73",
"    </a>",
"    ]. Intestinal lesions in Beh&ccedil;et&rsquo;s disease patients expressed increased toll-like receptor 2 and 4 mRNA compared with healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cellular immunity and cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Beh&ccedil;et&rsquo;s disease, there are alterations in the numbers of T cell subpopulations and evidence of cellular activation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/5\">",
"     5",
"    </a>",
"    ]. Autoreactive T cells appear to play a critical role in the pathogenesis of Beh&ccedil;et&rsquo;s, and a small clinical trial of lymphocyte depletion with an anti-CD52 monoclonal antibody CAMPATH-1H shows promise for future disease treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/75\">",
"     75",
"    </a>",
"    ]. As noted above, heat shock proteins or streptococcal antigens may play a role in stimulating oligoclonal T cell expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/60\">",
"     60",
"    </a>",
"    ]. Adenosine deaminase, an enzyme involved in lymphocyte proliferation, maturation, and differentiation, is activated in Beh&ccedil;et&rsquo;s disease, particularly during disease exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A T helper (Th) 1 predominant response has been observed in many studies of Beh&ccedil;et&rsquo;s, but some studies have shown evidence for a Th2 response. In reality there may be a mix of Th1 and Th2 activity in Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,79-81\">",
"     13,79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Th1 lymphocytes, which produce cytokines IL-2, IL-6, IL-8, IL-12, IL-18, tumor necrosis factor (TNF) alpha, and interferon gamma, are increased in many studies in patients with Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,79,82-88\">",
"     13,79,82-88",
"    </a>",
"    ]. Some studies have shown that serum levels of IL-12, soluble TNF-alpha receptors, and IL-8 may correlate with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/89-93\">",
"     89-93",
"    </a>",
"    ], while others have noted increased production of such cytokines from peripheral blood mononuclear cells of Beh&ccedil;et&rsquo;s patients regardless of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/94\">",
"     94",
"    </a>",
"    ]. Twenty-four patients with active ocular Beh&ccedil;et&rsquo;s demonstrated elevated levels of IgA, C3, C4, IL-6, IL-8, and TNF-alpha compared with controls; a study of 43 patients with active versus inactive Beh&ccedil;et's posterior uveitis showed activity correlated with increased serum levels of IL-6, IL-8, TNF-alpha, VEGF, and malondialdehyde (MDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/86,95\">",
"     86,95",
"    </a>",
"    ]. Elevated CSF IL-6 levels have been observed in Beh&ccedil;et's patients with active neurological disease and may be a marker of disease activity and persistence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/96\">",
"     96",
"    </a>",
"    ]. Increased IL-8, monocyte chemoattractant protein 1, interferon-gamma, and IL-12 messenger RNA were observed in biopsy specimens from 20 patients with active Beh&ccedil;et&rsquo;s compared with healthy controls; no increase in IL-4 and IL-13 was observed in this study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/85\">",
"     85",
"    </a>",
"    ]. Increased expression of IL-23 mRNA has been described in Beh&ccedil;et&rsquo;s erythema nodosum-like lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/97\">",
"     97",
"    </a>",
"    ]. It has been suggested that plasmacytoid dendritic cells and type I interferons play a role in polarizing the immune activity toward Th1 activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Th2 phenotype associated changes have also been observed. Studies have shown peripheral blood mononuclear cells from patients with Beh&ccedil;et&rsquo;s disease produce increased amounts of IL-4, IL-10, and IL-13 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/29,80,99\">",
"     29,80,99",
"    </a>",
"    ]. Analysis of T cell subpopulations in patients with Beh&ccedil;et&rsquo;s disease has shown relative increases in the CD8:CD4 ratio, with relative reductions in percentages of suppressor T cells, particularly in patients with active disease. Levels of serum soluble CD30, which is released from CD4+ Th2 cells and which is a marker of TH2 activity, is elevated in Beh&ccedil;et&rsquo;s patients with active disease.",
"   </p>",
"   <p>",
"    T helper 17 (Th17) cells, which produce IL-17 and which are distinct from Th1 and Th2 lymphocytes, have been found to be increased and activated in patients with Beh&ccedil;et's and may explain some of the apparently conflicting findings regarding Th1 and Th2 activity in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/100-104\">",
"     100-104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in T cell subsets have been identified in a number of studies, including increased numbers of T cells carrying the activation markers CD29 and CD69 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,105-108\">",
"     13,105-108",
"    </a>",
"    ]. Patients with Beh&ccedil;et&rsquo;s disease have relatively high levels of gamma-delta T cells in the circulation and at inflammatory sites [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/58,60,105,109,110\">",
"     58,60,105,109,110",
"    </a>",
"    ]; such cells are also present in peripheral blood in higher numbers during active versus quiescent Beh&ccedil;et&rsquo;s disease (9 versus 2 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/109\">",
"     109",
"    </a>",
"    ]. Gamma-delta T cell activation may be polyclonal; the response may be to a variety of antigenic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/111\">",
"     111",
"    </a>",
"    ]. Soluble CD28, which may play a role in T cell regulation, is elevated in the serum of patients with active Beh&ccedil;et&rsquo;s disease, levels may correlate with disease activity, and polymorphisms of CD28 and CTLA-4 (which binds CD28) have been associated with Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/48,52,112\">",
"     48,52,112",
"    </a>",
"    ]. HLA-B51 restricted CD8+ cytotoxic T lymphocytes autoreactive to MHC class I chain related gene A (MICA), a protein preferentially expressed on epithelial and endothelial cells in a stress-dependent manner, have been described in Beh&ccedil;et&rsquo;s patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flow cytometric analysis of immune cells from the aqueous humor of patients with active Beh&ccedil;et&rsquo;s uveitis showed elevated levels of CD8+ T cells and CD3+CD56+ NK T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/114\">",
"     114",
"    </a>",
"    ]. Other studies have also shown T lymphocyte infiltration into the eye in Beh&ccedil;et&rsquo;s by CD4+ Th1 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. Th1 cytokines are elevated in the aqueous humor and serum of patients with Beh&ccedil;et&rsquo;s uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. Ocular fluid from Beh&ccedil;et's patients with active uveitis demonstrated inflammatory cytokines, including interferon, IL-2, TNF, IL-6, and IL-17, and activated ocular CD4+ T cells produced large amounts of TNF and IL-17, which were blocked in the presence of the TNF inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synovial fluid in Beh&ccedil;et&rsquo;s disease demonstrates lower levels of inflammatory cytokines than that in patients with rheumatoid arthritis, a more erosive disease. One study showed elevated levels of IL-8 and soluble IL-2 receptor but relatively lower levels of TNF-alpha, IL-1 beta, IL-1 receptor antagonist, and transforming growth factor (TGF) beta than the synovial fluid from patients with rheumatoid arthritis. Another study showed elevated levels of IL-1 beta but lower levels of IL-18, TNF-alpha, and matrix metalloproteinase (MMP)-3 compared with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/120\">",
"     120",
"    </a>",
"    ]. Bronchoalveolar lavage from patients with Beh&ccedil;et&rsquo;s pulmonary disease shows higher levels of IL-18 and interferon-gamma before and after LPS stimulation than in controls.",
"   </p>",
"   <p>",
"    The inflammatory response in Beh&ccedil;et&rsquo;s may be accentuated by refractoriness of activated T cells and neutrophils to apoptosis. T cells from patients with Beh&ccedil;et&rsquo;s demonstrate resistance to spontaneous and CD95-induced apoptosis, and this may be mediated by NF-kappaB via regulation of apoptosis-related factors and death receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/121\">",
"     121",
"    </a>",
"    ]. Circulating neutrophils are resistant to apoptosis in the remission stage of Beh&ccedil;et&rsquo;s uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neopterin is secreted by monocytes and macrophages as a result of IFN-gamma secretion by activated T lymphocytes and may, therefore, be an indicator of cellular immune activation. Elevated serum and urine neopterin levels have been observed in Beh&ccedil;et's patients compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/123,124\">",
"     123,124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Autoantibody and immune complex formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to cellular immune activation, there is also evidence of humoral immune activation in Beh&ccedil;et&rsquo;s. Increased numbers of circulating B lymphocytes have been observed; this appears to be antigen driven, not simply a polyclonal increase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,125,126\">",
"     13,125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoantibodies appear to play a role in the pathogenesis of Beh&ccedil;et&rsquo;s. Autoantibodies have been described against a number of targets including oral mucosal antigens, endothelial cells, T cell costimulatory molecule CTLA-4, killer immunoglobulin-like receptors, oxidized low-density lipoprotein, and kinectin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/127-132\">",
"     127-132",
"    </a>",
"    ]. Anti-saccharomyces cerevisiae antibodies (ASCA) have been observed in some Beh&ccedil;et&rsquo;s patients, at rates similar to that in ulcerative colitis and ankylosing spondylitis and less commonly than in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune activity against retinal self antigens appears to be important in the pathogenesis of Beh&ccedil;et&rsquo;s uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/134\">",
"     134",
"    </a>",
"    ]. Retinal-S antigen is localized to the photoreceptor of the retina, and has been shown to be a potent uveitic autoantigen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/135\">",
"     135",
"    </a>",
"    ]. Peripheral blood S-antigen responsive lymphocytes are elevated during exacerbations of ocular inflammation in Beh&ccedil;et&rsquo;s patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. Other suspected Beh&ccedil;et&rsquo;s retinal autoantigens are alpha tropomyosin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    binding protein, and interphotoreceptor retinoid binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/138-140\">",
"     138-140",
"    </a>",
"    ]. Alpha-tropomyosin or kinectin is a membrane protein predominantly confined to the endoplasmic reticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/138,141,142\">",
"     138,141,142",
"    </a>",
"    ]. Immunization of rodents with alpha-tropomyosin can cause inflammation of the uveal tract and the skin, reminiscent of lesions seen in Beh&ccedil;et&rsquo;s disease. Antikinectin antibodies are present at modestly higher rates and titers in Beh&ccedil;et&rsquo;s patients than in patients with other autoimmune connective tissue diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endothelial activation and altered coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction is a characteristic finding in Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/143\">",
"     143",
"    </a>",
"    ]. Endothelium-dependent flow-mediated dilation is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/144,145\">",
"     144,145",
"    </a>",
"    ]. Endothelial activation in affected blood vessels is a mediator of vascular inflammation as well as thrombosis in Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/127,128,146,147\">",
"     127,128,146,147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of molecules have been identified that interact to mediate endothelial dysfunction in Beh&ccedil;et&rsquo;s. Nitric oxide (NO) is a highly reactive molecule associated with inflammatory activity and endothelial function. A number of lines of research have documented the role of NO in endothelial activation in Beh&ccedil;et&rsquo;s, including increased serum, erythrocyte, synovial, and aqueous humor NO concentrations in Beh&ccedil;et&rsquo;s, and elevated levels of NO metabolites compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/128,148-152\">",
"     128,148-152",
"    </a>",
"    ]. Polymorphisms of endothelial NO synthase genes and related genes have been associated with susceptibility to Beh&ccedil;et&rsquo;s in some populations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/34,35,37,41\">",
"     34,35,37,41",
"    </a>",
"    ]. Elevated levels of symmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, have been observed in Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased oxidative stress has been observed in patients with Beh&ccedil;et&rsquo;s. Findings have included increased plasma malondialdehyde (MDA), reduced glutathione:oxidized glutathione ratio, reduced superoxide dismutase, and elevated catalase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/144,154\">",
"     144,154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated mean plasma homocysteine levels have been observed in Beh&ccedil;et&rsquo;s, and this has been found to be associated with NO concentrations and decreased flow-mediated vessel dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/155,156\">",
"     155,156",
"    </a>",
"    ]. A number of studies have shown an association between Beh&ccedil;et&rsquo;s and elevated homocysteine levels; hyperhomocysteinemia may be an acquired and potentially reversible risk factor for Beh&ccedil;et&rsquo;s, may be a clinical marker of disease activity, and may be associated with thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,123,157-159\">",
"     13,123,157-159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular endothelial growth factor levels are higher in patients with Beh&ccedil;et&rsquo;s and have been associated with increased disease activity and NO concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/51,160-162\">",
"     51,160-162",
"    </a>",
"    ]. Cerebrospinal fluid VEGF levels were higher in a group of Beh&ccedil;et's patients with neurological involvement compared with patients with noninflammatory neurological diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/163\">",
"     163",
"    </a>",
"    ]. Polymorphisms of the vascular endothelial growth factor (VGEF) gene are associated with Beh&ccedil;et&rsquo;s, but not in all populations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/34-36,164\">",
"     34-36,164",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IgM-antiendothelial antibodies were found to be reactive with alpha enolase in some Korean Beh&ccedil;et's patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/165\">",
"     165",
"    </a>",
"    ]. A follow-up study demonstrated IgM-antiendothelial antibodies in patients with Beh&ccedil;et's (56 percent), systemic sclerosis (71.4 percent), rheumatoid arthritis (65 percent), Takayasu&rsquo;s (50 percent), dermatomyositis (52.9 percent), and mixed connective tissue disease (45.5 percent); these antibodies were associated with the presence of vascular lesions in patients with Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/166\">",
"     166",
"    </a>",
"    ]. Leptin is expressed by endothelial cells, and increased levels in Beh&ccedil;et&rsquo;s may correlate with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/167\">",
"     167",
"    </a>",
"    ]. Endothelial cell activation and a generalized hypercoagulable state were observed in 24 patients with ocular Beh&ccedil;et&rsquo;s characterized by increased mean levels of factor VIII, factor XI, von Willebrand factor antigen and ristocetin, antithrombin III, and fibrinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A generalized hypercoagulable state appears to exist in many Beh&ccedil;et&rsquo;s patients. Thrombin formation is increased, and fibrinolysis is decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,169,170\">",
"     13,169,170",
"    </a>",
"    ]. Lower activated protein C (APC) and soluble thrombomodulin concentrations in the plasma of patients with Beh&ccedil;et&rsquo;s disease have been observed. Thrombomodulin, present on the endothelial cell surface, binds thrombin, and the substrate specificity of thrombin thus bound is changed so that it preferentially activates protein C rather than cleaving fibrinogen. The APC generated at the endothelial surface is an important inhibitor of coagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The findings of significantly decreased mean concentrations of plasma APC among 39 Spanish patients with Beh&ccedil;et&rsquo;s disease versus healthy controls, and of lower levels of APC among patients with Beh&ccedil;et&rsquo;s disease who had a prior thromboembolic episode versus those who had not, suggest that an acquired deficiency of APC in Beh&ccedil;et&rsquo;s disease may contribute to the risk of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/171\">",
"     171",
"    </a>",
"    ]. Platelet activity is increased in Beh&ccedil;et&rsquo;s patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/172\">",
"     172",
"    </a>",
"    ]. Studies have shown decreased erythrocyte deformability in Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/173,174\">",
"     173,174",
"    </a>",
"    ]. Tissue-type plasminogen activator levels are lower in patients with deep venous thrombosis who have Beh&ccedil;et&rsquo;s than in those who do not have Beh&ccedil;et&rsquo;s; this suggests a defect in fibrinolysis in Beh&ccedil;et&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/175\">",
"     175",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombophilic factors such as factor V Leiden and prothrombin G20210A gene have not been linked to Beh&ccedil;et&rsquo;s, although Beh&ccedil;et&rsquo;s patients with coexisting thrombophilic factors may be at higher risk for thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/176,177\">",
"     176,177",
"    </a>",
"    ]. Levels of the fibrinolytic inhibitors thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) were higher in Beh&ccedil;et&rsquo;s patients than in controls, particularly in those patients with thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the majority of available evidence suggests that the pathogenesis of thrombosis in Beh&ccedil;et's is probably not due to a hypercoagulable state but rather to vascular damage induced by inflammation or intrinsic endothelial dysfunction that, by itself, may serve as a source of thrombogenic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/179-181\">",
"     179-181",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Beh&ccedil;et&rsquo;s have increased intima-media thickness and decreased arterial distensibility compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/182\">",
"     182",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neutrophil activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphonuclear leukocytes (PMNs) are activated in Beh&ccedil;et&rsquo;s disease.",
"   </p>",
"   <p>",
"    In Beh&ccedil;et&rsquo;s disease, PMN motility is increased. Increased circulating levels of cytokines such as IL-8 and TNF-alpha lead to activation of PMNs and the endothelial surface [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/183,184\">",
"     183,184",
"    </a>",
"    ]. Cell surface markers indicative of activation, such as CD64, are increased in patients with active disease to levels similar to those of patients with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/185\">",
"     185",
"    </a>",
"    ]. PMNs exhibit increased motility and enhanced adhesion to endothelial cells in vitro, a property due, in part, to increased expression of cell surface receptors including CD11a, CD18, and ICAM-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/186\">",
"     186",
"    </a>",
"    ]. Neutrophil binding to the endothelium is also facilitated by upregulated surface expression of adhesion molecules such as E-selectin. Increased E-selectin on the luminal surface favors neutrophil adhesion and facilitates neutrophil migration into the wall of the affected vessel and beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurements of serum soluble levels of this activity have been observed. Serum soluble ICAM-1 is increased in patients with Beh&ccedil;et&rsquo;s disease, and the concentration may correlate with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/77,187\">",
"     77,187",
"    </a>",
"    ]. The serum of patients with active Beh&ccedil;et&rsquo;s disease may promote increased E-selectin presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/80\">",
"     80",
"    </a>",
"    ]. Some of this may be due to anti-endothelial antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/146\">",
"     146",
"    </a>",
"    ]. Serum soluble levels of selectin have been shown to be elevated in patients with active untreated disease but not if it is treated or inactive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/188,189\">",
"     188,189",
"    </a>",
"    ]. A study of patients with Beh&ccedil;et&rsquo;s retinal vasculitis showed elevated levels of soluble E-selectin, s-ICAM-1, and Interferon-beta. In vitro studies showed that these were produced by activated retinal vascular endothelial cells and that this could be inhibited by pretreatment with anti-Toll-like receptor 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/190\">",
"     190",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protein actin is required for PMN mobility. The presence of high levels of a truncated actin with an N-terminus of Met-44 has been observed in neutrophils from Beh&ccedil;et&rsquo;s patients; PMN-elastase responsible for this cleavage has been isolated. Resulting altered PMN activity has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/191,192\">",
"     191,192",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=see_link\">",
"     \"Determinants of neutrophil movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased amount of reactive oxygen species suggest neutrophil mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,193,194\">",
"     13,193,194",
"    </a>",
"    ]. Endogenous free radical scavenging enzymes appear to be reduced in Beh&ccedil;et&rsquo;s, creating an imbalance in the oxidant antioxidant equilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,76\">",
"     13,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) levels and neutrophil apoptosis are increased in active Beh&ccedil;et&rsquo;s patients compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/195\">",
"     195",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Markers of neutrophil activity have been proposed as possible indicators of disease activity and severity. These include polymorphonuclear elastase, plasma myeloperoxidase, and advanced oxidation protein products [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/77,196,197\">",
"     77,196,197",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Matrix metalloproteinases play a role in leucocyte invasion of the central nervous system. Elevated levels of matrix metalloprotein-9 have been described in Beh&ccedil;et's patients compared with controls, and levels correlated with CSF neutrophil and mononuclear cells in a study of Beh&ccedil;et's patients with neurologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/198\">",
"     198",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beh&ccedil;et's arthritis is characterized by synovial inflammation with significant neutrophilic greater than lymphocytic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/199\">",
"     199",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monocytes from patients with Beh&ccedil;et&rsquo;s have enhanced activity, with increased differentiation and expression of adhesion molecules and cytokines, which, in turn, leads to neutrophil activation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13,200,201\">",
"     13,200,201",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination of involved tissue in patients with Beh&ccedil;et&rsquo;s disease frequently reveals a vasculitis, although this finding may not be demonstrated in all lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/5,202\">",
"     5,202",
"    </a>",
"    ]. The classic Beh&ccedil;et&rsquo;s lesion is necrotizing leukocytoclastic obliterative perivasculitis and venous thrombosis with lymphocytic infiltration of capillaries, veins, and arteries of all sizes. Cellular infiltration is often in a perivascular distribution; neutrophils and CD4+ T lymphocytes are present around the vasa vasorum and perivascular area. When a frank leukocytoclastic vasculitis is present, there may be endothelial swelling, extravasation of erythrocytes, and fibrinoid necrosis of blood vessel walls. Thrombosis is often present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucocutaneous lesions demonstrate lymphocytic infiltration, immunoglobulin and complement deposition, and liquefaction-degeneration at the dermal-epidermal junction in association with necrosis and ulcer formation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/203,204\">",
"     203,204",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophilic and mononuclear infiltrates are frequently observed in spontaneous acute lesions and following testing for pathergy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/5,205\">",
"     5,205",
"    </a>",
"    ]. Papulopustular lesions may show leukocytoclastic vasculitis with IgM, IgG, C3, and fibrin deposits, consistent with an immune complex vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/206,207\">",
"     206,207",
"    </a>",
"    ]. Pustular skin lesions are often not sterile and may contain Staphylococcus aureus and Prevotella species [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/208\">",
"     208",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythema nodosum type lesions in Beh&ccedil;et&rsquo;s demonstrate lobular or mixed lobular and septal panniculitis; demonstrate variable numbers of neutrophils, lymphocytes, and histiocytes; and often show leukocytoclastic vasculitis.",
"   </p>",
"   <p>",
"    Ocular Beh&ccedil;et&rsquo;s lesions may show leukocyte infiltration around blood vessels, occlusive retinal perivasculitis, and thrombosis. Nongranulomatous panuveitis is characteristic. During active disease, neutrophils may be present in the anterior chamber of the eye, as well as the corneal epithelium, iris, ciliary body, and choroids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central nervous system lesions in Beh&ccedil;et&rsquo;s demonstrate perivascular cuffing of T lymphocytes and monocytes, as well as apoptosis of affected neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/209\">",
"     209",
"    </a>",
"    ]. Involved areas include the spinal cord, brainstem (including the pons, medulla oblongata, and midbrain), cerebellum, basal ganglia, thalamus, internal capsule, and periventricular white matter.",
"   </p>",
"   <p>",
"    Although renal involvement is infrequent and usually mild, when present, renal histology may show mesangial proliferation, proliferative glomerulonephritis, crescent formation, and deposits of immunoglobulin, complement, and immune complex in the glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/210\">",
"     210",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beh&ccedil;et's arthritis is characterized by synovial inflammation with significant neutrophilic greater than lymphocytic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/12/28874/abstract/199\">",
"     199",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17358645\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many, but not all, clinical manifestations of Beh&ccedil;et&rsquo;s disease are believed to be due to vasculitis. Among the systemic vasculitides, Beh&ccedil;et&rsquo;s disease is remarkable for its ability to involve blood vessels of all sizes (small, medium, and large) on both the arterial and venous sides of the circulation. Beh&ccedil;et&rsquo;s disease is more common (and often more severe) along the ancient silk road, which extends from eastern Asia to the Mediterranean. It is most common in Turkey (80 to 370 cases per 100,000). The prevalence is from 1 per 15,000 to 1 per 500,000 in Northern American and Northern European countries. It typically affects young adults 20 to 40 years of age. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The underlying cause of Beh&ccedil;et&rsquo;s disease is unknown. As with autoimmune diseases, the disorder may represent aberrant immune activity triggered by exposure to an agent, perhaps infectious, in patients with a genetic predisposition to develop the disease. Proposed triggering agents include viral and bacterial antigens or other environmental sources, such as chemicals or heavy metals. Although still a possible contributor, direct infection of affected tissues has not been observed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic predisposition to the disease is likely polygenic. Genetic influences include association with certain human leukocyte antigens (HLA), including HLA-B51, but both HLA and non-HLA genes may play a role. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'HLA genes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Non-HLA genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies suggest a possible pathogenic role of certain bacterial antigens that have crossreactivity with human peptides. Different studies have implicated various antigens and organisms, including heat shock proteins, streptococcal antigens, Helicobacter pylori, Herpes simplex virus, and parvovirus B19.",
"     </li>",
"     <li>",
"      Altered innate immune function has been suggested by some studies. These include investigations suggesting deficiencies in mannose-binding lectin and alterations in the expression of toll-like receptors. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Molecular mimicry'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Altered innate immune function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are alterations in the numbers of T cell subpopulations and evidence of cellular activation. Autoreactive T cells appear to play a critical role in the pathogenesis of Beh&ccedil;et&rsquo;s. A T helper (Th) 1 predominant response has been observed in many studies of Beh&ccedil;et&rsquo;s, but some studies have shown evidence for a Th2 response. There may be a mix of Th1 and Th2 activity in Beh&ccedil;et&rsquo;s and increased activity of Th17 cells. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cellular immunity and cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to cellular immune activation, there is also evidence of humoral immune activation in Beh&ccedil;et&rsquo;s, and autoantibodies have been described against a number of targets. Immune complexes may also play a role. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Autoantibody and immune complex formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endothelial dysfunction is a characteristic finding in Beh&ccedil;et&rsquo;s. Endothelium-dependent flow-mediated dilation is reduced, and endothelial activation in affected blood vessels is a mediator of vascular inflammation as well as thrombosis in Beh&ccedil;et&rsquo;s.",
"     </li>",
"     <li>",
"      Polymorphonuclear leukocytes (PMNs) are activated in Beh&ccedil;et&rsquo;s disease; PMNs exhibit increased motility and enhanced adhesion to endothelial cells in vitro. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Endothelial activation and altered coagulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Neutrophil activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologic examination of involved tissue in patients with Beh&ccedil;et&rsquo;s disease frequently reveals a vasculitis, although this finding may not be demonstrated in all lesions. The classic Beh&ccedil;et&rsquo;s lesion is necrotizing leukocytoclastic obliterative perivasculitis and venous thrombosis with lymphocytic infiltration of capillaries, veins, and arteries of all sizes. Cellular infiltration is often in a perivascular distribution; neutrophils and CD4+ T lymphocytes are present around the vasa vasorum and perivascular area. Other histologic findings may include panniculitis in erythema nodosum-like lesions and neutrophilic and mononuclear infiltrates in spontaneous acute lesions and following testing for pathergy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/1\">",
"      Sakane T, Takeno M, Suzuki N, Inaba G. Beh&ccedil;et's disease. N Engl J Med 1999; 341:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/2\">",
"      Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Beh&ccedil;et's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/3\">",
"      Yazici H, Seyahi E, Yurdakul S. Beh&ccedil;et's syndrome is not so rare: why do we need to know? Arthritis Rheum 2008; 58:3640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/4\">",
"      Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Beh&ccedil;et's disease in the US: a population-based study. Arthritis Rheum 2009; 61:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/5\">",
"      Direskeneli H. Beh&ccedil;et's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001; 60:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/6\">",
"      de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Beh&ccedil;et's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009; 61:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/7\">",
"      Arber N, Klein T, Meiner Z, et al. Close association of HLA-B51 and B52 in Israeli patients with Beh&ccedil;et's syndrome. Ann Rheum Dis 1991; 50:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/8\">",
"      Salvarani C, Boiardi L, Mantovani V, et al. Association of MICA alleles and HLA-B51 in Italian patients with Beh&ccedil;et's disease. J Rheumatol 2001; 28:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/9\">",
"      K&ouml;tter I, G&uuml;naydin I, St&uuml;biger N, et al. Comparative analysis of the association of HLA-B*51 suballeles with Beh&ccedil;et's disease in patients of German and Turkish origin. Tissue Antigens 2001; 58:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/10\">",
"      Ahmad T, Wallace GR, James T, et al. Mapping the HLA association in Beh&ccedil;et's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 2003; 48:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/11\">",
"      Baskan EB, Yilmaz E, Saricaoglu H, et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Beh&ccedil;et's disease. Clin Exp Dermatol 2007; 32:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/12\">",
"      Mizuki N, Meguro A, Tohnai I, et al. Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Beh&ccedil;et's Disease in Turkey. Jpn J Ophthalmol 2007; 51:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/13\">",
"      Evereklioglu C. Current concepts in the etiology and treatment of Beh&ccedil;et disease. Surv Ophthalmol 2005; 50:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/14\">",
"      Bennani N, Atouf O, Benseffaj N, et al. [HLA polymorphism and Beh&ccedil;et's disease in Moroccan population]. Pathol Biol (Paris) 2009; 57:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/15\">",
"      Kamiishi T, Itoh Y, Meguro A, et al. [Four-digit allele genotyping of HLA-A and HLA-B genes in Japanese patients with Beh&ccedil;et's disease (BD) by a PCR-SSOP-luminex method and stratification analysis according to each major symptom of BD]. Nihon Ganka Gakkai Zasshi 2008; 112:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/16\">",
"      Meguro A, Inoko H, Ota M, et al. Genetics of Beh&ccedil;et disease inside and outside the MHC. Ann Rheum Dis 2010; 69:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/17\">",
"      G&uuml;l A, Hajeer AH, Worthington J, et al. Evidence for linkage of the HLA-B locus in Beh&ccedil;et's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001; 44:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/18\">",
"      Sakane T, Takeno M. Novel approaches to Beh&ccedil;et's disease. Expert Opin Investig Drugs 2000; 9:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/19\">",
"      Ermakova NA, Alekberova ZS, Prokaeva TB, Poljanskaja IB. Frequency of HLA in patients with Beh&ccedil;et's disease and association with occlusive retinal vasculitis. Adv Exp Med Biol 2003; 528:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/20\">",
"      Choukri F, Chakib A, Himmich H, et al. HLA-B phenotype modifies the course of Beh&ccedil;et's disease in Moroccan patients. Tissue Antigens 2003; 61:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/21\">",
"      G&uuml;l A, Uyar FA, Inanc M, et al. Lack of association of HLA-B*51 with a severe disease course in Beh&ccedil;et's disease. Rheumatology (Oxford) 2001; 40:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/22\">",
"      Mizuki N, Inoko H, Ohno S. Pathogenic gene responsible for the predisposition of Beh&ccedil;et's disease. Int Rev Immunol 1997; 14:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/23\">",
"      Gebreselassie D, Spiegel H, Vukmanovic S. Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 2006; 67:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/24\">",
"      Wildner G, Thurau SR. Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol 1994; 24:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/25\">",
"      Ota M, Mizuki N, Katsuyama Y, et al. The critical region for Beh&ccedil;et disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet 1999; 64:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/26\">",
"      Mu&ntilde;oz-Sa&aacute; I, Cambra A, Pallar&eacute;s L, et al. Allelic diversity and affinity variants of MICA are imbalanced in Spanish patients with Beh&ccedil;et's disease. Scand J Immunol 2006; 64:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/27\">",
"      Hughes EH, Collins RW, Kondeatis E, et al. Associations of major histocompatibility complex class I chain-related molecule polymorphisms with Behcet's disease in Caucasian patients. Tissue Antigens 2005; 66:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/28\">",
"      G&uuml;l A, Hajeer AH, Worthington J, et al. Linkage mapping of a novel susceptibility locus for Beh&ccedil;et's disease to chromosome 6p22-23. Arthritis Rheum 2001; 44:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/29\">",
"      Akpolat T, Ko&ccedil; Y, Yeniay I, et al. Familial Beh&ccedil;et's disease. Eur J Med 1992; 1:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/30\">",
"      Kon&eacute;-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Beh&ccedil;et's disease: high frequency in siblings and parents of pediatric probands. J Pediatr 1999; 135:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/31\">",
"      Fresko I, Soy M, Hamuryudan V, et al. Genetic anticipation in Beh&ccedil;et's syndrome. Ann Rheum Dis 1998; 57:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/32\">",
"      Mizuki N, Ota M, Kimura M, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Beh&ccedil;et disease. Proc Natl Acad Sci U S A 1997; 94:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/33\">",
"      Karasneh J, G&uuml;l A, Ollier WE, et al. Whole-genome screening for susceptibility genes in multicase families with Beh&ccedil;et's disease. Arthritis Rheum 2005; 52:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/34\">",
"      Salvarani C, Boiardi L, Casali B, et al. Endothelial nitric oxide synthase gene polymorphisms in Beh&ccedil;et's disease. J Rheumatol 2002; 29:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/35\">",
"      Karasneh JA, Hajeer AH, Silman A, et al. Polymorphisms in the endothelial nitric oxide synthase gene are associated with Beh&ccedil;et's disease. Rheumatology (Oxford) 2005; 44:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/36\">",
"      Salvarani C, Boiardi L, Casali B, et al. Vascular endothelial growth factor gene polymorphisms in Beh&ccedil;et's disease. J Rheumatol 2004; 31:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/37\">",
"      Kim JU, Chang HK, Lee SS, et al. Endothelial nitric oxide synthase gene polymorphisms in Beh&ccedil;et's disease and rheumatic diseases with vasculitis. Ann Rheum Dis 2003; 62:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/38\">",
"      Verity DH, Wallace GR, Vaughan RW, et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Beh&ccedil;et's disease. Tissue Antigens 1999; 54:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/39\">",
"      Lee EB, Kim JY, Lee YJ, et al. TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum Immunol 2003; 64:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/40\">",
"      Kamoun M, Chelbi H, Houman MH, et al. Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet's disease. Hum Immunol 2007; 68:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/41\">",
"      Nakao K, Isashiki Y, Sonoda S, et al. Nitric oxide synthase and superoxide dismutase gene polymorphisms in Beh&ccedil;et disease. Arch Ophthalmol 2007; 125:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/42\">",
"      Tursen U, Tamer L, Api H, et al. Cytochrome P450 polymorphisms in patients with Behcet's disease. Int J Dermatol 2007; 46:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/43\">",
"      Alayli G, Aydin F, Coban AY, et al. T helper 1 type cytokines polymorphisms: association with susceptibility to Beh&ccedil;et's disease. Clin Rheumatol 2007; 26:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/44\">",
"      Lee YJ, Kang SW, Park JJ, et al. Interleukin-18 promoter polymorphisms in patients with Beh&ccedil;et's disease. Hum Immunol 2006; 67:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/45\">",
"      Akman A, Sallakci N, Coskun M, et al. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Beh&ccedil;et's disease. Br J Dermatol 2006; 155:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/46\">",
"      Chmaisse HN, Fakhoury HA, Salti NN, Makki RF. The ICAM-1 469 T/C gene polymorphism but not 241 G/A is associated with Beh&ccedil;ets disease in the Lebanese population. Saudi Med J 2006; 27:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/47\">",
"      Fei Y, Webb R, Cobb BL, et al. Identification of novel genetic susceptibility loci for Beh&ccedil;et's disease using a genome-wide association study. Arthritis Res Ther 2009; 11:R66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/48\">",
"      Gunesacar R, Erken E, Bozkurt B, et al. Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet's disease. Int J Immunogenet 2007; 34:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/49\">",
"      Touma Z, Farra C, Hamdan A, et al. TNF polymorphisms in patients with Beh&ccedil;et disease: a meta-analysis. Arch Med Res 2010; 41:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/50\">",
"      Dilek K, Oz&ccedil;imen AA, Saricao��lu H, et al. Cytokine gene polymorphisms in Beh&ccedil;et's disease and their association with clinical and laboratory findings. Clin Exp Rheumatol 2009; 27:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/51\">",
"      Kamoun M, Houman MH, Hamzaoui A, Hamzaoui K. Vascular endothelial growth factor gene polymorphisms and serum levels in Beh&ccedil;et's disease. Tissue Antigens 2008; 72:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/52\">",
"      Park KS, Baek JA, Do JE, et al. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet's disease. Tissue Antigens 2009; 74:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/53\">",
"      Horie Y, Meguro A, Ota M, et al. Association of TLR4 polymorphisms with Behcet's disease in a Korean population. Rheumatology (Oxford) 2009; 48:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/54\">",
"      Livneh A, Aksentijevich I, Langevitz P, et al. A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Beh&ccedil;et's disease (FMF-BD). Eur J Hum Genet 2001; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/55\">",
"      Kogan A, Shinar Y, Lidar M, et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 2001; 102:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/56\">",
"      Rabinovich E, Shinar Y, Leiba M, et al. Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis. Scand J Rheumatol 2007; 36:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/57\">",
"      Dursun A, Durakbasi-Dursun HG, Zamani AG, et al. Genetic analysis of MEFV gene pyrin domain in patients with Beh&ccedil;et's disease. Mediators Inflamm 2006; 2006:41783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/58\">",
"      Direskeneli H, Hasan A, Shinnick T, et al. Recognition of B-cell epitopes of the 65 kDa HSP in Beh&ccedil;et's disease. Scand J Immunol 1996; 43:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/59\">",
"      de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Inflamm 2001; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/60\">",
"      Suzuki Y, Hoshi K, Matsuda T, Mizushima Y. Increased peripheral blood gamma delta+ T cells and natural killer cells in Beh&ccedil;et's disease. J Rheumatol 1992; 19:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/61\">",
"      Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Beh&ccedil;et's disease--a multicenter study. The Behcet's Disease Research Committee of Japan. J Rheumatol 1989; 16:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/62\">",
"      Mumcu G, Inanc N, Aydin SZ, et al. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Beh&ccedil;et's disease. Clin Exp Rheumatol 2009; 27:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/63\">",
"      Yokota K, Hayashi S, Fujii N, et al. Antibody response to oral streptococci in Beh&ccedil;et's disease. Microbiol Immunol 1992; 36:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/64\">",
"      Isogai E, Ohno S, Kotake S, et al. Chemiluminescence of neutrophils from patients with Beh&ccedil;et's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol 1990; 35:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/65\">",
"      Calg&uuml;neri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Beh&ccedil;et's disease. Dermatology 1996; 192:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/66\">",
"      Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol 1992; 140:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/67\">",
"      Mochizuki M, Suzuki N, Takeno M, et al. Fine antigen specificity of human gamma delta T cell lines (V gamma 9+) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Immunol 1994; 24:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/68\">",
"      Evereklioglu C, Er H, T&uuml;rk&ouml;z Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh&ccedil;et's disease. Mediators Inflamm 2002; 11:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/69\">",
"      Tanaka T, Yamakawa N, Koike N, et al. Beh&ccedil;et's disease and antibody titers to various heat-shock protein 60s. Ocul Immunol Inflamm 1999; 7:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/70\">",
"      Apan TZ, G&uuml;rsel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin-associated gene-A in Beh&ccedil;et's disease. Clin Rheumatol 2007; 26:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/71\">",
"      Inanc N, Mumcu G, Birtas E, et al. Serum mannose-binding lectin levels are decreased in behcet's disease and associated with disease severity. J Rheumatol 2005; 32:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/72\">",
"      Yavuz S, Elbir Y, Tulunay A, et al. Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet's disease etiopathogenesis. Rheumatol Int 2008; 28:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/73\">",
"      Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease. Rheumatology (Oxford) 2008; 47:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/74\">",
"      Nara K, Kurokawa MS, Chiba S, et al. Involvement of innate immunity in the pathogenesis of intestinal Beh&ccedil;et's disease. Clin Exp Immunol 2008; 152:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/75\">",
"      Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Beh&ccedil;et's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003; 42:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/76\">",
"      Erkili&ccedil; K, Evereklioglu C, Cekmen M, et al. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Beh&ccedil;et's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003; 12:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/77\">",
"      Calis M, Ates F, Yazici C, et al. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Beh&ccedil;et's disease. Rheumatol Int 2005; 25:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/78\">",
"      Canpolat F, Unver M, Eskio��lu F, et al. Serum and erythrocyte adenosine deaminase activities in patients with Beh&ccedil;et's disease. Int J Dermatol 2006; 45:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/79\">",
"      Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Beh&ccedil;et's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/80\">",
"      Raziuddin S, al-Dalaan A, Bahabri S, et al. Divergent cytokine production profile in Beh&ccedil;et's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998; 25:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/81\">",
"      Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol 2006; 35:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/82\">",
"      Sugi-Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Beh&ccedil;et's disease. Invest Ophthalmol Vis Sci 1998; 39:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/83\">",
"      Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Beh&ccedil;et's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999; 42:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/84\">",
"      Boiardi L, Salvarani C, Casali B, et al. Intercellular adhesion molecule-1 gene polymorphisms in Beh&ccedil;et's Disease. J Rheumatol 2001; 28:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/85\">",
"      Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Beh&ccedil;et's disease. Arthritis Rheum 2004; 50:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/86\">",
"      Bardak Y, Arido��an BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Beh&ccedil;et's disease with ocular involvement. Ocul Immunol Inflamm 2004; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/87\">",
"      Suzuki N, Nara K, Suzuki T. Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet's disease. Clin Med Res 2006; 4:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/88\">",
"      Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol 2005; 139:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/89\">",
"      Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bech&ccedil;et's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997; 24:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/90\">",
"      Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades-Beh&ccedil;et's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000; 201:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/91\">",
"      Musabak U, Pay S, Erdem H, et al. Serum interleukin-18 levels in patients with Beh&ccedil;et's disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 2006; 26:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/92\">",
"      Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Beh&ccedil;et's disease. Scand J Rheumatol 2008; 37:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/93\">",
"      Durmazlar SP, Ulkar GB, Eskioglu F, et al. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement. Int J Dermatol 2009; 48:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/94\">",
"      Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh&ccedil;et's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/95\">",
"      Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol 2009; 19:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/96\">",
"      Akman-Demir G, T&uuml;z&uuml;n E, I&ccedil;&ouml;z S, et al. Interleukin-6 in neuro-Beh&ccedil;et's disease: association with disease subsets and long-term outcome. Cytokine 2008; 44:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/97\">",
"      Lew W, Chang JY, Jung JY, Bang D. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Beh&ccedil;et's disease. Br J Dermatol 2008; 158:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/98\">",
"      Pay S, Simsek I, Erdem H, et al. Dendritic cell subsets and type I interferon system in Beh&ccedil;et's disease: does functional abnormality in plasmacytoid dendritic cells contribute to Th1 polarization? Clin Exp Rheumatol 2007; 25:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/99\">",
"      Manta�� C, Direskeneli H, Ek��ioglu-Demiralp E, Akoglu T. Serum levels of Th2 cytokines IL-4 and IL-10 in Beh&ccedil;et's disease. J Rheumatol 1999; 26:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/100\">",
"      Sugita S, Kawazoe Y, Imai A, et al. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh&ccedil;et's disease. Arthritis Res Ther 2012; 14:R99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/101\">",
"      Shimizu J, Takai K, Fujiwara N, et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-&gamma; in patients with Beh&ccedil;et's disease. Clin Exp Immunol 2012; 168:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/102\">",
"      Hamzaoui K. Th17 cells in Beh&ccedil;et's disease: a new immunoregulatory axis. Clin Exp Rheumatol 2011; 29:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/103\">",
"      Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh&ccedil;et disease. J Allergy Clin Immunol 2011; 128:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/104\">",
"      Liang L, Wang H, Peng XY, Zhao M. [The changes of Th lymphocyte subsets in patients with Behcet disease]. Zhonghua Yan Ke Za Zhi 2011; 47:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/105\">",
"      Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Beh&ccedil;et's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/106\">",
"      Yato H, Matsumoto Y. CD56+ T cells in the peripheral blood of uveitis patients. Br J Ophthalmol 1999; 83:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/107\">",
"      Eksioglu-Demiralp E, Direskeneli H, Ergun T, et al. Increased CD4+CD16+ and CD4+CD56+ T cell subsets in Beh&ccedil;et's disease. Rheumatol Int 1999; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/108\">",
"      Kim TW, Chung H, Yu HG. Chemokine expression of intraocular lymphocytes in patients with Beh&ccedil;et uveitis. Ophthalmic Res 2011; 45:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/109\">",
"      Bank I, Duvdevani M, Livneh A. Expansion of gammadelta T-cells in Beh&ccedil;et's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 2003; 141:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/110\">",
"      Clemente A, Cambra A, Munoz-Sa&aacute; I, et al. Phenotype markers and cytokine intracellular production by CD8+ gammadelta T lymphocytes do not support a regulatory T profile in Beh&ccedil;et's disease patients and healthy controls. Immunol Lett 2010; 129:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/111\">",
"      Freysdottir J, Hussain L, Farmer I, et al. Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis 2006; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/112\">",
"      Ben Dhifallah I, Chelbi H, Braham A, et al. CTLA-4 +49A/G polymorphism is associated with Beh&ccedil;et's disease in a Tunisian population. Tissue Antigens 2009; 73:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/113\">",
"      Yasuoka H, Okazaki Y, Kawakami Y, et al. Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Beh&ccedil;et's disease. Arthritis Rheum 2004; 50:3658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/114\">",
"      Yu HG, Lee DS, Seo JM, et al. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Beh&ccedil;et's uveitis. Clin Exp Immunol 2004; 137:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/115\">",
"      Keino H, Sakai J, Nishioka K, et al. Clonally accumulating T cells in the anterior chamber of Beh&ccedil;et disease. Am J Ophthalmol 2000; 130:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/116\">",
"      Takase H, Sugita S, Taguchi C, et al. Capacity of ocular infiltrating T helper type 1 cells of patients with non-infectious uveitis to produce chemokines. Br J Ophthalmol 2006; 90:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/117\">",
"      Ahn JK, Chung H, Lee DS, et al. CD8brightCD56+ T cells are cytotoxic effectors in patients with active Behcet's uveitis. J Immunol 2005; 175:6133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/118\">",
"      Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Beh&ccedil;et uveitis. Am J Ophthalmol 2006; 142:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/119\">",
"      Guenane H, Hartani D, Chachoua L, et al. [Production of Th1/Th2 cytokines and nitric oxide in Beh&ccedil;et's uveitis and idiopathic uveitis]. J Fr Ophtalmol 2006; 29:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/120\">",
"      Pay S, Erdem H, Pekel A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Beh&ccedil;et's disease. Does interleukin-1beta play a major role in Beh&ccedil;et's synovitis? Rheumatol Int 2006; 26:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/121\">",
"      Todaro M, Zerilli M, Triolo G, et al. NF-kappaB protects Beh&ccedil;et's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum 2005; 52:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/122\">",
"      Fujimori K, Oh-i K, Takeuchi M, et al. Circulating neutrophils in Beh&ccedil;et disease is resistant for apoptotic cell death in the remission phase of uveitis. Graefes Arch Clin Exp Ophthalmol 2008; 246:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/123\">",
"      Ozkan Y, Yardim-Akaydin S, Sepici A, et al. Assessment of homocysteine, neopterin and nitric oxide levels in Beh&ccedil;et's disease. Clin Chem Lab Med 2007; 45:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/124\">",
"      Erturan I, Basak PY, Ozturk O, et al. Is there any relationship between serum and urine neopterin and serum interferon-gamma levels in the activity of Behcet's disease? J Eur Acad Dermatol Venereol 2009; 23:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/125\">",
"      Suh CH, Park YB, Song J, et al. Oligoclonal B lymphocyte expansion in the synovium of a patient with Beh&ccedil;et's disease. Arthritis Rheum 2001; 44:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/126\">",
"      Ek��ioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Beh&ccedil;et's disease: increased activity in B cell subsets. J Rheumatol 1999; 26:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/127\">",
"      Ayd&igrave;ntug AO, Tokg&ouml;z G, D'Cruz DP, et al. Antibodies to endothelial cells in patients with Beh&ccedil;et's disease. Clin Immunol Immunopathol 1993; 67:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/128\">",
"      Direskeneli H, Keser G, D'Cruz D, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Beh&ccedil;et's disease. Clin Rheumatol 1995; 14:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/129\">",
"      Matsui T, Kurokawa M, Kobata T, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999; 162:4328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/130\">",
"      Matsui T, Otsuka M, Maenaka K, et al. Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases. Arthritis Rheum 2001; 44:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/131\">",
"      Orem A, Cim��it G, De��er O, et al. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Beh&ccedil;et's disease. Dermatology 1999; 198:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/132\">",
"      Feng XG, Ye S, Lu Y, et al. Antikinectin autoantibody in Beh&ccedil;et's disease and several other autoimmune connective tissue diseases. Clin Exp Rheumatol 2007; 25:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/133\">",
"      Choi CH, Kim TI, Kim BC, et al. Anti-Saccharomyces cerevisiae antibody in intestinal Beh&ccedil;et's disease patients: relation to clinical course. Dis Colon Rectum 2006; 49:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/134\">",
"      Kurhan-Yavuz S, Direskeneli H, Bozkurt N, et al. Anti-MHC autoimmunity in Beh&ccedil;et's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis. Clin Exp Immunol 2000; 120:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/135\">",
"      Yamamoto JH, Minami M, Inaba G, et al. Cellular autoimmunity to retinal specific antigens in patients with Beh&ccedil;et's disease. Br J Ophthalmol 1993; 77:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/136\">",
"      de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Beh&ccedil;et's disease patients and controls. Invest Ophthalmol Vis Sci 2000; 41:3480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/137\">",
"      Zhao C, Yang P, He H, et al. S-antigen specific T helper type 1 response is present in Behcet's disease. Mol Vis 2008; 14:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/138\">",
"      Mahesh SP, Li Z, Buggage R, et al. Alpha tropomyosin as a self-antigen in patients with Beh&ccedil;et's disease. Clin Exp Immunol 2005; 140:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/139\">",
"      Okunuki Y, Usui Y, Takeuchi M, et al. Proteomic surveillance of autoimmunity in Behcet's disease with uveitis: selenium binding protein is a novel autoantigen in Behcet's disease. Exp Eye Res 2007; 84:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/140\">",
"      Takeuchi M, Usui Y, Okunuki Y, et al. Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. Invest Ophthalmol Vis Sci 2010; 51:3067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/141\">",
"      Mor F, Weinberger A, Cohen IR. Identification of alpha-tropomyosin as a target self-antigen in Beh&ccedil;et's syndrome. Eur J Immunol 2002; 32:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/142\">",
"      Lu Y, Ye P, Chen SL, et al. Identification of kinectin as a novel Beh&ccedil;et's disease autoantigen. Arthritis Res Ther 2005; 7:R1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/143\">",
"      Kayik&ccedil;io��lu M, Aksu K, Hasdemir C, et al. Endothelial functions in Beh&ccedil;et's disease. Rheumatol Int 2006; 26:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/144\">",
"      Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Beh&ccedil;et's syndrome. J Am Coll Cardiol 2001; 37:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/145\">",
"      Oflaz H, Mercanoglu F, Karaman O, et al. Impaired endothelium-dependent flow-mediated dilation in Beh&ccedil;et's disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract 2005; 59:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/146\">",
"      Triolo G, Accardo-Palumbo A, Triolo G, et al. Enhancement of endothelial cell E-selectin expression by sera from patients with active Beh&ccedil;et's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999; 91:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/147\">",
"      Kansu E, Sahin G, Sahin F, et al. Impaired prostacyclin synthesis by vessel walls in Beh&ccedil;et's disease. Lancet 1986; 2:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/148\">",
"      Evereklioglu C, Turkoz Y, Er H, et al. Increased nitric oxide production in patients with Beh&ccedil;et's disease: is it a new activity marker? J Am Acad Dermatol 2002; 46:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/149\">",
"      Evereklioglu C, Cekmen M, Ozkiri�� A, et al. The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Beh&ccedil;et's disease. Mediators Inflamm 2003; 12:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/150\">",
"      Yilmaz G, Sizmaz S, Yilmaz ED, et al. Aqueous humor nitric oxide levels in patients with Beh&ccedil;et disease. Retina 2002; 22:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/151\">",
"      Buldanlioglu S, Turkmen S, Ayabakan HB, et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Beh&ccedil;et's disease. Br J Dermatol 2005; 153:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/152\">",
"      Duygulu F, Evereklioglu C, Calis M, et al. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Beh&ccedil;et's disease: a pilot study. Clin Rheumatol 2005; 24:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/153\">",
"      Sahin M, Arslan C, Naziroglu M, et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. Ann Clin Lab Sci 2006; 36:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/154\">",
"      Harzallah O, Kerkeni A, Baati T, Mahjoub S. Oxidative stress: correlation with Beh&ccedil;et's disease duration, activity and severity. Eur J Intern Med 2008; 19:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/155\">",
"      Ozdemir R, Barutcu I, Sezgin AT, et al. Vascular endothelial function and plasma homocysteine levels in Behcet's disease. Am J Cardiol 2004; 94:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/156\">",
"      Er H, Evereklioglu C, Cumurcu T, et al. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Beh&ccedil;et's disease. Br J Ophthalmol 2002; 86:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/157\">",
"      Ate�� A, Aydintu�� O, Olmez U, et al. Serum homocysteine level is higher in Beh&ccedil;et's disease with vascular involvement. Rheumatol Int 2005; 25:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/158\">",
"      Sarican T, Ayabakan H, Turkmen S, et al. Homocysteine: an activity marker in Beh&ccedil;et's disease? J Dermatol Sci 2007; 45:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/159\">",
"      La Regina M, Orlandini F, Prisco D, Dentali F. Homocysteine in vascular Behcet disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2010; 30:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/160\">",
"      Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Beh&ccedil;et's syndrome. Int J Dermatol 2003; 42:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/161\">",
"      Bozoglu E, Dinc A, Erdem H, et al. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Beh&ccedil;et's patients with venous thrombosis. Clin Exp Rheumatol 2005; 23:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/162\">",
"      Yal&ccedil;in B, Arda N, Tezel GG, et al. Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Beh&ccedil;et's disease. Anal Quant Cytol Histol 2006; 28:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/163\">",
"      Hamzaoui K, Ayed K, Hamza M, Hamzaoui A. VEGF and mRNA VEGF expression in CSF from Beh&ccedil;et's disease with neurological involvement. J Neuroimmunol 2009; 213:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/164\">",
"      Nam EJ, Han SW, Kim SU, et al. Association of vascular endothelial growth factor gene polymorphisms with behcet disease in a Korean population. Hum Immunol 2005; 66:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/165\">",
"      Lee KH, Chung HS, Kim HS, et al. Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Beh&ccedil;et's disease. Arthritis Rheum 2003; 48:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/166\">",
"      Lee JH, Cho SB, Bang D, et al. Human anti-alpha-enolase antibody in sera from patients with Beh&ccedil;et's disease and rheumatologic disorders. Clin Exp Rheumatol 2009; 27:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/167\">",
"      Evereklioglu C, Inal&ouml;z HS, Kirtak N, et al. Serum leptin concentration is increased in patients with Beh&ccedil;et's syndrome and is correlated with disease activity. Br J Dermatol 2002; 147:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/168\">",
"      Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Beh&ccedil;et's disease. Am J Ophthalmol 2004; 137:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/169\">",
"      Espinosa G, Font J, T&agrave;ssies D, et al. Vascular involvement in Beh&ccedil;et's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/170\">",
"      Haznedaro��lu IC, Ozcebe O, Celik I, et al. Haemostatic markers of procoagulant imbalance in Beh&ccedil;et's disease. Eur J Haematol 1996; 57:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/171\">",
"      Navarro S, Ricart JM, Medina P, et al. Activated protein C levels in Beh&ccedil;et's disease and risk of venous thrombosis. Br J Haematol 2004; 126:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/172\">",
"      Akar S, Ozcan MA, Ate�� H, et al. Circulated activated platelets and increased platelet reactivity in patients with Beh&ccedil;et's disease. Clin Appl Thromb Hemost 2006; 12:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/173\">",
"      Usk&uuml;dar O, Erdem A, Demiro��lu H, Dikmeno��lu N. Decreased erythrocyte deformability in Beh&ccedil;et's disease. Clin Hemorheol Microcirc 2005; 33:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/174\">",
"      Tatlican S, Duran FS, Eren C, et al. Reduced erythrocyte deformability in active and untreated Beh&ccedil;et's disease patients. Int J Dermatol 2010; 49:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/175\">",
"      Yurdakul S, Hekim N, Soysal T, et al. Fibrinolytic activity and d-dimer levels in Beh&ccedil;et's syndrome. Clin Exp Rheumatol 2005; 23:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/176\">",
"      Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Beh&ccedil;et's disease. Ann Rheum Dis 2004; 63:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/177\">",
"      Caramaschi P, Poli G, Bonora A, et al. A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine 2010; 77:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/178\">",
"      Ricart JM, Ram&oacute;n LA, Vay&aacute; A, et al. Fibrinolytic inhibitor levels and polymorphisms in Beh&ccedil;et disease and their association with thrombosis. Br J Haematol 2008; 141:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/179\">",
"      Espinosa G, Font J, T&agrave;ssies D, et al. Vascular involvement in Beh&ccedil;et's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/180\">",
"      Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Beh&ccedil;et's disease. Ann Rheum Dis 2004; 63:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/181\">",
"      Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Beh&ccedil;et's syndrome. J Am Coll Cardiol 2001; 37:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/182\">",
"      Alan S, Ulgen MS, Akdeniz S, et al. Intima-media thickness and arterial distensibility in Beh&ccedil;et's disease. Angiology 2004; 55:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/183\">",
"      Itoh R, Takenaka T, Okitsu-Negishi S, et al. Interleukin 8 in Beh&ccedil;et's disease. J Dermatol 1994; 21:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/184\">",
"      al-Dalaan A, al-Sedairy S, al-Balaa S, et al. Enhanced interleukin 8 secretion in circulation of patients with Beh&ccedil;et's disease. J Rheumatol 1995; 22:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/185\">",
"      Ureten K, Ertenli I, Ozt&uuml;rk MA, et al. Neutrophil CD64 expression in Beh&ccedil;et's disease. J Rheumatol 2005; 32:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/186\">",
"      Sahin S, Ako��lu T, Direskeneli H, et al. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Beh&ccedil;et's disease. Ann Rheum Dis 1996; 55:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/187\">",
"      Saglam K, Yilmaz MI, Saglam A, et al. Levels of circulating intercellular adhesion molecule-1 in patients with Beh&ccedil;et's disease. Rheumatol Int 2002; 21:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/188\">",
"      Ate�� A, Tiryaki OA, Olmez U, Tutkak H. Serum-soluble selectin levels in patients with Beh&ccedil;et's disease. Clin Rheumatol 2007; 26:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/189\">",
"      Turkoz Y, Evereklioglu C, Ozkiri�� A, et al. Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Beh&ccedil;et's syndrome. Mediators Inflamm 2005; 2005:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/190\">",
"      Lee MT, Hooper LC, Kump L, et al. Interferon-beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling. Clin Exp Immunol 2007; 147:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/191\">",
"      Yamashita S, Suzuki A, Kamada M, et al. Possible physiological roles of proteolytic products of actin in neutrophils of patients with Beh&ccedil;et's disease. Biol Pharm Bull 2001; 24:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/192\">",
"      Yamashita S, Suzuki A, Yanagita T, et al. Characterization of a protease responsible for truncated actin increase in neutrophils of patients with Beh&ccedil;et's disease. Biol Pharm Bull 2001; 24:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/193\">",
"      Orem A, Efe H, De��er O, et al. Relationship between lipid peroxidation and disease activity in patients with Beh&ccedil;et's disease. J Dermatol Sci 1997; 16:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/194\">",
"      Yoshida T, Tanaka M, Sotomatsu A, et al. Serum of Beh&ccedil;et's disease enhances superoxide production of normal neutrophils. Free Radic Res 1998; 28:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/195\">",
"      Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 2004; 140:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/196\">",
"      De��er O, Orem A, Akyol N, et al. Polymorphonuclear leukocyte elastase levels in patients with Beh&ccedil;et's disease. Clin Chim Acta 1995; 236:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/197\">",
"      Yazici C, K&ouml;se K, Cali�� M, et al. Increased advanced oxidation protein products in Beh&ccedil;et's disease: a new activity marker? Br J Dermatol 2004; 151:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/198\">",
"      Hamzaoui K, Ma&icirc;tre B, Hamzaoui A. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Beh&ccedil;et's disease. Clin Exp Rheumatol 2009; 27:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/199\">",
"      Ca&ntilde;ete JD, Celis R, Noordenbos T, et al. Distinct synovial immunopathology in Beh&ccedil;et disease and psoriatic arthritis. Arthritis Res Ther 2009; 11:R17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/200\">",
"      Sahin S, Lawrence R, Direskeneli H, et al. Monocyte activity in Beh&ccedil;et's disease. Br J Rheumatol 1996; 35:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/201\">",
"      Neves FS, Carrasco S, Goldenstein-Schainberg C, et al. Neutrophil hyperchemotaxis in Beh&ccedil;et's disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol 2009; 28:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/202\">",
"      Ehrlich GE. Vasculitis in Beh&ccedil;et's disease. Int Rev Immunol 1997; 14:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/203\">",
"      Onder M, G&uuml;rer MA. Beh&ccedil;et's disease: an enigmatic vasculitis. Clin Dermatol 1999; 17:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/204\">",
"      Kose AA. Direct immunofluorescence in Beh&ccedil;et's disease: a controlled study with 108 cases. Yonsei Med J 2009; 50:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/205\">",
"      Inaloz HS, Evereklioglu C, Unal B, et al. The significance of immunohistochemistry in the skin pathergy reaction of patients with Beh&ccedil;et's syndrome. J Eur Acad Dermatol Venereol 2004; 18:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/206\">",
"      Alpsoy E, Uzun S, Akman A, et al. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Beh&ccedil;et's disease. J Eur Acad Dermatol Venereol 2003; 17:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/207\">",
"      Ilknur T, Pabu&ccedil;&ccedil;uoglu U, Akin C, et al. Histopathologic and direct immunofluorescence findings of the papulopustular lesions in Beh&ccedil;et's disease. Eur J Dermatol 2006; 16:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/208\">",
"      Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behcet's syndrome are not sterile. Ann Rheum Dis 2004; 63:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/209\">",
"      Hirohata S. Histopathology of central nervous system lesions in Beh&ccedil;et's disease. J Neurol Sci 2008; 267:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/12/28874/abstract/210\">",
"      Ardalan MR, Sadreddini S, Noshad H, et al. Renal involvement in Behcet's disease. Saudi J Kidney Dis Transpl 2009; 20:618.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8233 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28874=[""].join("\n");
var outline_f28_12_28874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17358645\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - HLA genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Non-HLA genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Molecular mimicry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Altered innate immune function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cellular immunity and cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Autoantibody and immune complex formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endothelial activation and altered coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neutrophil activation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17358645\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=related_link\">",
"      Determinants of neutrophil movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=related_link\">",
"      Treatment of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_12_28875="Surgery prosthetic valve IE";
var content_f28_12_28875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Surgery for prosthetic valve endocarditis (PVE)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that surgery is indicated in patients with PVE who develop one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Valve dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Dehiscence seen by cine fluoroscopy or echocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Evidence of increasing valve obstruction or worsening regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Complications such as abscess formation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of surgery in patients with PVE who develop one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Persistent bacteremia or recurrent emboli despite appropriate antibiotic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Relapsing infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that surgery is NOT indicated in patients with PVE in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Uncomplicated IE caused by a first infection with a sensitive organism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28875=[""].join("\n");
var outline_f28_12_28875=null;
var title_f28_12_28876="HIV prophylaxis guidelines percutaneous injury";
var content_f28_12_28876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended HIV postexposure prophylaxis (PEP) for percutaneous injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Exposure type",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Infection",
"status of source",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        HIV-positive class 1*",
"       </td>",
"       <td class=\"subtitle2\">",
"        HIV-positive class 2*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Source of unknown HIV status&bull;",
"       </td>",
"       <td class=\"subtitle2\">",
"        Unknown source&Delta;",
"       </td>",
"       <td class=\"subtitle2\">",
"        HIV-negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less severe&loz;",
"       </td>",
"       <td>",
"        Recommend basic 2 drug PEP",
"       </td>",
"       <td>",
"        Recommend expanded &ge;3 drug PEP",
"       </td>",
"       <td>",
"        Generally, no PEP warranted; however, consider basic",
"2-drug PEP&sect; for source with HIV risk factors&yen;",
"       </td>",
"       <td>",
"        Generally, no PEP warranted; however, consider basic",
"2-drug PEP&sect; in settings in which exposure to HIV-infected",
"persons is likely",
"       </td>",
"       <td>",
"        No PEP warranted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        More severe&sect;",
"       </td>",
"       <td>",
"        Recommend expanded &ge;3 drug PEP",
"       </td>",
"       <td>",
"        Recommend expanded &ge;3 drug PEP",
"       </td>",
"       <td>",
"        Generally, no PEP warranted; however, consider basic",
"2-drug PEP&sect; for source with HIV risk factors&yen;",
"       </td>",
"       <td>",
"        Generally, no PEP warranted; however, consider basic",
"2-drug PEP&sect; in settings in which exposure to HIV-infected",
"persons is likely",
"       </td>",
"       <td>",
"        No PEP warranted",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * HIV-positive, Class 1: asymptomatic HIV infection or known low viral load (eg, &lt;1500 ribonucleic acid copies/mL). HIV-positive, Class 2: symptomatic HIV infection, acquired immunodeficiency syndrome, acute seroconversion, or known high viral load. If drug resistance is a concern, obtain expert consultation. Initiation of PEP should not be delayed pending expert consultation, and, because expert consultation alone cannot substitute for face-to-face counseling, resources should be available to provide immediate evaluation and follow-up care for all exposures.",
"     <br>",
"      &bull; For example, deceased source person with no samples available for HIV testing.",
"      <br>",
"       &Delta; For example, a needle from a sharps disposal container.",
"       <br>",
"        &loz; For example, solid needle or superficial injury",
"        <br>",
"         &sect; The recommendation \"consider PEP\" indicates that PEP is optional; a decision to initiate PEP should be based on a discussion between the exposed person and the treating clinician regarding the risks versus benefits of PEP.",
"         <br>",
"          &yen; If PEP is offered and administered and the source is later determined to be HIV-negative, PEP should be discontinued.",
"          <br>",
"           &Dagger; For example, large-bore hollow needle, deep puncture, visible blood on device, or needle used in patient's artery or vein.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     MMWR Recomm Rep 2005; 54(RR-9):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28876=[""].join("\n");
var outline_f28_12_28876=null;
var title_f28_12_28877="Troponin LVEF chemotherapy";
var content_f28_12_28877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cardiac troponins predict left ventricular dysfunction from chemotherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 294px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 204 patients, left ventricular ejection fraction (LVEF) was significantly reduced at seven months, compared to baseline, in those who who had an elevated level of troponin I (cTnI +) during chemotherapy. In contrast, patients who did not have elevated cTnI (cTnI-) had a transient reduction in LVEF at three months, which returned to baseline at seven months.",
"    <div class=\"footnotes\">",
"     * p &lt; 0.001 versus baseline (month 0).",
"     <br>",
"      &bull; P &lt; 0.001 cTnI+ versus cTnI-. groups.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cardinale, D, Sandri, MT, Martinoni, A, et al. J Am Coll Cardiol 2000; 36:517.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28877=[""].join("\n");
var outline_f28_12_28877=null;
var title_f28_12_28878="Sandvik Severity Score";
var content_f28_12_28878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Sandvik Severity Score",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 194px; background-image: url(data:image/gif;base64,R0lGODlhOgLCANUAAP///wAAAICAgMDAwEBAQAAzmdDQ0BAQEPDw8MDN5qCgoODg4EBmsyAgIDAwMHBwcICZzGBgYFBQULCwsJCQkNDZ7PDz+RBAnzBZrODm86Cz2XCNxiBNpmCAv5Cm01BzubDA3wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAA6AsIAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxqkDA0YIAwZJBgMITMlQCwMLYNDOfNDST9RP3W3W2HPiZOR94IvnhwYEBBNCA/DbRwEBAAsCCvMBBEkIBFC2BB8UAQEEfJGADyAfgQSdGHwCsQ1ChV729YtS8YgCAeWwXKQCD97GLgIwApiIZoGEAwEOSAiZpWJKJ/TwNYggZ0BD/yEMByYx6NMhM3tGOiph2WRkFwMBGujro7QJUyZV0zjtUlRK1iFfqaSbQgCmg5NcWK4zgwBmBAEMI2YRdxWJzwMPBDjIF8cnvmv4hD4g4GywM4N7DxBQ8O4BAAUEBv+TBpHCYiEEeBKZqKBBzI0CY0aQNnIw471RMU7wXFJI589FEhOGTEGAYwOoHQN4F1UCYQDwMDt8fQA0AQEHigsxENTBu+EE5AqMANOxZdCah3D2rBw4vgOjvUfzbQC3TtWsgz/mjhZAhN/vKAAYkPgB6YQADOf/PViA5werBaAbce3J1g8FnjUgXxG8NQCTMgQ+ZhZACARFgDS02Qbcccl91P/hY5f1958QFTbkDREdiSjgcs0tgMADZhEED3LKPdCQY8G9E0EEUW0DY4+7ZcZjA9tMgJoEAJQ4GRE+OTCEAdiYtyI9ug0mzY9EBvkAZPsZYOM/D1yHWXYAIKQbAPKgeaQ+Qc2kJZdKXnhFUYpRV9GdQhk0pADJ/FNmanvJB5FPUk2A32b5GCoBfQE4E8EEjMp3EQV+ejnABDBBic9bBinKKFJ77hNTZAsc0MAAPMq313GeKTNRpwEsutdhAUTA0AH6uOVfTv04cMCJ3nHYKKFoHqpdorF+6h6kgYrHkEKWYtroApsihKysjRJho2M2TlDqARPw6NhIeCojUGQNWWv/gKezErHnpQE4wGiaQ6zq30DsDuvZWwDsNQGlSCKkmGObBrVjTH8qdO6XzvgLcFJCBctwqbXuauOjyWFTMMIK4MPPSvnc9cBeSNooAKa4ikxysXjB2G8A/8ZKBLUNUYBNqaemigA+COzspMkoz9cQQBB1nJACxBqq0mPfSaCANIa2jGuglDrpV3AOy2xFUdYKUK54IAvtUFcjGUq0UJ4ZwCNNYTP0lkAK7SOBZwohxFAD3gzg9YMIaWaQ214bK7YQTlF6HI+ERYVZnnz9XTHcYYdNqWY9dzxTrUVUZDIAaa9dhONv4yc33d4xhOQ8ew/UtxCgB740tVI1IBWlju2M/yu5Qn1dLuCQD9EVAAzJoygRUEnl7OP4VVR8SgZt9Wrj+eBu7kDLWwuxjLkPNDmJbQVwZQDyPc86X2F31RVMKbVqvp8MbbRA9VcF+N0ChguAuHsBKNBxP+jf26dDYGNJ5wLANuQExkntE8L74iWEWf0OfuSjQlF25j3dMW5wgxtJV2xSK60hyjsOKAnSRAM5azkIGwhpwANa5RSDCCSEJmGSnxJGuKiU5AG/q4j4XijCyDVPcN3jEVLANpK+efBYIBThXd6TvKgw8E8qZOGhXBivHqIof/hpYfSaOL0ugg0iPIyh72ZYkd/5wyFgrGIMyziq1jgPeuOjYbnuUhIAgv8lYuXaSuRGIr7Ilc9PXRlaPdZ3tojQsTVGMIAC9sK8BtxQaBJ4iTQESRgz6pB8RjydEQZAgQcpJYcD+d0h1VOFrpTni+BDwF5cFbIZkg0/DMGRUGgGMyMYZHNJ0lsWd4lDBpbLUA2YgNHycyhmyNAhTjHbELwVExetEmSaygcujSk+YGLjGvh74hWnJw9a0guJ09Rl3Zo4ATOhEl7BHGY4i2A0AhYLIE2SYyqfacEBrHOMDtmcOYdArQM4cyDrrIjtvCGPN8YxbNITz0CF8M35BAobv4zKNRdAz1r2kSVEAaSfnrkba2gUIDaSAIYWiiYmLQoo+VMmQ4XgGcy9jCD/ULLkBRUYmIamxBkI8MwCQjrSmPQMJsyYIUkbKgUzEjEwDwpb947zSqRCNGJ3u0c+VFnFhNARfTQ0WQp9JZSgwGSqewmh4H63lSGVBSA8+k72YmIQqopVIX1M6192g4/2gDCsQ4iqLcFaVT6NCqsVWeVWk+rVtoa1d0NYal7jlRxlFBGp2fMiRNyK2CTB5Dg5/UdUgJVNtkbjsLuUHdMU4xkaHlR8Ca1Ix0gbQZB57JydDWVyVuZDvrwQSRmFZ6Uuu0pCJgk1BlktAUo7xsDM0KyKqWHEDMDbUM4QlQ44nV6JYK3AKISqgQEApWQHPgyOdritlcJRiBcN14BEHODY/4cADDDevlGAAt44By6LsI5ynkwaersGNtPBDAidt7zl6ZPx0JSSCQBrvPrA5pNSooByfIQ3ykDAe/u7zALjlyDrMECBSeTTRDbjY0OYL5MiYl8Dz4dP6RCHNZzxkfcBGBrEYqiFPUyTctpMgQpusTh2DODyEvi+RVAvTj/yNI/8l6AzfowAFkS/JTtjLPPBsJQTHKUee6PJFBhiMpJRZWmcQ8MnU2Bt6AUOcEg4zNQYL4IR8BE+5RKnzajwesXs5CDXZs4L5kc5KJzYNkc4zssp75nTJOI831jO2wDzNhBM5yzbQY9G0CkaQlNXMYQFCx0jExMkfQZK5+8YoCYCp/85kd8kaCQNYHa0GFr8BVY74dRoSPUQQ10MWNP61rjOta53zete+/rXwA62sIdN7GIb+9jITrayl83sZjv72dCOtrSnTe1qW/va2M62trfN7W57+9vgDre4x03ucpsbFsZNt7rXze52u/vd8I63vOdN73rb+97qPre+P6fv8O673P4Od8D/Le6Bf9vgBD94vxO+8HMjnOHcfnjEIW5uiW/b4hS/NsazvfGMU/vhGYCABoSgAQhkgAsV4EABGJCBBFjACgkoAAQGsfIzdNzj0n54zBkgBAYUIAFc+EABQFABCPwc5jIfRAIqYHOcF5wJO+/50SuAgQJwYOQQYDkAGLD/AQCAgAEgIALVrT5yDVxg5RpQOQa6DgKVXx0AG+D6BS4wcrG7Peljf/sQLMB1AFSAAR4AQNoLgAGma4ABhke82H1+ga4fPuxZr8DhITD3ulOe8Eznugd43ncAXL7wW++A0DnAdAt04OwYyMDfC9B4qzhd4FBnPQMYcHagX4ADCRC65AuggQoUoACmL8DJh3D73BegAglQOQQS4PMO9L4AHUhA1fkO/Q2wvghzB4EHkl583RNh+tZfegE+kPwLeP7oRgc68TGQgA4MHQAYuMD2Z270DSQf+Nv3AAgugAEA/H72/sdz+bd//cd6GyB0HwAA7ucBuZcA/Nd+71cQrwdu/zone7T3czE3cxloAdXnc23Xf0OQgQAggj4nBOl3fhjAACrHfAUgdUQQc12XgSIogkOgAbzHARxwfkCXfid4gkIQcxzAAFU3cxZwdjyngzroc7N3dgE4BDWnhBfYhE1IeCFodUKYdBI4gd5WgUfoc+LHdgUQeBjAARjgAR/gczM3BL4HhoFXgkg4fwkQh9TnglUYgzK3hl4XhkTAgWcXeNsXdtZXdO/ng343fnGYACdXhDWHhIEodCBwiFLYhI4IiYtYc/wnBBYQc+QXh8O3FFq4hbHXhUcXfxAQfye3fcKHikz3fRdQihdwcm64fR/gARkwdxtQiixIh0PAAa2Ihv/w14qmWATuJ3wAUIsYQHn9Z4MX4HNHNwRV1wEQ8AEzF3/b13VG1wHW138gYHUQsAE5uIhNuI0c0I3feIQ1Z33SiHvPGI1p6ImfOHFL8HddB3eKZwFx1wGrmAEMkID6mIBFYI8MgI9CEHeY2AEMMHMZEHdcB5ADeYRqeIZZN3IAKZBFYIP+6HcGuQEv53map3h7t3kBKXlgx5GCeIYdsJHtN3ttOI9bN48pCXgt2XPzqAEmaQEWAJIU6Y7vqG03pwjuF3ZgQIh20JM7iWxEiQj7KAaHt4p3cJRFWWxOmXNPyXENN5XWFpVqIJROAI5LQINWkJCzBwEbOQdYaZW/Vpb/aNByY/kEXKkEXlkFzFeK0FcHaDkGKXGXeJmXermXfNmXfvmXgBmYgjmYfJlwdakFBEmPgscAGuB8SymPVccAL7d6rUcEi/h5TGd9BjiCSRd3FZByvwd61JeCXRd84zeWUUcHhxkGCUGYrvmasBmbshmYq/lstXkFbliCRheEJYeB3Fh1gfeAP2mZAhiGBOh5j+hzyCdz+ed3y2eRWxeGUfcBF6B9BTCPFlB1QEmWfXCbnuCdzAaeVJCbLeiD6TeDMgeEV9iOTQiFTPh1v+ebQneEpqdyNUeFU7iMSigEVqd+qtmdvSCeyiagUuBzL6ebzXieSZeBvreJiEicADCJ/3HYoCHnmzh4fBH6fvcJgpaIexMqk00JoLxAoEZZB+5Hhr+HhDqIntMIfewIoeJIjr53jCsog4RnAUK3Ae7Hczm6o3C3chAgeibIntzJBySKCUdqbEnqBKYHeAS5lCSHeH83clMKADc5ezkZkyNokDB5eB/gmVUakTh6kH3XpEZ3hDS5j0AJgEMporuwpMQGp4ugAbfoc4EXCHI6BXkqCXsKbH16CMy3j3WHp26qC3/qa4eaa4nqensQcv4ZBQlgclXgqE+wqLtmqbSGqTppBCl6fkR6Bm8JBVBKBaG6qVUJcIVaBJ1qdGlYdLRYjC7nd+q3dETQchngAYEXqaX3oP+ZOHxFBwHLCQEgsHxFoJawagFqmQHKGqtLV3SDGqmvWpEQwKpCMKwasJb8RnCaCmrbigQD93tx6H4zZ4NjeAEVsI0t2nLXSQRGd3Yr93sXkIkL2pmEV3Ux567NaILo93NGN4QnyHrxOXM7OnedqID1mnQDiwHYqh2Geap58K3x+Xszh4PFOJfLmAFW5wFGx5Tnd603Gn4sirFH+IhzOX/suq+Rmp4VCnQ36nssZ4hGd6cVy3MZiLEdIHi8560N63CpapkYKK5SWHNC5wEcIHoqWAT/ynMKqoHpiYWcybTs2YP8mqBHV4kMoJ6z96zzunxbq7OV4DXxEAWstg9LABL/ClQ3KcE2/8mzRpoEq5p08SevjmeA2ziXJ8uySuub7Gd9Ynmj9siiJxt9XmieVWuOkkl4J4d8QyCyONu3ebud2ToJUFFOvwIF0yE0BYFhWxQBalukFdezTtiCnup37qqwVgquHBiBQ5C0SFh1hJd0ZgevgLu4pTu16se6TRi7vyezPwqw4xqfN+u1k+A1rCMXWCEQHvVb+HAmxesPzfuwDosHAxeHQmCrIcixiiurRmCstGqsI5gBvRqCLhe+4buHLpessXqsI7iKtPqDD1oEyFe+5Su8kkC8wLE0z/FIKOI1EeAT7oE3UIEUEeO/K2G8dBm9ITqiX4tGS9NfWzZE/0yFRffbQEszwI1jwGv7uW2rwJRgvxGzHHUUGZmjMKV1HBRMBN1hKM8rvQjcphwsudrjPUTgwMkAwQrhF2UCLpRCExHgHLjhEB+cwBq8B7dJqVk5qEpQclOQielrS5bgH2fBERghEEKwQlE8wxEgOyLlWhgsB91qDF/sxF5QqmXQlkTQeYkJBTEHr5DLsNr6DL4RHk+wD2mCNMMWxpErdrEav84Zre3bvj+Ihda6kRZQch6wiiV3rUYArYlYcsK6uBobdivnrPBLeC6XvUunqzcpsyEHrLAKANvnkJuxs0fgAP17AAuCEx1mwsImcXe2l0SFBK+sl5x1D0ewfSPHi/84W65MZ7UviLArx382yYsqKJnx53MgOAQD+4oOqIJJJ45eCLASe8bxmYv+5678N83kqnLbuX3Bm8ctXMBlYkfT8A8KoxAKABMHYAAUoBkTAFI6AVHvYVeG2gSGwm7+xAT3vG5LMxRHgLEfgIcUa7NBK8o1O5c2qAE7R3QZYIPL533VC7NhaAGSd6YAwIuTibEK67KqKor8qbDW57E8h4MJsI3+aH2SactvfAQEbL8hFsJI4RMD8CvHQS3KQB7Zkhnp7EwE4wBu9gsW9yXrRs7L8FXq5iSMagQISIy+7MtVyLVQ27suSniz55GcGYRZS64WzZVO7YQe3YSsa4GdZ8b/bvxvAdfS5AxjWwYs/nscEQwPpWXKNo0ccA0QQewLFpdZ7NbPmYPPnavSRmCD+Bm3MHjNIGCDBi1zHPi4kkfRZ7eNJ+l1nciBqSerBsq48cd0h9zVH22lblhzrBt/QJcBQAnIYmzWQ+FY5DwYdRTTIXMAPi3TWyYhelEm8lLD4hwMGAcV7TZrQkAp7EbP9It9OUu6oflymhmZv/y7v3ezvhefI6eZv8exuhuGgm2Efmefx8fZ0flzn523eJvd8emPnQrY+zZwpmwACsIgW5YMbG1bCdEWEbAupwMT/eATNqMABNPF9fwE1XXUR0Ax66ZpWXgEc7eWpv2Z62u+wze//0w8lg9+BJwoBPELyMh3cn/Mse6rvQvOvUyJfExJvcPNtkfwDuBRy0pAwD4BLS/hAFVSuWhyLuHD37nQcZ6WbnwNXOmGN1AQcDb4za+Ax8cg5MLQcQK+bkjx3+nm26a6uE0c5KSMqmLbbkhNV3stBUQuCFmeBAMg3JvkG2ELBcwBD/NdwGS7Sa3lYyxM4lAQFPysvEOtpwFKCC9B1EiQEqiCK1AAHpciAXDVDHZOwNpB43Cw5UA9Bd3Dbl6CzyjOBIb+Bzen1u096ZRe6e3d6GVLSqocBbWkQAX8DruRILrFHQvQMSEEvWwOBX6xbi21brGc1P1tufjWboSeBC7tBP8rxCAhzLz9ohg/7VzAgSQqLNNtYTPgU+tt8OhzTgVCLW+83uPLLuuzvm7IfgS3vjiC4xp3TcOARgT6vRf9AOxC4b8EbMJ3fcCpDgXYFW9VLucvTBHTTu1UcO1KsD+JtOtJ8B4F7L/j3kqY8ed6oOzvLgW8DW/rbAUCv8HSHu/GVe1GQO9IYO/LMOlD1AANhikz7r/RhSr+PsF44fBqkPCxTgXA/W6pTAUiH/BewfDpBvLHMldL4GkgLxk+Xbz+ixuK0fEm3Bntju56oGCQwAyYDgZYeePqpklVkPKovvAsf+6AcCnM0fOQrgQL8BtQwCVX8Ot8jQj7cE1OLwZYeeT/SI4FSr/mtbBIMsHkCm8EP+LyCBFkQJ9has46GJEQpzQPQJ9gAT731jBiT4LBXGYXNxMRzEATQi80yiDbf/0FWFnw7GbnnB7t550ECsAjbh9B1fU0LTU1gWEP1bXqK0JpOPJVPZ9W4OId+OAkzPUd2HXwd/RaY/RVoeEk0oI5AtNMlHYX+PDqXhCVeu1uJ+/ubxrlaG7A6iYXb78csAQ+MLMA/RvfD2AP1NK/OyNSZfEY5bEXwHEqlBIRUGEfDiAVwyUq79AAC+ASMAIl4OHt0OAgMgQSpqJhjdIADoAACCH/jHE0x+4TDwAEiwYBUDQekUnlshhgPo+RwJRapR4M/1CoU9v1fsFh8Zg7Np/RafWa/SwrB4FBclC3I46CMsUaDxAUFg7+BPCMAgSaEvUAHqoACIji5ooUArIYIwEmEY0IqoiMHKmOJiEl5ToREBkBEE1NNdvc0Casbqsc0N5me31/D4GFh4mLd59MkW4pi1oBLCnsNgUcLhcEPimOOl0XLwMiDDJRmS0xnTQ5Hzwb7LKK4h6u32LJOxcCKFpf5Tb7ZYvxAiMIV0FuZIwlVLhlYUOHD9kINGKAD4V3RuzcySPHTgAHExQ0ECBhgB5qE2xpOyQhUCc9BhBNqHbKHzN8BCY0aEBzkoQDCkKaLBnKnwCZ9P6RI3BggpR5ivA9UP9QL6FEL58MFrwYxipEr7O6MsGaleyyr2fRNhFLhWgXPVSMNpgiIecUedX+GGo2Baa3RgEOyOXZz4iCQQ2ypJODAKuERoMOJDIi5cBMjElrGvj0E8C+RFJSzQFILOwTPriYGmygF0zptK+/uE4ytmxtwrBxV829m3fEMTALTvhbcJ0Y2b17Hz9C2zZZZsihr1Eenfru6UUQ4L3lGAACuQWfe7le/ex45s0Nhu+yQEIkBWBAhlEgGYC+LeqhDGDtcDx5/17HG+WWA/TyA7X9tOjvP/7EOA89XPDLT4CSAljAC0va6uKT9/y4j6sIdVtQxOTCsCU4JATcjqsRoTPvwbL/QNQiDgu1MKCyDLVYSpcIPgHAgO/eyw6wfkZxAAHNsAHOIwQscYCIIhEURkEWqfxlOgQGwYW7I7wzSLjYquRtPAMyKtPMM8+MsgspioNCkPky1CySSNosgoAHfgrAFgAkcGzGCIxcZQDDEPBuQkIWmANLCvCJhlBDFZoyzEnVmE6CggiEw6ADaOxC0v+u0UKATs349CuKLlluCvoAcCCCzjJEoMytIBFAjwjiAIAzVwYgQDI5BDggkiFy7e7SVXntTNilcJSS0mcbUu40XL5UIkUrml1iPARsiVFTKiJQE5hcsWnkPUjeua3UMEVKEJQj5JyzzlpXSdSJBlSSw9cm/0pywJ1iBWjAwn37ocadSKFN2JjjbCxoSyW6LEilBMV4y1s6uFjASQAWMIDMaQTIQtYJBFCJ5AmRKClkeBLtNNdBs8MVpmiSVfniJEx9CChUaX2iXC5nRWJfeJwAtCQCjdajjnwWUOABgBEzLJFX4mDUaYQVzhqY47SzItMnTEStZyUUVLcIMjNirViOLwl2inh8steBYEMO4IEHHoabU1eQJRpWG4dwZGOO7Hbk5m1G7NWjc734+Yuh/ekugsqEQ8AnKeaY4BNAirX8AAnaDZYIzf9gPCCtUe9FtmurqPaJY3HRhWIy1Htgzki2WpvXgC2MgLu5ASaAjwkKjeL3qf8n9rvcoQmTg8c65l4x9enBYsJ2AsINY4D2hF8Qco7fGRQ5A2j8XlstELBV/fVNfyL99eEfW5lS1UNbo8uMEPTnoX0NHoHJA/Aw/k0tPOQiAvMooa8huEd61HNgGrrykQkcIHkyeoXU/vO9n12tNwOcXXTKVrvbESB3ZYjATn4GqCLgq1i+WwAeLHGEB8gOX8kqhROW96tzOU92HGvgA4FonByxSgs8KswBnuETjxQBNEY6gmEAkwUF9IkojJnCTn40hakQAA8LICEUmdIIHtluClio1REaICygrANvq5JLpqDUsACYblrzIsCxArYkK4LDTtU4wAAAR0ICfKeCiKP/zngoFIH25QcRoEMMrIogCAdMUlYe+cTRTthDjlXGAZkymwH5JCwDgI4IchBEA0BHxA8GkZXicdMcUTTCrUAOH+IQGD4GtRpIGYGCnUGh3egTh0KtowHr4IOutME7PTVCF0sRwFTw0J4zTsZf1zigY16yKMO8UCQqXIDrBmChPW2DjYgRFAV0yZl8tCpcrtLPHX3JhJydTnvqW+QTrlEyZogvkkDBQxwoQqOSEA8JTFKAIUaFhFCJj0nEa2hnLMQtlP2wlRWVp/s2hgT71YE1tGxbKJy3rMhMJAD/xGGGTokrVzjpkg/YiUjiEImZDM1tf5hmM0KRw8jVSnSDFJ5H/+RRCu0oYw4/k4MEXnXGgh1QMvvS3fwOiZynVmeeFoVWV7LjxFjebivSrAQSjToAo9WhUzCxECgVSoFLNeoOjSrpJKTh1KXeFJKQlKudbOWvOmTBlm1pQLieOlde+Q6vydLpGacajKj2JlQLqqpVKWWV7HBRCRvVzw1DNsF1hDUlBgAKGnElTcedLWR88KIDyBQOPvERSxH4pmPkOgEDbEyD7bAmYrnQP6Y5TSrs8esDDOAIotZVDoZBST/mesd3JiKxalksZH3xWOhWySoGsikYelUZyYS1Ppt7zigDiAmU+sQBQTrhX8VJmFFW5lVDw9Oc6OrFn+i0WPsiHSAosP+5rcgElbwQbMF08quiSkInSNop2ag63egqWMHSZTB5HGylB7chwhOGsIVZWWHVYbhSLPrfaJjwYfPViHuqzZqGOZwbFFM4xccYkQNIcs8kuHQAfJDfEg6AqwlIQJWRbbEDV+ybHyNERIT6wgkLZbYtVMtCo0CMAIpDgXBhhYuasV1wr3hjBg05dUGWDpeFKKKaCqxGgJmkRkc4r072bxNmxJ4l8CASdBaKhQF8ZqqwBxsvg/khe4agGGQFyBT7eRbU6E4xVXUQZjZlmfkLGhKcVo35LGsIAKizFxcYGYBROlt95rPWCH0G8wyh0V6IaSUU/axQs+FneNPCrr4XLzr/MYFHATtYwCLQXgLYwV7NaMde9fzpEydYe0WwHXYBIxpV6ONc5BP0ybSMm1WvoWoD6CUUJIDaCSYv0AdDYyC23RcDkIxtf3zGTzw7lYwhYtw9hsi0hT0MeFMUDISFV5nUZrddCysRkwzWOpZSusj4RFzSZlFI2oU+8rrbep+IHgDuqxLQGYEaf1iaEUjngEICKN4Jm3drzNCtrc6phPiYm6/Mem5ISAAP7kwGCDsO6oZjr+Bw4N7GofO9jsFDxmcZ8SqR0x8bqdKy+QbA5BhzKL8xb4EkJHbMPc6Ejwwg4aa+4Ej9o8FQcDA3P2fIc79g7R5fj+Q35JhwfIXLeA4N/8bYqflrPg51CWMU50sw4leTOAjZNZE1YJQiFfOHFSwCqVdd/CJkhPOAMWLFzaxKIyCu1kZEvBEPccwSHalQp175iAiaOTdg3gPG9+wLb293Lsy5MjdbIXs5n/kcLIc2QRibG+xyn1RYLLE3Gcqy9UaoJe9wGRI6s6qXAesMMC8zTEsb0wnFF9gyZwiJyECTT0yNQjWXh81LaJNThvImONN7hFo6YgIU0EUvKUAgzhjfV5OLtiFRDwb4DYRVU4GHRSphk/K/H+62vyo+B8BVNArfei+SPopfJicSsM5HSipyRmuT/moOLKmlXupQZAodtitLrI/icsr66stWOI0PHP8gqDBiqL7tr3Ltaf6AAKohplgQHQaB/xQr/vwP/mqQukQlQ8gOd47Aq1QurMYqnEjqrE4qCRZArSokH9oqH96KI+oAtwaMrn6GvnIrrw6mr0CrklDEAQSGcmBiKjpiAuJqEOoOwWrvBuPuBr+ssnCF6pJqIgjwMjLrADYLpAagsz7LCCJQtOKktCqEBVMrCy7lVVrrtXBLtmiLVWzttu6qVqqmae4mEHxw+bAMCWyBmBpwCFJLVyRgE33FEnoOZ55ODV2BFHFQCdhDJ7IHu3Rku+ywuywOXi6lE+vK98jLvFQxvShhvQTQvZZlAyNpKeAEtwrrvhQgv/5gv7jwUgr/KlWiz0d84q+gkb3OiPxc6QxrMA1NUdS28T+0EejQsBtH5BvFERzFpBvJsRyvUR1bZBTVMB3Z8evikUSw0f/gcR7PBx/PsR5t7x71Ear+0eAOCX4IsiAN8iARMiEVciEZsiEb0h8D8vQiMi0gEgkc8iIxMiM1ciMdciL30SPRoiJBciTfjSTLwyRRcrpEMh5XMiVdcmugIH1IRQvyyVZCcQyaSw3WRgE6TQvsbzZYRVZK8iWJEojCQkgOh2jsqRdyMg3WprzOQCqU4HuaUt6K8iqpJywARcmQ4Q2grBIc41iq7E6wJ6mmCF6yxAkMpL2+RAKSJ0vILBK0yEcgI2My/8USAuCR7uZOlgMrEu893gIqWXAQXkUK+DJasDIxZW4JZkhQRo4HL0NebMFC5EyX6uwTUwXRjKDt9mQBLAQmDMCIZuSJiiB67KYRiEAax0nx2GYO+kT6nmkbPoOpYGIOoicSuMUJLEHQEFMxfVPVlmCCssBsiu6GDubSfMqZnhJXKmQb5iBXZosKliY0H+Z/soSAIKkfiqUddsow6Ipf7KpkduKM7qoqneU30fMUk+AtpHP3uMrs8uCvwnLXyGonP+cNwTNX7ggPkkJd0k80sLNctNMJcsJvVG7Ekks8C6s84a0l0/NBzdANwqM48Uf8ku0Z5ijddGcQwgPGxAodOv9RaTB0PI0g/cZtpOZqD4tGMrBkQnpRlRL0C3MiERhUtrYMQnHUHckmKf2BLZiIRCuOPt9AhTRqGZ1gtv6qH1ahfawzlQyr84wUSzpFJnIMDxA0CvclWLiQRpnLCTxnXhYmR8WUBtMCS25yCYJFDXiyDULG2s60N8c0TlUsN9DJDBbwDJ6QDZZCMwVSTv2UIv/UxQJ1UD2NUMPMUBE1TBMVTBa1UWHSUc0RUiV1XSb1oir1UikVUwFSUzk1Ui/VQTs1IEFVHEc1VPHxRVA1VVV1VVm1VV31RUw1VmV1Vmm1Vm31VnE1V3V1V3m1V331V4E1WIV1WIm1WI31WJE1WZUfdVmZtVmd9VmhNVqldVqptVqt9VqxNVu1dVu5VQ2DAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28878=[""].join("\n");
var outline_f28_12_28878=null;
var title_f28_12_28879="Ulnar gutter splint";
var content_f28_12_28879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulnar gutter splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulnar gutter splint that supports the 4th and 5th fingers and leaves the index and middle fingers free.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_12_28879=[""].join("\n");
var outline_f28_12_28879=null;
